

CURRICULUM VITAE

July 31, 2025

NAME: V. Michael Holers, M.D.

TITLE: Smyth Professor of Rheumatology
Director of Faculty Ventures, CU Innovations
Professor of Medicine and Immunology

ADDRESS: University of Colorado School of Medicine
Division of Rheumatology
Mail Stop B115
CU Innovations
Suite 6202, Anschutz Health Sciences Building
Aurora, CO 80045
Phone: (admin) 303-724-7605
Email: michael.holers@cuanschutz.edu

SOCIAL SECURITY NUMBER: Available on request

DATE OF BIRTH: 1-28-52

PLACE OF BIRTH: Napoleon, Ohio

CITIZENSHIP: USA

PERSONAL DATA:

Married:	Jill Marie Norris, Ph.D. Professor and Chair Department of Epidemiology Colorado School of Public Health Aurora, CO
Children:	Emma Page Holers (02/25/99) Nathaniel Michael Holers (03/06/01)

EDUCATION:

1970-73	B.S. Biology, Purdue University W. Lafayette, IN
1974-78	M.D., Washington University Medical School, St. Louis, MO

POSTGRADUATE TRAINING:

1978-79	Internship - Internal Medicine Barnes Hospital, St. Louis, MO
1979-81	Residency - Internal Medicine Barnes Hospital, St. Louis, MO
1981-83	Clinical Fellowship in Rheumatology University of Colorado School of Medicine Denver, CO
1983-85	Research Associate

Howard Hughes Medical Institute
St. Louis, MO

1983-85 Research Fellowship in Rheumatology
Washington University School of Medicine

APPOINTMENTS:

1985-86 Instructor in Medicine
Washington University School of Medicine

1986-92 Assistant Professor of Medicine
Washington University School of Medicine

1986-93 Assistant Investigator
Howard Hughes Medical Institute

1987-93 Assistant Professor of Pathology
Washington University School of Medicine

1987-93 Member, Division of Biology and Biomedical Sciences,
Washington University School of Medicine

1992-93 Associate Professor of Medicine (with tenure)
Washington University School of Medicine

1993-97 Associate Professor of Medicine (with tenure)
University of Colorado Health Sciences Center

1994-98 Associate Professor of Immunology
University of Colorado Health Sciences Center

1993-2008, 2021- Smyth Professor of Rheumatology
University of Colorado Health Sciences Center/School of Medicine

1997- Professor of Medicine (with tenure)
University of Colorado Denver School of Medicine

1998- Professor of Immunology
University of Colorado Denver School of Medicine

2000 Visiting Professor, INSERM U561, Paris, France

2000-2021 Head, Division of Rheumatology
University of Colorado Denver School of Medicine

2008-2021 Scoville Professor of Rheumatology
University of Colorado Denver School of Medicine

2021- Director of Faculty Ventures, CU Innovations

LICENSURE:

Missouri No. R3A67 (1978-95)
Colorado No. 23841 (1981-present)

CERTIFICATION:

1982 American Board of Internal Medicine
1984 American Board of Rheumatology

MILITARY SERVICE:

None

HONORS:

1974 Phi Beta Kappa

1985	American Rheumatism Association Senior Fellowship Award
1988-91	Hulda Irene Duggan Investigator, Arthritis Foundation
1993	Member, American Society for Clinical Investigation (ASCI)
1996	Ecker Lectureship, Case Western Reserve University Cleveland, OH
1997	Robert Wood Johnson Award, Arthritis Foundation
1997	Schwartz-Weinstein Research Award, Arthritis Foundation Rocky Mountain Chapter
1998	Harmon Foundation Award, Arthritis Foundation Rocky Mountain Chapter
1999	Kroc Lectureship, University of Iowa, Iowa City, IA
1999	Volunteer Leadership Award, National Arthritis Foundation
2000	Member, Association of American Physicians (AAP)
2002	Member, Henry Kunkel Society
2003	Pfizer Visiting Professor, Medical University of South Carolina
2004	Inventor of the Year, University of Colorado Denver School of Medicine
2007	Ogryzlo Day Merck Frosst Canada and Schering Canada Visiting Professor, University of Toronto
2008	Ephraim P. and Jean S. Engleman Visiting Professor, University of California San Francisco
2008	Pfizer Visiting Professor, Emory University School of Medicine
2008	American College of Rheumatology Distinguished Basic Investigator Award
2009	University of Colorado Technology Transfer Lifetime Pinnacle Awardee
2009	Kroc Lectureship, University of Texas Southwestern, Dallas, TX
2009	Eric Bywaters Lectureship, Hammersmith Hospital, London, UK
2009	Physician Pro Tempore, Hospital for Special Surgery, New York, NY
2009	Christian Lectureship, Hospital for Special Surgery, New York, NY
2009	Freyberg Lectureship, Hospital for Special Surgery, New York, NY
2010	Senior Fellow of the American Asthma Foundation
2011	Castle Connolly Top Doctor
2011	Zvaifler Lectureship, University of California San Diego, San Diego, CA
2014	Cochran Lectureship, University of Alabama Birmingham
2015	Rheumatology Research Foundation Memorial Lectureship San Francisco, CA
2016	Lane Lectureship, University of Washington

2016	Everett D. Reese Immunology and Rheumatology Lecturer, Ohio State University
2016	The Walter Bauer Lectureship, Harvard Medical School
2016	<i>Arthritis and Rheumatology</i> , Top 5% Reviewer
2017	SCARI Lectureship, University of Arizona
2017	<i>Journal of Rheumatology</i> , Duncan Gordon Manuscript Award
2017	Master, American College of Rheumatology
2018	Riven Lectureship, Vanderbilt University
2018	Washington University School of Medicine Alumni Achievement Award
2019	Napoleon High School Distinguished Alumnus Award
2020	John P. Atkinson Endowed Lectureship Inaugural Speaker, Washington University School of Medicine
2022	Lupus 21 st Century Meeting Randy T Fisher Award for Excellence in Basic Research
2022	Kroc Lectureship, Washington University School of Medicine
2022	National Institute of Environmental Health Sciences (NIEHS) Distinguished Lecturer
2023	Weissmann Lectureship, NYU Seminar in Advanced Rheumatology Keynote Lecture
2024	American College of Rheumatology Presidential Gold Medal Awardee

PROFESSIONAL SOCIETY MEMBERSHIPS:

American Federation of Clinical Research
American College of Rheumatology
American Association of Immunologists
American College of Physicians
American Society for Clinical Investigation
Western Society for Clinical Investigation
International Complement Society
American Association of Physicians
Henry Kunkel Society
Clinical Immunology Society

EDITORIAL AND REVIEW:

1992-99	Associate Editor, <i>Journal of Immunology</i>
1995-2000	Associate Editor, <i>Arthritis & Rheumatism</i>
2013-	Consulting Editor, <i>Journal of Clinical Investigation</i>
Ad hoc reviews	<i>Immunity, Journal of Experimental Medicine, Journal of Clinical Investigation, Nature, Nature Immunology, Proceedings of the National Academy of Science, Molecular Immunology, Blood, Journal of Immunology, Arthritis and Rheumatism, New England Journal of Medicine, Nature Reviews</i>

NATIONAL PEER GRANT REVIEW SERVICE:

1989-93	National Arthritis Foundation Biomedical Research Grant Review Committee
1993	Ad hoc member "Research in causal mechanisms of SLE" RFA Study Section, NIAMS
1993	Ad hoc member ALY Study Section, NIAID
1993-	NIH P0-1 and R0-1 ad hoc reviews, special study sections
1993-	Ad hoc reviewer for VA Career Development Awards
1991-	Ad hoc reviewer for National Science Foundation
1996-2000	Member, Allergy and Immunology (ALY) Study Section, Center for Scientific Review, NIH
2000-02	Pfizer Postdoctoral Fellowship Academic Advisory Board
2000-	Ad hoc reviewer for Immune Tolerance Network
2000-06	Chair, Scientific Advisory Board, North American Rheumatoid Arthritis Consortium (NARAC)
2001-04	Abbott Postdoctoral Fellowship Review Panel
2001-05	Advisory Board, Multiple Autoimmune Diseases Genetic Consortium (MADGC)
2003	Ad hoc member "Microcirculation and Target Organ Damage in Rheumatic and Skin Diseases" RFA Study Section, NIAMS
2003-04	Chair, American College of Rheumatology Research and Education Foundation Research Review Panel
2005	Chair, NIH CSR Special Study Section for Systemic Lupus Erythematosus Applications
2007-10	Chair, NIH CSR Special Study Sections
2012	Member, NIAMS P60 Centers Review Study Section
2020	Member, NIAID Immune Tolerance Network Review Study Section

NATIONAL PROFESSIONAL ACTIVITIES:

1992-	American College of Rheumatology Abstract Selection Subcommittees
1997	Subcommittee Chairman, American College of Rheumatology National Meeting Abstract Selection Committee
1995-98	Member, Committee on Research, American College of Rheumatology
1997-98	Annual Meeting Planning Committee, American College of Rheumatology
1998	ACR Basic Research Conference Co-Organizer
1995, 1998	Co-Chair, Complement Symposium, AAI Meeting
1998-2000	National Arthritis Foundation Publications Committee
1998-2000	International Complement Workshop Organizing Committee
1999	Co-Chair, ACR Basic Research Conference
1999-2002	Chair, Committee on Research, American College of

	Rheumatology
1999-2002	Member, Board of Directors, American College of Rheumatology Research and Education Foundation
2000-02, 2004	Arthritis Foundation Fellows Research Conference Planning Committee
2000-01	Blue Ribbon Panel on Research, National Arthritis Foundation
2000-04	Founding Member and Secretary, International Complement Society
2002	Member, NIH Study Section Boundaries Team for Integrated Review Group (IRG) #10 (Immunology)
2001-03	Member, Abstract Oversight Committee, American College of Rheumatology
2002-04	Member, Board of Directors, American College of Rheumatology
2003-06	Program Committee Block Chair, American Association of Immunologists
2003-04	Chair, Task Force on Research Funding, American College of Rheumatology
2003-08	Steering Committee, NIH/NIAMS SLE Biomarkers Consortium
2004-07	Site Director, Lupus Clinical Trials Consortium
2004-07	Chair, Scientific Advisory Council, American College of Rheumatology Research and Education Foundation
2004-10	Member, Board of Directors, American College of Rheumatology Research and Education Foundation
2007	Member, ad hoc, FDA Guidance Panel "Abatacept"
2005-06	Chair, Rheumatoid Arthritis Initiative Task Force, American College of Rheumatology Research and Education Foundation
2007-09	Member, Nominating Committee, Henry Kunkel Society
2007-09	Member, ITN Strategic Planning Group for Autoimmunity
2011	Co-Chair, NIAMS Arthritis Biology Research Roundtable
2011-12	Co-Chair, American College of Rheumatology Blue Ribbon Task Force on Academic Rheumatology
2011-17	Member, Scientific Advisory Board, Lupus Research Institute
2011-14	Member, American College of Rheumatology Board of Directors
2012-	Member, International Complement Society Board of Councilors
2012-13	Member, NIAMS Centers Evaluation Working Group
2013	Member, NIAMS Target Evaluation Consortium Working Group
2013-14	Member, National Arthritis Foundation RA Task Force

2013-17	Member, Arthritis Foundation Great West Region Medical and Scientific Committee
2014-15	Chair, American College of Rheumatology Division Directors Task Force
2014-15	Member, American College of Rheumatology Finance Committee
2015-16	President-Elect, International Complement Society
2015-18	Member, NIAMS Advisory Council
2015-18	Chair, American College of Rheumatology Division Directors Special Committee
2015-16	Chair, Accelerating Medicines Partnership RA/SLE National Leadership Council Executive Committee
2017-18	President, International Complement Society
2019-21	Past-President, International Complement Society
2017-18	Lupus Research Alliance Working Group on FDA Strategy
2018	Lupus Research Alliance Strategic Planning Committee
2018-19	Member, American College of Rheumatology Board of Directors
2018-21	Lupus Research Alliance LUCIN Drug Candidate Vetting Committee
2019-21	Vice President, ACR Rheumatology Research Foundation
2019-21	American College of Rheumatology Executive Committee ad hoc member
2019-20	NIAMS AMP Lessons Learned Working Group
2019-21	Member, American College of Rheumatology Committee on Nominations
2021-22	Member, ACR Rheumatology Research Foundation Strategic Planning Task Force
2021-	Member, Arthritis Foundation Expert Working Group on Rheumatoid Arthritis
2021-23	President, ACR Rheumatology Research Foundation
2021-23	Member, American College of Rheumatology Executive Committee
2023-24	Member, ACR/ARP/RRF Volunteer Development Task Force
2023-	Chair, ACR Rheumatology Research Foundation Leadership Development Council
2024-	Member External Advisory Committee, Colton Center for Autoimmunity New York University Grossman School of Medicine

UNIVERSITY ACTIVITIES:

1996	Dean's Committee on Technology Transfer, UCSOM
1996-2001	Dean's Hughes Research Review Committee

1998-2005	Advisory Committee – Dean’s Distinguished Seminar Series
2002-04	Member and Chair, Dept of Medicine Space Committee
2000-05	Advisory Committee Member and Chair – Dean’s Distinguished Seminar Series
2007-10	Member, University of Colorado Committee on University Discoveries
2016-17	Chair, Search Committee, HI ³ Autoimmunity Program Director
2018-2020	CU Innovations/SPARK Program Liaison
2023-24	Member, CU President’s Innovation and Entrepreneurial (I&E) Working Group on Recruiting & Retaining Top I&E Talent: Promotion and Tenure

DEPARTMENTAL ACTIVITIES:

1990-92	Admissions Committee, Division of Biology and Biomedical Sciences, Washington University School of Medicine
1994-	Member, Immunology Program, UCSOM
1994-96	Seminar Series Committee, Department of Immunology, UCSOM
1994-97	Ph.D. in Clinical Sciences Program Development, Department of Medicine, UCSOM
1999-2006	Member, Executive and Admissions Committees, Ph.D. in Clinical Sciences Program, UCSOM
2000-	Member, Interdepartment Biomedical Sciences Program, UCSOM
2001-	Member, Structural Biology Program, UCSOM
2004-	Member, Reproductive Sciences Program, UCSOM
2006-	Member, Molecular Biology Program, UCSOM
2014-2015	Chair, Biomedical Informatics Division Head Search Committee

CLINICAL ACTIVITIES (Washington University, 1987-93):

1987-93	One half-day outpatient rheumatology teaching clinic/week, Barnes Hospital
1987-93	Rheumatology inpatient consultation service attending, Barnes Hospital (one month/year)
1987-93	Medicine service attending, Barnes Hospital (six weeks/year)

CLINICAL ACTIVITIES (UCSOM, 1993-present):

1995-96	One half-day outpatient rheumatology clinic/week, Denver Health and Hospitals
1995-2009	Rheumatology inpatient consultation service attending, University of Colorado Hospital (2-3 months/year)
2000-09	Fellows outpatient training clinic, University of Colorado Hospital (one half-day per week)

FORMAL TEACHING ACTIVITIES:

1986-	Clinical Translational Rheumatology instruction for
-------	---

	residents, fellows and medical students
1987-2009	Rheumatology Pathophysiology Course instructor
1993	Coursemaster, Molecular Mechanisms of Disease, Immunology Program, Washington University School of Medicine
1994-2009	“Complement, Innate Immunity and the Immune Response” lectures - in IMMU 7662/7663/7664 - Immune Mechanisms, Interdepartmental Immunology Program, UCHSC
1996-97	Coursemaster, IMMU 7664 - Immune Mechanisms, Interdepartmental Immunology Program, UCHSC
1998	“Methods and Presentation of Journal Article Reviews”, Interdepartment Biomedical Sciences Program
2000-	“Complement” and “B Cells” lecture – Rheumatology Fellows Lectures
2005-09	“Immunopathology/Autoimmunity Secondary to Infection” lecture - in MICB 7704 - Host Response to Infectious Disease, Microbiology Program, UCSOM
2011-2017	“Autoimmunity: Basic Concepts of Disease and Rheumatoid Arthritis as an Example” lecture – in IDPT 7646 - Tissue Biology and Disease Mechanisms, UCSOM
2025	“Microbial (and Other) Environmental Drivers of Rheumatoid Arthritis: What is the Evidence?” - in EPID 6655 - Evidence and Methods Link between Infectious and Chronic Disease

COMMUNITY ACTIVITIES:

1994-2008	Member, Board of Directors, Rocky Mountain Chapter, Arthritis Foundation
1996-2005	Executive Committee of the Board of Directors, Rocky Mountain Chapter, Arthritis Foundation
1997-2000	Chair, Medical and Education Committee, Rocky Mountain Chapter, Arthritis Foundation
1998-2000	Secretary, Rocky Mountain Chapter, Arthritis Foundation
1999-2001	Member, Colorado Arthritis Advisory Committee
2000-02	House of Delegates, National Arthritis Foundation
2000-02	Chair-Elect, Rocky Mountain Chapter, Arthritis Foundation
2002-03	Chair, Rocky Mountain Chapter, Arthritis Foundation
2003-05	Chair, Board Development Committee, Rocky Mountain Chapter, Arthritis Foundation

COMMERCIAL CONSULTATION (RECURRING):

1991-92	Monsanto Corporation, St. Louis, MO
1996-98	Amgen, Boulder, CO
2011-13	Alexion Pharmaceuticals, Cheshire, CT
2012-2014	Ignitya, Inc., La Jolla, CA

2015-2016	Padlock Therapeutics, Inc., Cambridge, MA
2015-2019	Janssen Research and Development
2016-2019	Amgen Data Sharing Independent Review Panel, Thousand Oaks, CA
2017-	AdMIRx, Inc./Q32 Bio, Waltham, MA
2018-2019	Celgene, Inc., Boston, MA
2018-2019	BMS, Inc., Princeton, NJ

OTHER:

1987-90	Director, Antinuclear Antibody Laboratory, Barnes Hospital, St. Louis, MO
1998	Co-founder, Touch of Life Technologies (ToLTech), Denver, CO
1998-	Member, Board of Directors, ToLTech, Denver, CO
2004-2016	Director, Rheumatology Clinical Laboratory, University of Colorado School of Medicine, Denver, CO
2004	Co-founder, Taligen Therapeutics, Denver, CO
2004-2011	Chief Scientific Officer, Taligen Therapeutics, Denver, CO and Cambridge, MA
2017	Co-founder, AdMIRx, Inc./Q32 Bio, Aurora, CO and Cambridge, MA
2018-2020	Member, Board of Directors, AdMIRx Inc./Q32 Bio, Cambridge, MA
2019-	Co-Chair, Scientific Advisory Board, Q32 Bio, Waltham, MA

PAST TRAINEES:

Predoctoral level (years, degree, research award(s) and current position):

- 1) Karen Makar, Ph.D. (Immunology Ph.D. Program)
1994-99
B.S., Occidental College, 1993
Deputy Director, Global Health Discovery Collaboratory, Bill & Melinda Gates Foundation
Seattle, WA
- 2) Kristine A. Kuhn, MD/PhD (MSTP Program, UCHSC)
2002-2007
B.S., University of Kansas
ACR Rheumatology Research Foundation Physician Scientist Development Grant Awardee, NIH K08
and R01 Awardee, Boettcher Foundation Scholar
Division Head of Rheumatology
Professor of Medicine, University of Colorado School of Medicine
Aurora, CO
- 3) James Kovacs, Ph.D. (Structural Biology Program, UCSOM)
2006-2010
B.A., Goshen College
M.S., University of Colorado at Boulder
American Heart Association Pre-Doctoral Trainee Award
Assistant Professor, University of Colorado Colorado Springs, CO
- 4) Kristen M. (Nordick) Cordova, Ph.D. (Molecular Biology Program, UCSOM)

2006-2012
B.S., Metropolitan State College of Denver
Medical Writer, Oncology Resource Group, Palo Alto, CA

- 5) Van Willis (Molecular Biology Program, UCSOM)
2008-2012
B.S., University of Utah
Senior Scientific Communications Analyst, Inari Medical
Salt Lake City, UT
- 6) Rosa Rodriguez (MD/Masters Program, UCSOM)
2013-2014
Staff Physician, Veterans Administration Medical Center, University of Miami School of Medicine
- 7) Alexandra Antonioli (MD/PhD Program, UCSOM)
2011-2019
B.S., Yale University
Private Practice, Adjunct Faculty University of Texas Southwestern Medical Center

Postdoctoral level (years, degree, research award(s) and current position):

- 1) Deborah Parks, M.D.
1987-89
M.D., University of Kentucky School of Medicine, 1983
Clinical Professor of Medicine, Washington University Sch. of Medicine, St. Louis, MO
- 2) Elizabeth Rayhel, Ph.D.
1988-90
Ph.D., Indiana State University, 1988
Instructor, Missouri Baptist College, St. Louis, MO
- 3) Jean-Claude Carel, M.D.
1989-91
M.D., Faculte de Medicine, Paris-Ouest, 1982
Professor and Department Chair Pediatric Endocrinology, INSERM U342, Université Paris Hopital Robert-Debré, Paris, France
- 4) Ernesto Levy, M.D.
1989-92
M.D., University of Buenos Aires, 1985
Private Practice
- 5) Hector Molina, M.D.
1989-93
M.D., University of Puerto Rico School of Medicine, 1985
NIH R01 Awardee
Associate Professor of Medicine, Washington University School of Med, St. Louis, MO
- 6) Christine Pham, M.D.
1990-1993
M.D., University of Florida College of Medicine, 1985
NIH R01 Awardee
Professor of Medicine, Division Head of Rheumatology
Washington University School of Med, St. Louis, MO
- 7) Susan Jacobi, M.D.
1990-92
M.D., University of Iowa School of Medicine, 1986
Private Practice

- 8) Sharon Foley, M.D.
1991-93
M.D., University of Nebraska Medical School, 1986
Private Practice
- 9) Siobhan O'Connor, M.D.
1991-93
M.D., University of Texas, Houston, 1987
Senior Medical Officer
Office of the Director, Centers for Disease Control, Atlanta, GA
- 10) Yuko Kozono, Ph.D.
1993-96
Ph.D., Osaka University, 1987
Research Scientist, Science University of Tokyo, Chiba, Japan
- 11) Susan Tiegs, M.D.
1993-97
M.D., Rush Medical School, 1981
Private Practice
- 12) Joel Guthridge, Ph.D.
1993-99
Ph.D., University of Kentucky, 1992
Director, Translational Informatics & Clinical Research Resources
Associate Member, Oklahoma Medical Research Foundation, Oklahoma City, OK
- 13) Kevin Marchbank, Ph.D.
1997-99
Ph.D., University of Wales College of Medicine, 1997
Wellcome International Prize Travelling Research Fellowship Awardee
Wellcome Career Development Award Recipient, 2002
Professor, Institute of Human Genetics, Newcastle University, Newcastle-upon-tyne, UK
- 14) Tim Nichols, Ph.D.
1994-2000
Ph.D., Chicago Medical School, 1994
National Arthritis Foundation Postdoctoral Fellowship Awardee
Senior Manager, Pfizer, Inc. San Diego, CA
- 15) Susan Boackle, M.D.
1996-2000
M.D., University of Alabama School of Medicine, 1989
Smyth Research Fellowship Awardee, Rocky Mountain Chapter of the Arthritis Foundation, NIH K08, R01, R21 Awardee, Professor of Medicine
Private Practice
- 16) Daniela Ulgiati, Ph.D.
1998-2001
Ph.D., University of Western Australia
National Arthritis Foundation Postdoctoral Fellowship Awardee
Senior Lecturer and Associate Dean, University of Western Australia
- 17) Darcy S. Majka, M.D.
2001-2003
M.D., University of Nebraska School of Medicine, 1997
ACR REF Physician Scientist Development Awardee
NIH K12, K23, R01, R21 Awardee

Physician, Division of Rheumatology, Northwestern University School of Medicine Chicago, IL

- 18) Joshua M. Thurman, M.D.
2001-2003
M.D., University of Chicago Pritzker School of Medicine, 1997
Postdoctoral Fellowship American Society of Nephrology, NIH K08, R21, R01 Awardee
Temple Hoyne Buell and National Kidney Foundation Endowed Chair
Professor of Medicine, Univ. of Colorado Denver School of Medicine
Denver, CO
- 19) Elizabeth D. Ferucci, M.D.
2002-2003
M.D., New York University School of Medicine, 1997
Medical Research Associate, Alaska Native Tribal Health Consortium, Anchorage, AK
Affiliate Associate Professor, Univ. of Washington School of Medicine
- 20) Kevin D. Deane, M.D., Ph.D.
2002-2004
M.D., Loma Linda University School of Medicine, 1997
NIH K-23 Awardee, ACR Research and Education Foundation Within Our Reach Awardee
Professor of Medicine, Univ. of Colorado School of Medicine
Arend Professor of Rheumatology
Denver, CO
- 21) Taras Lyubchenko, Ph.D.
2001-2007
Ph.D., National T. Shevchenko University, 2000
Arthritis National Research Foundation Awardee, NIH K01 Awardee
Associate Professor, National Jewish Health
Denver, CO
- 22) Pendleton B. Wickersham, M.D.
2004-2006
M.D., Baylor College of Medicine, 2000
Private Practice
- 23) Damian Kraus, Ph.D.
1997-2007
Ph.D., University of New Mexico, 1997
National Arthritis Foundation Postdoctoral Fellowship Awardee
Research Scientist
Denver, CO
- 24) Jonathan P. Hannan, Ph.D.
2000-2008
Ph.D., University of East Anglia, 2000
Research Scientist
Denver, CO
- 25) Rengasamy Asokan, Ph.D.
2000-2008
Ph.D., University of Madras, 1997
Research Scientist
Denver, CO
- 26) Liudmila Kulik, Ph.D.
2000-2008
Ph.D., Ovchinnikov Institute of Bioorganic Chemistry, 1991

Research Associate Professor, University of Colorado School of Medicine
Denver, CO

- 27) Alison Gizinski, M.D.
2005-2008
M.D., University of Washington School of Medicine, 2001
ACR REF Physician Scientist Development Award
Assistant Professor, Emory University School of Medicine
Atlanta, GA
- 28) Cassy Cozine, Ph.D.
2006-2008
Ph.D., University of Iowa, 2006
Assistant Professor, Coe College
Cedar Rapids, IA
- 29) Anne M. Lynch, MB, BCh, MSPH, DObst
2004-2010
M.D., University College Dublin Medical School, 1979
NIH K23 Awardee
Professor of Ophthalmology, Univ. of Colorado School of Medicine
Denver, CO
- 30) Jennifer Kinslow, PhD
2012-2016
Ph.D., University of Colorado Department of Immunology
Research Associate III, Loyola University School of Medicine
Chicago, IL
- 31) Heather Berens, M.D., Ph.D.
2017-2019
M.D./Ph.D., University of Colorado School of Medicine
Medical Leave
Private Practice
- 32) Sabrina Fechtner, Ph.D.
2019-2022
Ph.D., Washington State University
Research Scientist, Athira Pharma
Seattle, WA

CURRENT TRAINEES:

Pre-doctoral students:

1)

Postdoctoral level:

1)

Visiting Scientists:

1)

VISITING SCIENTISTSj:

- 1) Hee Jung Kang, M.D.
1998-99

M.D., Seoul National University College of Medicine
Director, Clinical Immunology Laboratory, Seoul National University College of Medicine

- 2) Yuko Okamoto, M.D.
2016-2019
Assistant Professor, Tokyo Women's Medical University
- 3) Hyoun-Ah Kim, M.D., Ph.D.
2019-2020
Associate Professor, Department of Rheumatology
Ajou University School of Medicine, Suwon, Korea

CURRENT INDIVIDUAL RESEARCH SUPPORT:

1. Source: NIH R01 R01DK138960
PI: V. Michael Holers, M.D. / Joshua M. Thurman, M.D. (Multiple PI)
Title: Role of the Factor H Related Proteins in Kidney Disease
Amount: \$3,145,297 (3/1/24-2/28/29) total direct costs
2. Source: NIH P30 AR079369
PI: V. Michael Holers, M.D.
Title: Center for Mucosal Immunobiology and Rheumatic Disease Pathogenesis
Amount: \$2,000,000 (10/1/2021 to 9/30/26) total direct costs
3. Source: NIH R01 AR051749
PI: V. Michael Holers, M.D.
Title: Complement in the pathogenesis of autoimmune arthritis
Amount: \$1,500,000 (9/1/2020 to 12/31/25) total direct costs
4. Source: NIH R01 DK125823
PI: V. Michael Holers, M.D. / Joshua M. Thurman, M.D. (Multiple PI)
Title: Novel therapeutic approaches for lupus nephritis
Amount: \$1,425,000 (7/1/20-6/30/25)
5. Source: Allen Institute for Immunology
PI: Kevin. D. Deane, M.D.,Ph.D. / V. Michael Holers, M.D. (Co-PI)
Title: Collaborative Research Agreement
Amount: \$3,200,000 (6/1/19-12/31/25) total direct costs
6. Source: Smyth Professorship in Rheumatology
PI: V. Michael Holers, M.D.
Title: Endowment to the University of Colorado Denver
Division of Rheumatology

PRIOR INDIVIDUAL RESEARCH SUPPORT:

1. Source: Howard Hughes Medical Institute, Assistant Investigator
PI: V. Michael Holers, M.D.
Title: Analysis of complement receptors and regulatory proteins
Amount: \$2,500,000 (7/1/87 to 6/30/93) total direct costs
2. Source: Arthritis Foundation Arthritis Investigator Award
PI: V. Michael Holers, M.D.
Title: Molecular characterization of the fibronectin receptor of human phagocytes
Amount: \$113,000 (7/1/88 to 6/30/91) total direct costs
3. Source: NIH R01 CA53615
PI: V. Michael Holers, M.D.
Title: Analysis of C3d/EBV receptor (CR2) ligand binding sites
Amount: \$2,000,000 (7/1/91 to 6/30/07) total direct costs

4. Source: Arthritis Foundation Biomedical Sciences Grant
PI: V. Michael Holers, M.D.
Title: Complement inhibitors and receptors in models of SLE
Amount: \$208,000 (7/1/93 to 6/30/96) total direct costs

5. Source: NIH R01 AI31105
PI: V. Michael Holers, M.D.
Title: Mouse membrane RCA proteins in the immune response
Amount: \$3,000,000 (6/1/93 to 5/31/09) total direct costs

6. Source: Arthritis Foundation Biomedical Sciences Grant
"Robert Wood Johnson, Jr. Biomedical Sciences Grant" Award
PI: V. Michael Holers, M.D.
Title: Analysis of an apoptotic defect in NZB mice
Amount: \$208,350 (7/1/97 to 6/30/00) total direct costs

7. Source: Juvenile Diabetes Foundation International
PI: V. Michael Holers, M.D.
Title: Manipulation of complement activities as a novel therapeutic strategy for autoimmune IDDM
Amount: \$181,800 (6/1/99 to 5/31/01) total direct costs

8. Source: Alliance for Lupus Research Project Grant
PI: Jane E. Salmon, M.D. (Holers as Co-P.I.)
Title: Complement activation as a mediator of anti-phospholipid antibody induced fetal loss
Amount: \$231,000 (3/1/01 to 2/28/03) total direct costs

9. Source: NIH U19 AI46374, Autoimmunity Center of Excellence (B. Kotzin, P.I.)
PI: V. Michael Holers, M.D. (P.I. of Clinical Project #2)
Title: Anti-C5 therapy of lupus nephritis
Amount: 462,240 (9/1/99 to 8/31/03) total direct costs Project #2

10. Source: NIH R01 AI42772
PI: David R. Karp, M.D. (subcontract to Holers)
Title: Gamma glutamyl transpeptidase and lymphocyte activation
Amount: \$85,824 (4/1/99 to 3/31/03) total direct costs

11. Source: NIH R01 DK55357
PI: Richard J. Quigg, M.D. (subcontract to Holers)
Title: Pathogenic role of the complement system in murine lupus
Amount: \$318,549 (7/1/99 to 6/30/03) total direct costs

12. Source: NIH R01 AI47469
PI: Gary S. Gilkeson, M.D. (subcontract to Holers)
Title: Role of complement factor B in the pathogenesis of SLE
Amount: \$250,000 (4/1/00 to 3/31/05) total direct costs

13. Source: Alliance for Lupus Research Project Grant
PI: Jane E. Salmon, M.D. (Holers as Co-P.I.)
Title: Complement activation as a mediator of anti-phospholipid antibody induced fetal loss
Amount: \$325,000 (3/1/03 to 2/28/05) total direct costs

14. Source: NIH R21 AI61479
PI: V. Michael Holers, M.D.
Title: Evolution of autoimmunity in rheumatoid arthritis
Amount: \$250,000 (7/1/04 to 6/30/06) total direct costs

15. Source: NIH U19 AI50864 Cooperative Study Group in Autoimmune Disease Prevention (G. Eisenbarth, P.I.)
PI: V. Michael Holers, M.D. (P.I. of Project #2)
Title: RA associated autoimmunity in high risk populations
Amount: (\$980,000 (9/1/01 to 6/30/06) total direct costs
16. Source: US Army Medical Research and Materiel Command
PI: V. Michael Holers, M.D.
Title: Liposomes and liposome-annexin complexes as adjunctive therapy for reperfusion injury and hemorrhagic shock
Amount: \$80,000 (4/10/06 to 4/9/07) total direct costs
17. Source: Lupus Research Institute
PI: V. Michael Holers, M.D.
Title: Complement receptor 2 as a DNA receptor
Amount: \$215,000 (5/1/04 to 4/30/07) total direct costs
18. Source: NIH R01 AI55007
PI: Jane E. Salmon, M.D. (subcontract to Holers)
Title: Complement as a mediator of recurrent miscarriages
Amount: \$380,000 (12/15/03 to 11/30/08) total direct costs
19. Source: NIH U19 AI46374, Autoimmunity Center of Excellence (ACE)
PI: V. Michael Holers, M.D.
Title: Denver Autoimmunity Center of Excellence
Amount: \$2,950,000 (10/1/03 to 3/31/09) total direct costs to Denver ACE
20. Source: NIH U19 AI46374, Autoimmunity Center of Excellence (V. M. Holers, P.I.)
PI: V. Michael Holers, M.D. (P.I. of Basic Project #2)
Title: Complement in the immunopathogenesis of autoimmune diabetes
Amount: \$675,000 (10/1/03 to 3/31/09) total direct costs Project #2
21. Source: Sandler Program for Asthma Research Senior Investigator Award
PI: V. Michael Holers, M.D.
Title: Mechanisms of complement mediated inflammation in asthma
Amount: \$750,000 (7/1/06 to 6/30/09) total direct costs
22. Source: American College of Rheumatology Research and Education Foundation Within Our Research Grant
PI: V. Michael Holers, M.D. (sub-contract)
Title: Inhibition of PAD function as a novel treatment strategy for rheumatoid arthritis
Amount: \$200,000 (7/1/08 to 6/30/10) total direct costs
23. Source: NIH T32 AR07534
PI: V. Michael Holers, M.D.
Title: Research Training in Rheumatology
Amount: \$1,565,000 (7/1/01 to 6/30/11) total direct costs
24. Source: Taligen Therapeutics
PI: V. Michael Holers, M.D.
Title: Modulators of CR2-C3d interactions
Amount: \$450,000 (7/1/09 to 6/30/11) total direct costs
25. Source: NIH U19 AI50864 Cooperative Study Group in Autoimmune Disease Prevention (G. Eisenbarth, P.I.)
PI: V. Michael Holers, M.D. (P.I. of Project #1)
Title: Rheumatoid arthritis: biomarkers of progression from autoimmunity to disease

- Amount: \$1,150,000 (9/15/06 to 8/31/12) total direct costs Project #2
26. Source: NIH R01 AR051394
 PI: V. Michael Holers, M.D.
 Title: RA-related autoantibodies in healthy FDR of RA patients
 Amount: \$2,250,000 (7/18/05 to 6/30/12) total direct costs
27. Source: Beckman Institute for Macular Research
 PI: V. Michael Holers, M.D.
 Title: Development of a non-invasive method in progressive age-related macular degeneration to detect and quantitate disease-associated complement C3 activation fragments
 Amount: \$100,000 (7/1/11 to 6/30/12) total direct costs
28. Source: GlaxoSmithKline
 PI: V. Michael Holers, M.D.
 Title: PAD inhibition in collagen-induced arthritis
 Amount: \$75,000 (8/1/11-6/30/12) total direct costs
29. Source: Alnylam, Inc.
 PI: V. Michael Holers, M.D.
 Title: siRNA treatment of CAIA
 Amount: \$42,000 (12/1/13-2/28/14) total direct costs
30. Source: NIH R01 AR051749
 PI: V. Michael Holers, M.D.
 Title: Complement in the pathogenesis of autoimmune arthritis
 Amount: \$1,250,000 (12/1/09 to 11/30/14) total direct costs
31. Source: American College of Rheumatology
 Rheumatology Research Foundation
 PI: V. Michael Holers, M.D.
 Title: Pathogenic humoral autoimmunity in the transition to clinically apparent rheumatoid arthritis
 Amount: \$370,000 (7/1/12 to 6/30/14) total direct costs
32. Source: Arnold and Mabel Beckman Foundation
 PI: V. Michael Holers, M.D.
 Title: Inhibition of complement factor H related protein de-regulatory activity as a therapeutic strategy in age-related macular degeneration: Proof of concept in a murine model
 Amount: \$100,000 (07/01/14-06/30/15) total direct costs
33. Source: NIH R21 AI105717
 PI: V. Michael Holers, M.D.
 Title: Disconnecting CR2/CD21 from its C3d ligand to ameliorate lupus
 Amount: \$275,000 (04/01/13-03/31/15) total direct costs
34. Source: Target Identification in Lupus, Alliance for Lupus Research
 PI: V. Michael Holers, M.D.
 Title: CR2:C3d receptor:ligand interaction as a therapeutic target in lupus
 Amount: \$528,909 (02/01/13-01/31/16) total direct costs
35. Source: NIH U01 AI101981
 PI: V. Michael Holers, M.D.
 Title: CSGADP: Early targets for antigen specific tolerance induction in preclinical rheumatoid arthritis
 Amount: \$2,150,000 (7/5/12 to 6/30/17) total direct costs

36. Source: CO OEDIT
PI: V. Michael Holers, M.D.
Title: Novel tissue-targeted complement therapeutic agents for treatment of autoimmune and inflammatory diseases
Amount: \$125,000 (07/01/16 – 04/30/18)
37. Source: NIH R01 DK102912
PI: Steve Tomlinson, PhD. (subcontract to Holers)
Title: Antibodies and complement in ischemia reperfusion injury and regeneration
Amount: \$460,000 (7/1/15 to 6/30/19) total direct costs
38. Source: NIH UM2 AR067678
PI: Paul J. Utz, M.D. and V. Michael Holers, M.D. (Co-PI)
Title: Accelerating Medicines Partnership RA/Lupus Leadership Center
Amount: \$125,000 (9/24/14 to 9/23/19) total sub-contract direct costs
39. Source: NIH R21 NS097653
PI: Steve Tomlinson, PhD. (subcontract to Holers)
Title: Complement inhibitors targeted to the ischemic brain for the treatment of stroke
Amount: \$55,000 (4/15/17-3/31/20) total subcontract direct costs
40. Source: Pfizer ASPIRE Program
PI: V. Michael Holers, M.D.
Title: Causal inter-relationships between peripheral immune dysregulation and mucosal inflammation in subjects at-risk for future rheumatoid arthritis
Amount: \$152,604 (6/28/18-12/31/20) total direct costs
41. Source: AdMIRx
PI: V. Michael Holers, M.D.
Title: SRA-001
Amount: \$337,000 (5/7/18-6/30/21) total direct costs
42. Source: Janssen Research and Development, LLC
PI: Kevin D. Deane, M.D., Ph.D. (Holers is Co-PI)
Title: Targeting immune responses for prevention of RA (TIP-RA)
Amount: \$2,560,000 (5/1/16-12/31/20)
43. Source: NIH UH2 AR067681
PI: V. Michael Holers, M.D.
Title: Evolving adaptive and effector mechanisms from pre-RA through established disease
Amount: \$1,500,000 (9/24/14 to 9/23/16) total direct costs (additional annual request funded to 9/23/2021)
44. Source: NIH U01 AI130830
PI: John Harley, M.D., Ph.D. (subcontract to Holers)
Title: Exploration of Cytomegalovirus as compared to Epstein-Barr Virus infection as viral environmental factors that drive initial loss of tolerance and pathogenesis in populations at-risk for future RA
Amount: \$118,094 (12/15/20-12/14/21) total direct costs
45. Source: NIH U01 AI101981
PI: V. Michael Holers, M.D.
Title: CSGADP: Early targets for antigen specific tolerance induction in preclinical rheumatoid arthritis
Amount: \$4,900,000 (7/1/17 to 6/30/22) total direct costs
46. Source: NIH T32 AR07534
PI: V. Michael Holers, M.D.

- Title: Research Training in Rheumatology
Amount: \$2,000,000 (7/1/17 to 6/30/22) total direct costs
47. Source: NIH UM1 AI110503
PI: V. Michael Holers, M.D.
Title: Colorado Autoimmunity Center of Excellence
Amount: \$350,000 (5/1/14 to 4/30/19 total direct cost; additional annual clinical trials support funded for StopRA to 10/31/23)
48. Source: NIH U01 HL152405
PI: Richard Duke, Ph.D. (Co-Investigator Holers)
Title: Colorado AMC REACH Hub
Amount: \$999,434 (9/23/19-8/31/23) total direct costs
49. Source: NIH R01 EY032456
PI: Anne M. Lynch, M.D., M.S.P.H.
Title: Biomarkers of systemic inflammation in intermediate age-related macular degeneration
Amount: \$1,632,000 (5/1/21-4/30/25) total direct costs
50. Source: NIH T3207534
PI: V. Michael Holers, M.D (PI changed 7/1/23 to Kristine A. Kuhn, M.D./Ph.D.)
Title: Research Training in Rheumatology
Amount: \$1,850,000 (9-1-22 to 8-31-27) total direct costs

RESEARCH INTERESTS:

- B lymphocyte activation and development
- Role of complement in inflammation and autoimmunity
- Complement receptor and regulatory protein molecular structure
- Complement therapeutic strategies and optimization
- Transcriptional regulation in B lymphocyte development
- Computer-based haptic simulations in rheumatology education
- Development of pre-clinical autoimmunity in rheumatoid arthritis
- Etiopathogenesis and prevention of rheumatoid arthritis

PATENTS (issued):

1. "3-Dimensional Structure of Complement Receptor Type 2 and Uses Thereof", U.S. Patent 6,820,011, November 16, 2004
2. "Targeting complement factor H for treatment of diseases", U.S. Patent 7,759,304, July 20, 2010
3. "Anti-factor B antibodies" U.S. Patent 7,999,082, August 16, 2011
4. "Humaneered anti-factor B antibody" U.S. Patent 7,964,705, June 21, 2011
5. "Complement receptor 2 targeted complement modulators", U.S. Patent 8,007,804, August 30, 2011
6. "Biomarkers for rheumatoid arthritis", European Patent 2158326, June 20, 2012
7. "Inhibition of factor B, the alternative complement pathway, and methods related thereto" U.S. Patent 8652475, February 18, 2014
8. "Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles" U.S. Patent 8,840,868, September 23, 2014
9. "Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions" U.S. Patent 8,911,733, December 14, 2014
10. "Targeting complement factor H for treatment of diseases" U.S. Patent 9,212,212, December 15, 2015

11. "Anti-C3d antibody conjugates and methods of detecting complement activation" U.S. Patent 9,259,488, Feb 16, 2016
12. "Antibodies to the C3d fragment of complement component 3" U.S. Patent 9,815,890, November 14, 2017
13. "Modulating the alternative complement pathway" U.S. Patent 10,233,235, March 18, 2019
14. "Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis" U.S Patent 10,239,937, March 26, 2019
15. "Antibody-siRNA conjugates and uses thereof" U.S. Patent 10,278,986, May 7, 2019

h-INDEX: 90

PEER REVIEWED PUBLICATIONS:

1. Rosenberg, N. L., Lacy, J. R., Kennaugh, R. C., **Holers, V. M.**, Neville, H. E., and Kotzin, B. L. 1985. Treatment of refractory chronic demyelinating polyneuropathy with lymphoid irradiation. Muscle and Nerve 8:223-232.
2. **Holers, V. M.**, and Kotzin, B. L. 1985. Human peripheral blood monocytes display surface antigens recognized by monoclonal antinuclear antibodies. J. Clin. Invest. 76:991-998.
3. Seya, T., **Holers, V. M.**, and Atkinson, J. P. 1985. Purification and functional analysis of polymorphic variants of CR1. J. Immunol. 135:2661-2667.
4. **Holers, V. M.**, Seya, T., Brown, E., O'Shea, J. J., and Atkinson, J. P. 1986. Structural and functional studies on the human C3b/C4b receptor (CR1) purified by affinity chromatography using a monoclonal antibody. Complement 3:63-78.
5. Yu, G., **Holers, V. M.**, Seya, T., Ballard, L., and Atkinson, J. P. 1986. Structural and functional characterization of a C3-binding membrane protein of human platelets. J. Clin. Invest. 78:494-501.
6. Nickells, M., Seya, T., **Holers, V. M.**, McCourt, D., Leykam, J., and Atkinson, J. P. 1986. Analysis of C3b/C4b receptor (CR1) polymorphic variants by tryptic peptide mapping. Mol. Immunol. 23:661-668.
7. VanDyne, S., **Holers, V. M.**, Lublin, D. M., and Atkinson, J. P. 1987. The polymorphism of the C3b/C4b receptor in the normal population and in patients with systemic lupus erythematosus Clin. Exp. Immunol. 68:570-579.
8. **Holers, V. M.**, Chaplin, D. D., Leykam, J. F., Gruner, B. A., and Atkinson, J. P. 1987. A human C3b/C4b receptor (CR1) poly A-mRNA polymorphism related to the CR1 allelic M_r polymorphism. Proc. Natl. Acad. Sci. 84:2459-2463.
9. Medof, M. E., Lublin, D. M., **Holers, V. M.**, Ayers, D. J., Atkinson, J. P., Getty, R. N., Leykam, J. F., and Tykocinski, M. L. 1987. Characterization of cDNAs coding for the complete sequence of decay accelerating factor of human complement. Proc. Natl. Acad. Sci. 84:2007-2011.
10. Lublin, D. M., Lemons, R. S., LeBeau, M. M., **Holers, V. M.**, Tykocinski, M. L., Medof, M. E., and Atkinson, J. P. 1987. The gene encoding Decay-Accelerating Factor (DAF) is located in the complement regulatory locus on the long arm of chromosome 1. J. Exp. Med. 165:1731-1735.
11. McNearney, T. A., Odell, C., **Holers, V. M.**, Spear, P. G. and Atkinson, J. P. 1987. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement mediated neutralization of viral infectivity. J. Exp. Med. 166:1525-1535.
12. Stafford, H. A., Tykocinski, M. L., Lublin, D. M., **Holers, V. M.**, Rose, W. F., Atkinson, J. P. and Medoff, M. E. 1987. Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells. Proc. Nat'l. Acad. Sci. 85:880-884.

13. Hourcade, D., Miesner, D. R., Atkinson, J. P., and **Holers, V. M.** 1988. Identification of an alternative polyadenylation site in the human C3b/C4b receptor (CR1) transcriptional unit and prediction of a secreted form. J. Exp. Med. 168:1255-1270.
14. Bora, N. S., Lublin, D. M., Kumar, B. V., Hockett, R. D., **Holers, V. M.**, and Atkinson, J. P. 1989. Structural gene for MCP maps to within 100 kB of the 3' end of the C3b/C4b receptor (CR1) gene. J. Exp. Med. 169:597-602.
15. Fujisaku, A., Harley, J. B., Frank, M. B., Gruner, B. A., Frazier, B., and **Holers, V. M.** 1989. Genomic organization and polymorphisms of the human C3d/Epstein-Barr Virus receptor (CR2). J. Biol. Chem. 264:2118-2125.
16. O'Dell, J. R., Steigerwald, J. C., Kennaugh, R. C., Hawkins, R., **Holers, V. M.**, and Kotzin, B. L. 1989. Lack of clinical benefit after treatment of systemic sclerosis with total lymphoidal irradiation. J. Rheum. 16:1050-1054.
17. **Holers, V. M.**, Ruff, T. G., Parks, D. L., McDonald, J. A., Ballard, L. L., and Brown, E. J. 1989. Molecular cloning of a murine fibronectin receptor and its expression during inflammation. J. Exp. Med. 169:1589-1605.
18. Carel, J.-C., Frazier, B., Ley, T. J., and **Holers, V.M.** 1989. Analysis of epitope expression and the functional repertoire of recombinant Complement Receptor 2 (CR2/CD21) in mouse and human cells. J. Immunol. 143:923-930.
19. Carel, J.-C., Myones, B. L., Frazier, B., and **Holers, V. M.** 1990. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization and viral infection. J. Biol. Chem. 265:12293-12299.
20. Hourcade, D., Post, T. W., **Holers, V. M.**, Lublin, D. M., and Atkinson, J. P. 1990. Polymorphisms of the Complement activation (RCA) gene cluster. Complement Inflammation 7:302-314.
21. Molina, H., Kinoshita, T., Inoue, K., Carel, J.-C., and **Holers, V.M.** 1990. A molecular and immunochemical characterization of mouse CR2: Evidence for a single gene model of mouse Complement Receptors 1 and 2. J. Immunol. 145:2974-2983.
22. Rayhel, E. J., Dehoff, M. H., and **Holers, V. M.** 1991. Characterization of the human CR2 promoter reveals sequence identities with promoters for other developmentally restricted B cell proteins. J. Immunol. 146:2021-2026.
23. Ballard, L. L., Brown, E. J., and **Holers, V. M.** 1991. Expression of the fibronectin receptor VLA-5 is regulated during human B cell differentiation and activation. Clin. Exp. Immunol. 84:336-346.
24. Carel, J.-C., **Holers, V. M.**, Chick, W. L., Littman, D., and Lacy, P. E. 1991. Expression of functional human complement receptor 2 (CR2, CD21, C3d/EBV receptor) on an insulinoma cell line induces tumor rejection but not diabetes in syngeneic rats. Diabetes 40:809-814.
25. Molina, H., Brenner, C., Jacobi, S., Gorka, J., Carel, J.-C., Kinoshita, T., and **Holers, V. M.** 1991. Analysis of Epstein-Barr Virus binding sites on Complement Receptor 2 using human-mouse chimeras and peptides. J. Biol. Chem. 266:12173-12179.
26. Secrist, H., **Holers, V. M.**, Egan, M., Nahm, M. H., Butch, A. W. and Peters, M. 1991. Induction of IL-4 and IL-6 in vitro: variation in signalling requirements and kinetics are dependent on the anatomic source of the responding mononuclear cells. Regional Immunol. 3:341-348.
27. Molina, H., Wong, W., Kinoshita, T., Brenner, C., Foley, S., and **Holers, V. M.** 1992. Distinct receptor and regulatory properties of recombinant mouse Complement Receptor 1 (CR1) and Crry, the two genetic homologs of human CR1. J. Exp. Med. 175:121-129.
28. Hourcade, D., Garcia, A. D., Post, T. W., Taillon-Miller, P., **Holers, V. M.**, Wagner, L. M., Bora, N. S. and Atkinson, J. P. 1992. Analysis of the Regulators of Complement Activation (RCA) gene cluster with yeast artificial chromosomes (YACs). Genomics 12:289-300.

29. Emlen, W., **Holers, V. M.**, Arend, W. P., and Kotzin, B. 1992. Regulation of nuclear antigen expression on the cell surface of human monocytes. J. Immunol. 148:3042-3048.
30. Levy, E., Tung, K., Ambrus, J., Kahl, L., White, G., and **Holers, V. M.** 1992. Complement Receptor 2 expression on a T cell subpopulation in normals and patients with Systemic Lupus Erythematosus: Expansion in a patient with active disease. Clin. Exp. Immunol. 90:235-244.
31. Foley, S., Li, B., Dehoff, M., Molina, H., and **Holers, V. M.** 1993. Mouse Crry/p65 is a regulator of the alternative pathway of complement activation. Eur. J. Immunol. 23:1381-1384
32. Li, B., Sallee, C., Dehoff, M., Foley, S., Molina, H., and **Holers, V. M.** 1993. Mouse Crry/p65: Characterization of mAbs and the tissue distribution of a functional homologue of human MCP and DAF. J. Immunol. 151:4295-4305.
33. **Holers, V. M.**, Hollis, G. F., Schwartz, B. D., Evans, R. J., Strauss-Schoenberger, J., Carel, J.-C., Barney, D. L., Li, B., Stafford-Hollis, J., and Lacy, P. E. 1993. Induction of peri-insulitis but not diabetes in islet transplants expressing a single foreign antigen: a multi-stage model of disease. J. Immunol. 151:5041-5052.
34. Aubry, J.-P., Pochon, S., Gauchat, J.-F., **Holers, V. M.**, Graber, P., Siegfried, C., and Bonnefoy, J.-Y. 1994. Mapping of the CD23 binding site on CD21. J. Immunol. 152:5806-5813.
35. Molina, H., Kinoshita, T., Webster, C. B., and **Holers, V. M.** 1994. Analysis of C3b/C3d binding sites and the factor I cofactor regions within mouse complement receptors 1 and 2. J. Immunol. 153:789-795.
36. Graham, I., Anderson, D. C., **Holers, V. M.**, and Brown, E. J. 1994. Complement receptor 3 (CR3, Mac-1, Integrin $\alpha_M\beta_2$, CD11b/CD18) is required for tyrosine phosphorylation of paxillin in adherent and non-adherent neutrophils. J. Cell Biol. 127:1139-1147.
37. Kim, Y. U., Kinoshita, T., Molina, H., Hourcade, D., Seya, T., Wagner, L. M., and **Holers, V. M.** 1995. Mouse complement regulatory protein Crry/p65 utilizes the specific mechanisms of both human decay-accelerating factor (DAF) and membrane cofactor protein (MCP). J. Exp. Med. 181:151-159.
38. Quigg, R. J., **Holers, V. M.**, Morgan, B. P., and Sneed, III, A. E. 1995. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J. Immunol. 154:3437-3443.
39. Molina, H., Perkins, S. J., Guthridge, J., Gorka, J., Kinoshita T., and **Holers, V. M.** 1995. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3: an initial model of ligand interaction with two linked SCR modules. J. Immunol. 154:5426-5435.
40. Kozono, Y., Duke, R. C., Schleicher, M., and **Holers, V. M.** 1995. Co-ligation of mouse complement receptors 1 and 2 with sIgM rescues splenic B cells and WEHI-231 cells from anti-sIgM-induced apoptosis. Eur. J. Immunol. 25:1013-1017.
41. Quigg, R. J., Morgan, B. P., **Holers, V. M.**, Adler, S., and Sneed, III, A. E. 1995. Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney Intl. 48:412-421.
42. Sima, M., Teitelbaum, S. L., **Holers, V. M.**, Ruzicka, C., Osmack, P., and Ross, F. P. 1995. Macrophage-colony-stimulating factor regulates expression of the integrins $\alpha_4\beta_1$ and $\alpha_5\beta_1$ by murine bone marrow macrophages. Proc. Natl. Acad. Sci. 92:5179-5183.
43. Quigg, R. J., and **Holers, V. M.** 1995. Characterization of rat complement receptors and regulatory proteins. CR2 and Crry are conserved while the C3b receptor of neutrophils and platelets is distinct from CR1. J. Immunol. 155:1481-1488.
44. Bouillie, S., Barel, M., Drane, P., Cassinat, B., Balbo, M., **Holers, V. M.**, and Frade, R. F. 1995. Epstein-Barr virus/C3d receptor (CR2,CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways. Eur. J. Immunol. 25:2661-2667.

45. Dunster, L. M., Schneider-Schaulies, J., Dehoff, M. H., **Holers, V. M.**, Schwartz-Albiez, R., and ter Meulen, V. 1995. Moesin, and not the murine functional homologue (Crry/p65) of human MCP (CD46), is involved in the entry of measles virus (strain Edmonston) into susceptible murine cell lines. J. Gen. Virol. 76:2085-2089.
46. Sawant-Mane, S., Piddlesden, S. J., Morgan, B. P., **Holers, V. M.**, and Koski, C. L. 1996. CD59 homologue regulates complement-dependent cytolysis of rat Schwann cells. J. Neuroimmunol. 69:63-71.
47. Molina, H., **Holers, V. M.**, Li, B., Fang, Y.-F., Mariathasan, S., Goellner, J., Strauss-Schoenberger, J., Karr, R. W., and Chaplin, D. D. 1996. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. 93:3357-3361.
48. Rogers, C. A., Gasque, P., Piddlesden, S.J., Okada, N., **Holers, V. M.**, and Morgan, B. P. 1996. Expression and function of membrane regulators of complement on rat astrocytes in culture. Immunology 88:153-161.
49. Kozono, Y., Kotzin, B. L., and **Holers, V. M.** 1996. Resting B cells from NZB mice demonstrate a defect in apoptosis induction following sIgM ligation. J. Immunol. 156:4498-4503.
50. Boackle, S. A., **Holers, V. M.**, and Karp, D. K. 1997. CD21 augments antigen presentation in immune individuals. Eur. J. Immunol. 27:122-130.
51. Alexander, J. J., He, C., Adler, S., **Holers, V. M.**, and Quigg, R. J. 1997. Characterization of C3 receptors on cultured rat glomerular endothelial cells. Kidney Intl. 51:1124-1132.
52. Kawamoto, Y., Kojima, K., Hitsumoto, Y., Okada, H., **Holers, V. M.**, and Miyama, A. 1997. Studies on the serum resistance of malaria-infected erythrocytes. Immunology 91:7-12.
53. Vigneau-Hermellin, M., Vitali, L., Tardivel, I., Rabaud, M, **Holers, V. M.**, and Carel, J.-C. 1997. Rejection of islets differing by a single antigen is dependent on donor MHC. Diabetes 46:765-769.
54. Quigg, R. J., Alexander, J. J., Lo, C. F., and **Holers, V. M.** 1997. Characterization of C3-binding proteins on mouse neutrophils and platelets. J. Immunol. 159:2438-2444.
55. Takahashi, K., Kozono, Y., Waldschmidt, T. J., Berthiaume, D., Quigg, R. J., Baron, A., and **Holers, V. M.** 1997. Mouse complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J. Immunol. 159:1557-1569.
56. Kearns-Jonker, M., Monell-Torrens, E., Abbasi, F., **Holers, V. M.**, Notkins, A. L., and Sigounas, G. 1997. EBV binds to lymphocytes of transgenic mice that express the human CR2 gene. Virus Research 50:85-94.
57. Makar, K. W., Pham, C., Dehoff, M., O'Connor, S., Jacobi, S., and **Holers, V. M.** 1998. An intronic silencer regulates B lymphocyte cell and stage specific expression of the human complement receptor type 2 (CR2,CD21) gene. J. Immunol. 160:1268-1278.
58. Kozono, Y., Abe, R., Kozono, H., Kelly, R. G., Azuma, T. and **Holers, V. M.** 1998. Crosslinking CD21/CD35 or CD19 rapidly increases both B7-1 and B7-2 expression on murine splenic B cells. J. Immunol. 160: 1565-1572.
59. Quigg, R. J., Kozono, Y., Berthiaume, D., Lim, A., Salant, D. J., Weinfeld, A., Griffin, P., Kremmer, E., and **Holers, V. M.** 1998. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J. Immunol. 160:4553-4560.
60. Fang, Y., Xu, C., **Holers, V. M.**, and Molina, H. 1998. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a normal antigen-specific IgG response. J. Immunol. 160:5273-5279.

61. Nichols, T. C., Guthridge, J. M., Karp, D. R., Molina, H., Fletcher, D. R., and **Holers, V. M.** 1998. γ -Glutamyl Transpeptidase, an ecto-enzyme regulator of intracellular redox potential, is a component of TM4 signal transduction complexes. Eur. J. Immunol. 28:4123-4129.
62. Boackle, S. A., Morris, M. A., **Holers, V. M.**, and Karp, D. R. 1998. Complement opsonization is required for presentation of immune complexes by resting peripheral blood B cells. J. Immunol. 161:6537-6543.
63. Quigg, R. J. He, C., Lim, A. Berthiaume, D., Alexander, J. J., Kraus, D., and **Holers, V. M.** 1998. Transgenic mice overexpressing the complement inhibitor Crry as a soluble protein are protected from antibody-induced glomerular injury. J. Exp Med. 188:1321-1331.
64. Nardin, A., Schlimgen, R., **Holers, V. M.**, and Taylor, R. P., 1999. A prototypic pathogen bound ex vivo to human erythrocyte complement receptor 1 via bispecific monoclonal antibody complexes is cleared to the liver in a mouse model. Eur. J. Immunol. 29:1581-1586.
65. Alexander, J. J., Lim, A., He, C., MacDonald, R. L., **Holers, V. M.**, and Quigg, R. J. 1999. Renal, central nervous system and pancreatic overexpression of recombinant soluble Crry in transgenic mice. A novel means of protection from complement-mediated injury. Immunopharmacology 42:245-254.
66. Henson, S. E., Nichols, T. C., **Holers, V. M.**, and Karp, D. R. 1999. The ectoenzyme gamma glutamyl transpeptidase regulates anti-proliferative effects of S-Nitrosoglutathione on human T and B lymphocytes. J. Immunol. 163:1845-1852.
67. Karp, D. K., Nichols, T. C., Oppenheimer-Marks, N., Brezinschek, R. I., and **Holers, V. M.** 1999. Gamma-glutamyl transpeptidase is upregulated on memory T lymphocytes. International Immunol. 11:1791-1800.
68. Davoust, N., Nataf, S., **Holers, V. M.**, and Barnum, S. R. 1999. Expression of the murine complement regulatory protein Crry by glial cells and neurons. Glia 27:162-170.
69. Davoust, N., Nataf, S., Reiman, R., **Holers, V. M.**, Campbell, I. L., and Barnum, S. R. 2000. CNS-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. J. Immunol. 163:6551-6556.
70. Watanabe, H., Garnier, G., Circolo, A., Wetsel, R. A., Ruiz, P., **Holers, V. M.**, Boackle, S. A., Colten, H. R., and Gilkeson, G. S. 2000. Modulation of renal disease and C3 consumption in MRL/lpr mice genetically deficient in factor B of the alternative complement pathway. J. Immunol. 164:786-794.
71. Cunningham, P., **Holers, V. M.**, Alexander, J. J., Guthridge, J. M., Carroll, M. C., and Quigg, R. J. 2000. Renal complement activation occurs with endotoxin administration, but is not responsible for the resultant acute renal failure. Kidney Intl. 58:1580-1587.
72. Xu, C., Mao, D., **Holers, V. M.**, Palanca, B., Cheng, A., and Molina, H. 2000. A critical role for the murine complement regulator Crry in fetomaternal tolerance. Science 287:498-501.
73. Marchbank, K. J., Watson, C. C., Ritsema, D. F., and **Holers, V. M.** 2000. Expression of complement receptor 2 (CR2/CD21) in *Cr2*^{-/-} mice restores humoral immune function. J. Immunol. 165:2354-2361.
74. Makar, K. W., Uligiati, D., Hagman, J., and **Holers, V. M.** 2001. A site in the complement receptor 2 (CR2/CD21) silencer is necessary for lineage specific transcriptional regulation. International Immunol. 13:657-664.
75. Schiller, B., Cunningham, P., Alexander, J. J., Couser, W. G., **Holers, V. M.**, and Quigg, R. J. 2001. Transgenic mice over-expressing soluble complement inhibitor Crry are protected from antibody induced acute renal failure. J. Am. Soc. Nephrol. 12:71-79.
76. Kaya, Z., Afanasyeva, M., Wang, Y., Dohman, K. M., Schlichting, J., Tretter, T., Fairweather, D., **Holers, V. M.**, and Rose, N. R. 2001. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nature Immunol. 2:739-745.

77. Szakonyi, G., Guthridge, J. M., Li, D., Young, K., **Holers, V. M.**, and Chen, X. S. 2001. Structure of complement receptor 2 in complex with its C3d ligand. Science 292:1725-1728.
78. Springall, T., Sheerin, N. S., Abe, K., **Holers, V. M.**, Wan, H., and Sacks, S. H. 2001. Epithelial secretion of C3 promotes colonization of the upper urinary tract by *Escherichia coli*. Nature Medicine 7:801-806.
79. Sekine, H., Reilly, C. M., Molano, I. D., Garnier, G., Circolo, A., Ruiz, P., **Holers, V. M.**, Boackle, S. A., and Gilkeson, G. S. 2001. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J. Immunol. 166:6444-6451.
80. Guthridge, J. M., Rakstang, J. K., Young, K. A., Hinshelwood, J., Aslam, M., Robertson, A., Gipson, M. G., Sarrias, M. and **Holers, V. M.** 2001. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg. Biochemistry 40:5931-5941.
81. Park, P., Haas, M., Cunningham, P. N., Alexander, J. J., Bao, L., Guthridge, J. M., Kraus D. M., **Holers, V. M.**, and Quigg, R. J. 2001. Inhibiting the complement system does not reduce injury in renal ischemia reperfusion. J. Am. Soc. Nephrol. 12:1383-1390.
82. Guthridge, J. M., Young, K., Gipson, M. G., Sarrias, M.-R., Szakonyi, G., Chen, X. S., Malaspina, A., Donoghue, E., James, J. A., Lambris, J. D., Moir, S. A., Perkins, S. J., and **Holers, V. M.** 2001. Epitope mapping using the x-ray crystallographic structure of complement receptor type 2 (CR2/CD21): Identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface. J. Immunol. 167:5758-5766.
83. Boackle, S. A., **Holers, V. M.**, Chen, X., Szakonyi, G., Karp, D. R., Wakeland, E. K., and Morel, L. 2001. *Cr2*, a candidate gene in the murine *Sle1c* lupus susceptibility locus, encodes a dysfunctional protein. Immunity 15:775-785.
84. Rehrig, S., Fleming, S., Anderson, J., Guthridge, J., McQueen, C., **Holers, V. M.**, Tsokos, G. C., and Shea-Donohue, T. 2001. Crry-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J. Immunol. 167:5921-5927.
85. Henson, S. E., Smith, D., Boackle, S. A., **Holers, V. M.**, and Karp, D. R. 2001. Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function. J. Immunol. Meth. 258:97-109.
86. Ulgiati, D., and **Holers, V. M.** 2001. CR2/CD21 proximal promoter activity is critically dependent on a cell type specific repressor. J. Immunol. 167:6912-6919.
87. Bao, L., Haas, M., Boackle, S. A., Kraus, D. M., Cunningham, P. N., Park, P., Alexander, J. J., Anderson, R. K., Culhane, K., **Holers, V. M.**, and Quigg, R. J. 2002. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice J. Immunol. 168:3601-3607.
88. **Holers, V. M.**, Girardi, G., Mo, L., Guthridge, J. M., Molina, H., Pierangeli, S. S., Espinola, R., Xiaowei, L. E., Mao, D., Vialpando, C. G., and Salmon, J. E. 2002. Complement C3 activation is required for anti-phospholipid antibody-induced fetal loss. J. Exp. Med. 195:211-220.
89. Ulgiati, D., Pham, C., and **Holers, V. M.** 2002. Functional analysis of the human CR2/CD21 promoter: Characterization of basal transcriptional mechanisms. J. Immunol. 168:6279-6285.
90. Ji, H., Ohmura, K., Mahmood, U., Lee, D. M., Hofhuis, F. M., Boackle, S. A., Takahashi, K., **Holers, V. M.**, Walport, M., Gerard, C., Ezekowitz, A., Carroll, M. C., Brenner, M., Weissleder, R., Verbeek, J. S., Duchatelle, V., Degott, C., Benoist, C., and D. Mathis. 2002. Arthritis critically dependent upon innate immune players. Immunity 16: 157-168.
91. Fleming, S. D., Shea-Donohue, T., Guthridge, J. M., Kulik, L., Waldschmidt, T. J., Gipson, M. G., Tsokos, G. C., and **Holers, V. M.** 2002. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J. Immunol. 169:2126-2133.

92. Banda, N. K., Kraus, D., Vondracek, A., Huynh, L. H., Bendele, A., **Holers, V. M.**, and Arend, W. P. 2002. Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arth. Rheum. 46:3065-3075.
93. Marchbank, K. J., Kulik, L., Gipson, M. G., Morgan, B. P., and **Holers, V. M.** 2002. Expression of human complement receptor type 2 (CR2/CD21) in mice during early B cell development results in a reduction in mature B cells and hypogammaglobulinemia. J. Immunol. 169:3526-3535.
94. Ji, S., **Holers, V. M.**, Boackle, S. A., and Blatteis, C. M. 2002. Modulation of mouse endotoxic fever by complement. Infect. Immun. 70:2519-2525.
95. Bao L., Haas, M. Kraus, D. M., Hack, B. K., Rakstang, J. K, **Holers, V. M.**, and Quigg, R. J. 2003. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J. Am. Soc. Nephrol. 14:670-679.
96. Thurman, J. M., Ljubanovic, D., Edelstein, C. L., Gilkeson, G. S, and **Holers, V. M.** 2003. Lack of a functional alternative complement pathway ameliorates ischemic renal failure in mice. J. Immunol. 170: 1517-1523.
97. Elliott, M. K., Ruiz, P., Xu, Y., **Holers, V. M.**, and Gilkeson, G. S. 2004. Effects of complement factor D deficiency on the development of renal disease in MRL/lpr mice. Kidney Intl. 65:129-138.
98. Alexander, J. J., Bao, L., Jacob, A., Dyanov, H. M., Rakstang, J. K., **Holers, V. M.**, and Quigg, R. J. 2003. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim. Biophys. Acta 1639:169-176.
99. Song, H., He, C., Knaak, C., Guthridge, J. M., **Holers, V. M.**, and Tomlinson, S. 2003. Complement receptor 2 (CR2)-mediated targeting of complement inhibitors to sites of complement activation. J. Clin. Invest. 111:1875-1885.
100. Bao, L., Zhou, J., **Holers, V. M.**, and Quigg, R. J. 2003. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation. J. Am. Soc. Nephrol. 14:2516-2525.
102. Girardi, G., Berman, J., Redecha, P., Spruce, L., Kraus, D., Hollmann, T., Casali, P., Wetsel, R. A., Lambris, J. D., **Holers, V. M.**, and Salmon, J. E. 2003. Complement C5a receptors and neutrophils, but not activating Fc γ receptors, are critical mediators of anti-phospholipid antibody-induced fetal loss. J. Clin. Invest. 112:1644-1654.
103. Aslam, M., Guthridge, J. M., Hack, B. K., Quigg, R. J., **Holers, V. M.**, and Perkins, S. J. 2003. The extended multidomain solution structures of the complement protein Crry and its chimaeric conjugate Crry-Ig by scattering, analytical ultracentrifugation and constrained modelling: implications for function and therapy. J. Mol. Bio. 329:525-550.
104. Banda, N.K., Kraus, D. M., Muggli, M., Bendele, A., **Holers, V. M.**, and Arend, W. P. 2003. Prevention of collagen-induced arthritis in mice transgenic for the complement inhibitor complement receptor 1-related gene/protein y. J. Immunol. 171:2109-2115.
105. Taube, C., Rha, Y.-H., Takeda, K., Park, J.-W., Joetham, A., Balhorn, A., Dakhama, A., Giclas, P. C., **Holers, V. M.**, and Gelfand, E. W. 2003. Inhibition of complement activation during airway challenge decreases airway inflammation and hyperresponsiveness. Am. J. Resp. and Crit. Care Med. 168:1333-1341.
106. Salmon, J.E., Girardi, G., and **Holers, V. M.** 2003. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus 12:535-538.
107. Park, J.W., Taube, C., Joetham, A., Takeda, K., Kodama, T., Dakhama, A., McConville, G., Allen, C.B., Sfyroera, G., Schultz, L.D., Lambris, J.D., Giclas, P.C., **Holers, V. M.**, and Gelfand, E. W. 2003. Complement activation is critical to airway hyperresponsiveness after acute ozone exposure. Am. J. Resp. and Crit. Care Med. 169:726-732.

108. Kang, H.J., Bao, L., Xu, Y., Quigg, R.J., Giclas, P.C., and **Holers, V.M.** 2004. Increased serum C3 levels in Crry transgenic mice partially abrogates its complement inhibitory effects. Clin. Exp. Immunol. 136:194-199.
109. Muhlfeld, A.S., Segerer, S., Hudkins, K., Farr, A.G., Boa, L., Kraus, D., **Holers, V.M.**, Quigg, R.J., Alpers, C.E. 2004. Overexpression of Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis. Kidney Intl. 65:1214-1223.
110. Boackle, S.A., Culhane, K.K., Brown, J.M., Haas, M., Bao, L., Quigg, R.J., and **Holers, V.M.** 2004. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in MRL/lpr model of SLE. Autoimmunity 37:111-123.
111. Ohta, R., Kondor, N., Dohi, N., Tomlinson, S., Imai, M., **Holers, V.M.**, Okada, N., and Okada, H. 2004. Mouse Crry/p65 neutralized tumor vaccine induces antitumor activity *in vivo*. J. Immunol. 173:205-213.
112. Mikuls, T.R., O'Dell, J.R., Stoner, J.A., Parrish, L.A., Arend, W.P., Norris, J.M., and **Holers, V.M.** 2004. The association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-CCP antibody. Arth. Rheum. 50:3776-3782.
113. Fleming, S.D., Egan, R.P., Chai, C., Girardi, G., **Holers, V.M.**, Salmon, J., Monestier, M., and Tsokos, G.C.. 2004. Antiphospholipid antibodies restore mesenteric ischemia-reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J. Immunol. 173:7055-7061.
114. Thurman, J.M., Kraus, D.M., Girardi, G., Hourcade, D., Kang, H.J., Royer, P.A., Mitchell, L.M., Giclas, P.C., Salmon, J.E., Gilkeson, G.S., and **Holers, V.M.** 2005. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol. Immunol. 42:87-97.
115. Ferucci, E.D., Majka, D.S., Parrish, L.A., Moroldo, M.B., Ryan, M., Passo, M., Thompson, S.D., Deane, K.D., Rewers, M., Arend, W.P., Glass, D.N., Norris, J.M., and **Holers, V.M.** 2005. Antibodies against citrullinated peptide (CCP) are associated with HLA-DR4 in simplex and multiplex polyarticular juvenile rheumatoid arthritis. Arth. Rheum. 52:239-246.
116. Lyubchenko, T., dal Porto, J., Cambier, J.C., and **Holers, V.M.** 2005. Co-ligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway. J. Immunol. 174:3264-3272.
117. Gilbert, H.E., Eaton, J.T., Hannan, J.P., **Holers, V.M.**, and Perkins, S.J. 2005. Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study. J. Mol. Biol. 346:859-873.
118. Hannan, J.P., Young, K.A., Guthridge, J.M., Asokan, R., Szakonyi, G., Chen, X.S., and **Holers, V.M.** 2005. Mutational analysis of the complement receptor type 2 (CR2/CD21)–C3d interaction reveals a putative charged SCR1 binding site for C3d. J. Mol. Biol. 346:845-858.
119. Thurman, J.M., Lucia, M.S., Ljubanovic, D., and **Holers, V.M.** 2005. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney. Intl. 67:524-530.
120. Li, S., Boackle, S.A., **Holers, V.M.**, Lambris, J.D., and Blatteis, C.M. 2005. Complement C5a is integral to the febrile response of mice to lipopolysaccharide. Neuroimmunomodulation 12:67-80.
121. Hibbert, R.G., Teriete, P., Grundy, G.J., **Holers, V.M.**, Hannan, J.P., Sutton, B.J., Gould, H.J. and McDonnell, J.M. 2005. The structure of soluble CD23 and its interactions with IgE and CD21. J. Exp. Med 202:751-760.
122. Birrell, L., Kulik, L., Morgan, B.P., **Holers, V.M.**, and Marchbank, K.J., 2005. B cells from mice prematurely expressing human CR2/CD21 are unresponsive to T-dependent antigens. J. Immunol. 174:6974-6982.

123. Atkinson, C., Song, H., Lu, B., Qiao, F., Burns, T.A., **Holers, V.M.**, Tsokos, G.C., and Tomlinson, S. 2005. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J. Clin. Invest. 115:2444-2453.
124. Kuhn, K.A., Kulik, L., Tomooka, B., Braschler, K.J., Arend, W.P., Robinson, W.H., and **Holers, V.M.** 2006. Antibodies to citrulline-modified proteins enhance tissue injury in inflammatory arthritis. J. Clin. Invest. 116:961-973.
125. Taube, C., Thurman, J.M., Joetham, A., Takeda, K., Miyahara, N., Dakhama, A., Carroll, M.C., Giclas, P.C., **Holers, V.M.**, and Gelfand, E.W. 2006. Factor B of the alternative pathway is critical to development of airway hyperresponsiveness. Proc. Natl. Acad. Sci. 103:8084-8089.
126. Gilbert, H.E., Aslam, M., Guthridge, J.M., **Holers, V.M.**, and Perkins, S.J. 2006. Extended flexible linker structures in the complement chimaeric conjugate CR2-Ig by scattering, analytical ultracentrifugation and constrained modelling: Implications for function and therapy. J. Mol. Biol. 356:397-412.
127. Thurman, J.M., Royer, P.A., Ljubanovic, D., Dursun, B., Lenderink, A.M., Edelstein, C.L., and **Holers, V.M.** 2006. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J. Am. Soc. Nephrol. 17:707-715..
128. Kraus, D.M., Elliott, G.S., Chute, H., Horan, T., Pfenninger, K.H., Sanford, S.D., Foster, S., Scully, S., Welcher, A.A. and **Holers, V.M.** 2006. Identification of a novel multiple domain complement regulatory protein highly expressed in the central nervous system and epithelial tissues. J. Immunol. 176:4419-4430.
129. Thurman, J.M., Ljubanovic, D., Royer, P.A., Kraus, D.M., Molina, H., Barry, N.P., Proctor, G., Levi, M., and **Holers, V.M.** 2006. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J. Clin. Invest. 116:357-368.
130. Leinhase, I., Schmidt, O.I., Thurman, J.M., Rozanski, M., Scheffler, A., John, T., Smith, W.R., **Holers, V.M.**, and Stahel, P.F. 2006. Pharmacological complement inhibition at the C3 convertase level induces neuroprotective intracerebral gene expression and decreases neurological impairment after traumatic brain injury. Exp. Neurol. 199:454-463.
131. Leinhase, I., **Holers, V.M.**, Thurman, J.M., Harhausen, D., Schmidt, O.I., Pietzcker, M., Taha, M.E., Rittirsch, D., Huber-Lang, M., Smith, W.R., Ward, P.A., and Stahel, P.F. 2006. Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation. BMC Neurosci. 7:55.
132. Mikuls, T.R., **Holers, V.M.**, Parrish, L.A., Alarcon, G.S., Conn, D.L., Gilkeson, G., Smith, E.A., Kamen, D.L., Jonas, B.L., Callahan, L., Howard, G., Moreland, L.W., and Bridges, Jr., S.L. 2006. Anti-cyclic citrullinated peptide (CCP) antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. Arth. Rheum. 154:3057-3059.
133. Banda, N.K., Thurman, J.M., Kraus, D.M., Wood, A., Carroll, M.C., Arend, W.P., and **Holers, V.M.** 2006. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J. Immunol. 177:1904-1912.
134. Schepers, A., de Vries, M.R., van Leuven, C.J., Grimbergen, J.M., **Holers, V.M.**, Daha, M.R., van Bockel, J.H., and Quaz, P.H.A. 2006. Inhibition of complement component C3 reduces intimal hyperplasia in apolipoprotein E3-Leiden transgenic mice. Circulation 114:2831-2838.
135. Asokan, R., Hua, J., Young, K.A., Gould, H.J., Hannan, J.P., Kraus, D.M., Szakonyi, G., Grundy, G.J., Chen, X.S., Crow, M.K., and **Holers, V.M.** 2006. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for interferon-alpha: a potential role in systemic lupus erythematosus. J. Immunol. 177:383-394.

136. Gilbert, H.E., Asokan, R., **Holers, V.M.**, and Perkins, S.J. 2006. The 15 SCR flexible extracellular domains of human complement receptor type 2 can mediate multiple ligand and antigen interactions. J. Mol. Biol. 362:1132-1147.
137. Szakonyi, G., Klein, M., Hannan, J.P., Young, K.A., Ma, R., **Holers, V.M.**, and Chen, X. 2006. Structure of the major envelope glycoprotein gp350 of Epstein-Barr virus. Nature Struct. and Molec. Biol. 13:996-1001.
138. Bhatia, S.S., Majka, D.S., Kittelson, J.M., Parrish, L.A., Ferucci, E.D., Deane, K.D., Arend, W.P., Rewers, M., **Holers, V.M.**, and Norris, J.M. 2006. Rheumatoid factor seropositivity is inversely associated with oral contraceptive use in women without rheumatoid arthritis. Ann. Rheum. Dis. 66:267-269.
139. Girardi, G., Yarilin, D., Thurman, J.M., **Holers, V.M.**, and Salmon, J.E. 2006. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 203:2165-2175.
140. Thorgersen, E.B., Ghebremariam, Y.T., Thurman, J.M., Fung, M., Nielsen, E.W., **Holers, V.M.**, Kotwal, G.J., and Molines, T.E. 2007. Candidate inhibitors of porcine complement. Mol. Immunol. 44:1827-1834.
141. Young, K.A., Parrish, L., Zerbe, G., Rewers, M., Deane, K.D., **Holers, V.M.**, and Norris, J.M. 2007. Perinatal and early childhood risk factors associated with rheumatoid factor positivity in a healthy pediatric population. Ann. Rheum. Dis. 66:179-183.
142. Kulik, L., Marchbank, K.J., Lyubchenko, T., Kuhn, K.K., Liubchenko, G.A., Haluszczak, C., Gibson, M.G., Boackle, S.A., and **Holers, V.M.** 2007. Intrinsic B cell hypo-responsiveness results from premature expression of human CR2/CD21 during B cell development. Eur. J. Immunol. 37:623-633.
143. Ho, J., Moir, S., Kulik, L., Malaspina, A., Donoghue, E.T., Miller, N.J., Chun, T.-W., Fauci, A.S., and **Holers, V.M.** 2007. Essential role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues. J. Immunol. 178:6968-6974.
144. Looney, R.J., Diamond, B., **Holers, V.M.**, Levesque, M., Moreland, L., Nahm, M., and St. Clair, W. 2007. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin. Immunol. 123:235-243.
145. Mihai, S., Chiriac, M.T., Takahashi, K., Thurman, J.M., **Holers, V.M.**, Zillikens, D., Botto, M., and Sitaru, C. 2007. The alternative pathway of complement activation is critical for blister formation in experimental epidermolysis acquisita. J. Immunol. 178:6514-6521.
146. Thurman, J.M., Lenderink, A.M., Royer, P.A., Coleman, K.E., Zhou, J., Lambris, J.D., Nemenoff, R.A., Quigg, R.J., and **Holers, V.M.** 2007. C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ischemia/reperfusion. J. Immunol. 178:1819-1828.
147. Lyubchenko, T., Dal Porto, J., **Holers, V.M.**, and Cambier, J.C. 2007. C3d-linked antigens break B cell anergy. J. Immunol. 179:2695-2699.
148. Banda, N.K., Takahashi, K., Wood, A.K., **Holers, V.M.**, and Arend, W.P. 2007. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J. Immunol. 179:4101-4109.
149. Twohig, J., Kulik, L., Haluszczak, C., Reuter, J., Rossbach, A., Bull, M., **Holers, V.M.**, and Marchbank, K.J. 2007. Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21) transgenic mice is partially recovered in the absence of C3. Mol. Immunol. 44:3434-3444.
150. Lenderink, A.M., Ljubanovic, D., **Holers, V.M.**, and Thurman, J.M. 2007. The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am. J. Physiol. – Renal Physiol. 293: F555-564.

151. Young, K.A., Chen, X.S., **Holers, V.M.**, and Hannan, J.P. 2007. Isolating the Epstein-Barr virus (EBV) gp350/220 binding site on complement receptor type 2 (CR2/CD21). J. Biol. Chem. 282:36614-36625.
152. Song, H., Qiao, F., Atkinson, C., **Holers, V.M.**, and Tomlinson, S. 2007. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J. Immunol. 179:7860-7867.
153. Leinase, I., Rozanski, M., Harhausen, D., Thurman, J.M., Schmidt, O.I., Hossini, A.M., Taha, M.E., Rittersch, D., Ward, P.A., **Holers, V.M.**, and Stahel, P.F. 2007. Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. J. Neuroinflamm. 4:13.
154. Majka, D.S., Deane, K.D., Parrish, L.A., Lazar, A.A., Baron, A.E., Walker, C.W., Rubertone, M.V., Gilliland, W.R., Norris, J.M., and **Holers, V.M.** 2008. Duration of pre-clinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann. Rheum. Dis. 67:801-807. PMCID: PMC3360701
155. Hughes, L.B., Morrison, D., Kelly, J.M., Padilla, M., Vaughn, K., Westfall, A.O., Dwividi, H., Mikuls, T.R., **Holers, V.M.**, Parrish, L., Alarcon, G.S., Conn, D.L., Jonas, B., Callahan, L.F., Smith, E.A., Gilkeson, G., Howard, G., Moreland, L.W., Patterson, N., Reich, D., and Bridges, Jr., S.L. 2008. The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African-Americans through European genetic admixture. Arth. Rheum. 58:349-358. PMID: 18240241
156. Lynch, A.M., Murphy, J., Byers, T., Gibbs, R.S., Neville, M.C., Giclas, P.C., Salmon, J.E., and **Holers, V.M.** 2008. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am. J. Obst. And Gyn. 198:385.e1-9. PMCID: PMC2362503
157. Clark, A., Weymann, A., Hartman, E., Turmelle, Y., Carroll, M., Thurman, J., **Holers, V.M.**, Hourcade, D.E., and Rudnick, D.A. 2008. Evidence for nontraditional activation of complement factor 3 during liver regeneration. Mol. Immunol. 45:3125-3132. PMCID: PMC2600895
158. Banda, N.K., Wood, A.K., Takahashi, K., Levitt, B., Rudd, P.M., Royle, L., Abrahams, J.L., Stahl, G.L., **Holers, V.M.**, and Arend, W.P. 2008. Initiation of the alternative pathway of complement by immune complexes is dependent on N-glycans in IgG antibodies. Arth. Rheum. 58:3081-3089. PMCID: PMC2574875
159. Zaiss, A.K., Cotter, M.J., White, L.R., Clark, S.A., Wong, N.C.W., **Holers, V.M.**, Bartlett, J.S., and Muruve, D.A. 2008. Complement is an essential component of the immune response to adeno-associated virus vectors. J. Virology 82:2727-2740. PMCID: PMC2259003
160. Mikuls, T.R., Hughes, L.B., Westfall, A.O., **Holers, V.M.**, Parrish, L., van der Heijde, D., van Everdingen, M., Alarcon, G.S., Conn, D.L., Jonas, B., Callahan, L.F., Smith, E.A., Gilkeson, G., Howard, G., Moreland, L.W., and Bridges, L. 2008. Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Ann. Rheum. Dis. 67:1529-1534. PMCID: PMC2731992
161. Kuhn, K.A., Cozine, C.L., Tomooka, B., Robinson, W.H., and **Holers, V.M.** 2008. Complement receptor CR2/CR1 deficiency protects mice from collagen-induced arthritis and associates with reduced autoantibodies to type II collagen and citrullinated antigens. Mol. Immunol. 45:2802-2819. PMID: 18374982
162. Huang, Y., Qiao, F., Atkinson, C., **Holers, V.M.**, and Tomlinson, S. 2008. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J. Immunol. 181:8068-8076. PMCID: PMC2782395
163. Li, K., Okemefuna, A.I., Gor, J., Hannan, J.P., Asokan, R., **Holers, V.M.**, and Perkins, S.J. 2008. Solution structure of the complex formed between human complement C3d and full-length complement receptor type 2. J. Mol. Biol. 384:137-150. PMID: 18804116

164. Young, K.A., Herbert, A.P., Barlow, P.N., **Holers, V.M.**, and Hannan, J.P. 2008. Molecular basis for the interaction between complement receptor 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J. Virol. 82:11217-11227. PMCID: PMC2573242
165. Lynch, A.M., Gibbs, R.S., Murphy, J.R., Byers, T., Neville, M.C., Giclas, P.C., Salmon, J.E., Van Hecke, T.M. and **Holers, V.M.** 2008. Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am. J. Obst. And Gyn. 199:327-328. PMCID: PMC2586079
166. Kulik, L., Fleming, S.D., Moratz, C., Reuter, J.W., Novikov, A., Chen, K., Andrews, K.A., Markaryan, A., Quigg, R.J., Silverman, G.J., Tsokos, G.C. and **Holers, V.M.** 2009. Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury. J. Immunol. 182:5363-5373. PMCID: PMC2820395
167. Lyubchenko, T., Nielsen, J.P., Miller, S.M., Liubchenko, G.A., and **Holers, V.M.** 2009. Role of initial protein phosphorylation events and localized release-activated calcium influx in B cell antigen receptor signaling. J. Leuk. Biol. 85:298-309. PMCID: PMC2631365
168. Kovacs, J.M., Hannan, J.P., Eisenmesser, E.Z., and **Holers, V.M.** 2009. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis. J. Biol. Chem. 284:9513-9520. PMCID: PMC2666603
169. Mikuls, T.R., Payne, J.B., Reinhardt, R.A, Thiele, G.M., Maziarz, E., Cannella, A.C., **Holers, V.M.**, Kuhn, K.A., and O'Dell, J.R. 2009. Antibody responses to *Porphyromonas gingivalis* (*P. gingivalis*) in subjects with rheumatoid arthritis and periodontitis. Int. Immunopharm. 9:38-42. PMCID: PMC2748386
170. Twohig, J.P., Pappworth, I.Y., Kulik, L., Bull, M., **Holers, V.M.**, Wang, E.C.Y., and Marchbank, K.J. 2009. Defective B cell ontogeny and immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice. Mol. Immunol. 46:2002-2013. PMCID: PMC2706330
171. Feser, M., Derber, L.A., Deane, K.D., Lezotte, D.C., Weisman, M.H., Buckner, J.H., Mikuls, T., O'Dell, J.R., Gregersen, P.K., **Holers, V.M.**, and Norris, J.M. 2009. Plasma 25,OH vitamin D levels are not associated with rheumatoid arthritis-related autoantibodies in individuals at elevated risk for rheumatoid arthritis. J. Rheum. 36:943-946. PMCID: PMC745328
172. Pappworth, I.Y., Kulik, L., Haluszczab, C., Reuter, J.W., **Holers, V.M.**, and Marchbank, K.J. 2009. Increased B cell deletion and significantly reduced autoantibody titre due to premature expression of human complement receptor type 2 (CR2, CD21). Mol. Immunol. 46:1042-1049. PMCID: PMC2657831
173. Xu, X., Hsu, H.-C., Chen, J., Grizzle, W.E., Chatham, W.W., Stockard, C.R., Wu, Q., Yang, P.A., **Holers, V.M.**, and Mountz, J.D. 2009. Increased expression of activation-induced cytidine deaminase is associated with anti-CCP and rheumatoid factor in rheumatoid arthritis. Scand. J. Immunol. 70:309-316. PMID: 19703021
174. Ricklin, D., Tzekou, A., Garcia, B.L., Hammel, M., McWhorter, W.J., Sfyroera, G., Wu, Y.Q., **Holers, V.M.**, Herbert, A.P., Barlow, P.M., Geisbrecht, B.V. and Lambris, J.D. 2009. A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J. Immunol. 183: 2565-2574. PMCID: PMC2881335
175. Kolfenbach, J.R., Deane, K.D., Derber, L.A., O'Donnell, C., Weisman, M.H., Buckner, J.H., Gersuk, V.H., Wei, S., Mikuls, T.R., O'Dell, J., Gregersen, P.K., Keating, R.M., Norris, J.M., and **Holers, V.M.** 2009. A prospective approach to investigating the natural history of pre-clinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. Arth. Care Res. 61: 1735-1742. PMCID: PMC2795101
176. Deane, K.D., Striebich, C., Goldstein, B.L., Derber, L.A., Parish, M.C., Feser, M.L., Hamburger, E.M., Brake, S., Belz, C., Goddard, J., Norris, J.M., Karlson, E.W., and **Holers, V.M.** 2009. Identification of undiagnosed inflammatory arthritis in a community health fair screen. Arth. Care Res. 61: 1642-1649. PMCID: PMC19950306

177. Banda, N.K., Levitt, B., Wood, A.K., Takahashi, K., Stahl, G.L., **Holers, V.M.**, and Arend, W.P. 2009. Complement activation pathways in murine immune complex arthritis and in C3a and C5a generation *in vitro*. Clin. Exp. Immunol. 159: 100-108. PMCID: PMC2802700
178. Thurman, J.M., Renner, B., Kunchithapautham, K., Ferreira, V.P., Pangburn, M.K., Ablonczy, Z., Tomlinson, S., **Holers, V.M.**, and Rohrer, B. 2009. Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J. Biol. Chem. 284:16939-16947. PMCID: PMC2719331
179. Gizinski, A.M., Mascolo, M., Kervitsky, D., Meehan, R., Brown, K., **Holers, V.M.**, and Deane, K.D. 2009. Rheumatoid arthritis-specific autoantibodies in interstitial lung disease in the absence of articular symptoms. Clin. Rheum. 28:611-613. PMID: 19252818
180. Banda, N.K., Levitt, B., Glogowska, M.J., Thurman, J.M., Takahashi, K., Stahl, G.L., Tomlinson, S., Arend, W.P., and **Holers, V.M.** 2009. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J. Immunol. 183:5928-5937. PMCID: PMC2828354
181. Thurman, J.M., Mariani, R., Emlen, W., Wood, S., Smith, C., Akana, H., **Holers, V.M.**, Lesser, M., Kline, M., Hoffman, C., Christen, E., and Trachtman, H. 2009. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 4:1920-1924. PMCID: PMC2798880
182. Gregersen, P.K., Amos, C.I., Lee, A.T., Lu, E., Remmers, E.F., Korman, B.D., Kastner, D.L., Seldin, M.F., Criswell, L.A., Plenge, R.M., **Holers, V.M.**, Mikuls, T., Sokka, T., Bridges, S.L., Begovich, A., and Siminovitch, K. 2009. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nature Genetics 41:820-823. PMCID: PMC2705058
183. Serkova, N., Renner, B., Larsen, B., Stoldt, C., Hasebroock, K., Bradshaw, E.L., **Holers, V.M.**, and Thurman, J.M. 2010. Renal inflammation: Targeted iron oxide nanoparticles for molecular MR Imaging in mice. Radiology 255:517-526. PMCID: PMC2858816
184. Lynch, A.M., Murphy, J.R., Gibbs, R.S., Levine, R.J., Giclas, P.C., Salmon, J.E., and **Holers, V.M.** 2010. Interrelationship of complement activation fragments and angiogenesis-related factors in early pregnancy and their association with preeclampsia. Brit. J. Obstet. Gynecol. 117:456-462. PMID: 20074261
185. Briggs, F.B.S., Ramsay, P.P., Madden, E., Norris, J.M., **Holers, V.M.**, Mikuls, T.R., Sokka, T., Seldin, M.F., Gregersen, P.K., Criswell, L.A., and Barcellos, L.F. 2010. Supervised machine learning and logistic regression identifies novel epistatic risk factors with *PTPN22* for rheumatoid arthritis. Genes Immun. 11:199-208. PMCID: PMC3118040
186. Ercan, A., Cui, J., Chatterton, D.E.W., Deane, K.D., Hazen, M.M., Brintnell, W., O'Donnell, C., Derber, L., Weinblatt, M.E., Shadick, N.A., Bell, D.A., Cairns, E., Solomon, D.H., **Holers, V.M.**, Rudd, P.M., and Lee, D.M. 2010. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity and is prevalent in autoantibodies in rheumatoid arthritis. Arth. Rheum. 62:2238-2248. PMID: 20506563
187. Kolfenbach, J.R., Deane, K.D., Derber, L.A., O'Donnell, C.I., Rosen, A., Darrah, E., Norris, J.M., and **Holers, V.M.** 2010 Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arth. Rheum. 62:2633-2639. PMCID: PMC2946499
188. Thurman, J.M., Renner, B., Kunchithapauthan, K., **Holers, V.M.**, and Rohrer, B. 2010. Aseptic injury to epithelial cells alters cell surface complement regulation in a tissue specific fashion. Adv. Exp. Med. Biol. 664:151-158. PMID: 20238013
189. Quan, T.E., Roman, R.M., Rudenga, B.J., **Holers, V.M.**, and Craft, J. 2010. Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells. Arth. Rheum. 62:1693-1701. PMCID: PMC2885535

190. Deane, K.D., O'Donnell, C.I., Hueber, W., Majka, D.S., Lazar, A.A., Derber, L.A., Gilliland, W.R., Edison, J.D., Norris, J.M., Robinson, W.H., and **Holers, V.M.** 2010. The number of elevated cytokines/chemokines in pre-clinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arth. Rheum. 62:3161-3172. PMCID: PMC2980824
191. Kovacs, J.M., Hannan, J.P., Eissensmeyer, E.Z., and **Holers, V.M.** 2010. Biophysical investigations of complement receptor 2 (CD21. CR2) ligand interactions reveal amino acid contacts unique to each receptor-ligand pair. J. Biol. Chem. 285:27251-27258. PMCID: PMC2930724
192. Renner, B., Strassheim, D., Amura, C.R., Ljubanovic, D., Glogowska, M.J., Takahashi, K., Stahl, G.L., Carroll, M.C., **Holers, V.M.**, and Thurman, J.M. 2010. B cell subsets contribute to both renal injury and renal protection after ischemia/reperfusion. J. Immunol. 185:3086-3094. PMCID: PMC3133676
193. Banda, N.K., Takahashi, M., Levitt, B., Glogowska, M., Nicholas, J., Takahashi, K., Stahl, G.L., Fujita, T., Arend, W.P., and **Holers, V.M.** 2010. Essential role of complement MASP-1/3 in the murine collagen antibody-induced arthritis model of inflammatory arthritis. J. Immunol. 185:5598-5606. PMCID: PMC3157645
194. Tan, W., Wu, H., Zhao, J., Derber, L.A., Lee, D.M., Shadick, N.A., Conn, D.L., Smith, E.A., Gersub, V., Nepom, G.T., Moreland, L.W., Furst, D.E., Thompson, S.D., Jonas, B.L., **Holers, V.M.**, Glass, D.N., Chen, P.P., Bridges, S.L., Weinblatt, M.E., Paulus, H.E., and Tsao, B.P. 2010. A functional *RANKL* polymorphism associated with younger age at onset of rheumatoid arthritis. Arth. Rheum. 62:2864-2875. PMCID: PMC2944013
195. Shaw, C.D., Storek, M.J., Young, K.A., Thurman, J.M., **Holers, V.M.**, and Hannan, J.P. 2010. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking. J. Mol. Biol. 404:697-710. PMID: 20951140
196. Renner, B., Ferreira, V.P., Cortes, C., Goldberg, R., Ljubanovic, D., Pangburn, M.K., Pickering, M.C., Tomlinson, S., **Holers, V.M.**, and Thurman, J.M. 2010. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J. Immunol. 185:3086-3094. PMCID: PMC3133690
197. Willis, V.C., Gizinski, A.M., Banda, N.K., Knuckley, B., Cordova, K., Luo, Y., Causey, C.P., Levitt, B., Glogowska, M., BenBarak, M., Chandra, P., Kulik, L., Robinson, W.H., Arend, W.P., Thompson, P.R., and **Holers, V.M.** 2011. Cl-amidine, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J. Immunol. 186:4396-4404. PMCID: PMC3085980
198. Lynch, A.M., Gibbs, R.S., Murphy, J.R., Giclas, P.C., Salmon, J.E., and **Holers V.M.** 2011. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet. Gynecol. 117:75-83. PMID: 21173647
199. Navarra, S.V., Ishimori, M.L., Uy, E.A., Hamijoyo, L., Sama, J., James, J.A., **Holers, V.M.**, and Weisman, M.H. 2011. Studies of Filipino patients with systemic lupus erythematosus (SLE): autoantibody profile of first degree relatives. Lupus 20:537-543. PMID: 21183559
200. Rohrer, B., Coughlin, B., Kunchithapautham, K., Long, Q., Tomlinson, S., Takahashi, K., and **Holers, V.M.** 2011. The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol. Immunol. 48(6-7):e1-8. PMCID: PMC3063365
201. Kulik, L., Chen, K., Huber, B.T., and **Holers, V.M.** 2011. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists. Mol. Immunol. 48:883-894. PMID: 21269698
202. Banda, N.K., Takahashi, M., Takahashi, K., Stahl, G.L., Hyatt, S., Glogowska, M., Wiles, T.A., Endo, Y., Fujita, T., **Holers, V.M.**, and Arend, W.P. 2011. Mechanisms of mannose-binding lectin-associated serine proteases-1/3 activation of the alternative pathway of complement. Mol. Immunol. 49:281-289. PMCID: PMC3226714

203. Renner, B., Ferreira, V.P., Cortes, C., Goldberg, R., Ljubanovic, D., Pangburn, M.K., Pickering, M.C., Tomlinson, S., Holland-Neidermyer, A., Strassheim, D., Holers, V.M., **Holers, V.M.**, and Thurman, J.M. 2011. Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Intl. 80:165-173. PMCID: PMC3133686
204. Fridkis-Hareli, M., Storek, M., Mazsaroff, I., Risitano, A., Lundberg, A.S., Horvath, C.J., and **Holers, V.M.** 2011. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 118:4705-4713. PMCID: PMC3208285
205. Khan, M.A., Jiang, X., Dhillon, G., Beilke, J., **Holers, V.M.**, Atkinson, C., Tomlinson, S., Nicolls, M.R. 2011. CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circulation Res. 109:1290-1301. PMCID: PMC3243047
206. Wang, Q., Rozelle, A.L., Lepus, C.M., Scanzello, C.R., Larsen, D.M., Crish, J.F., Bebek, G., Ritter, S.Y., Lindstrom, T.M., Hwang, I., Wong, H.H., Punzi, L., Encarnacion, A., Shamloo, M., Goodman, S.B., Wyss-Coray, T., Goldring, S.R., Gobeze, R., Crow, M.K., **Holers, V.M.**, Lee, D.M., and Robinson, W.H. 2011. Identification of a central role for complement in osteoarthritis. Nature Med. 17:1674-1679. PMCID: PMC3257059
207. Banda, N.K., Hyatt, S., Antonioli, A.H., Glogowska, M., Takahashi, K., Merkel, T.J., Stahl, G.L., Mueller-Ortiz, S., Wetsel, R., Arend, W.P., and **Holers, V.M.** 2012. Roles of C3a receptors, C5a receptors and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. 188:1469-1478. PMCID: PMC3262949
208. Rohrer, B., Coughlin, B., and **Holers, V.M.** 2012. Systemic CR2-targeted complement alternative pathway inhibitor treatment ameliorates mouse laser-induced choroidal neovascularization. 28:402-409. PMCID: PMC3406320
209. Takeda, K., Thurman, J.M., Tomlinson, S., Okamoto, M., Shiraishi, Y., Ferreira, V.P., Cortes, C., Pangburn, M.K., **Holers, V.M.**, and Gelfand, E.W. 2012. The critical role of complement alternative pathway regulator factor H in allergen-induced airway hyperresponsiveness (AHR) and inflammation. J. Immunol. 188:661-667. PMCID: PMC3253223
210. Demoruelle, M.K., Weisman, M.H., Simonian, P.L., Lynch, D.A., Sachs, P.B., Pedraza, I.F., Harrington, A.R., Kolfenbach, J.R., Striebich, C.C., Pham, Q.N., Strickland, C.D., Petersen, B.D., Parish, M.C., Derber, L.A., Norris, J.M., **Holers, V.M.**, and Deane, K.D. 2012. Airway abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arth. Rheum. 64:1756-1761. PMCID: PMC3319006
211. Sokolove, J., Bromberg, R., Tibshirani, R.J., Deane, K.D., Lahey, L.J., Derber, L.A., Chandra, P.E., Edison, J.D., Gilliland, W.R., Tibshirani, R.J., Norris, J.D., **Holers, V.M.**, and Robinson, W.H. 2012. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 7(5):e35296. PMCID: PMC3360701
212. Pappworth, I.Y., Hayes, C., Morgan, B.P., **Holers, V.M.**, and Marchbank, K.J. 2012. Mice expressing human CR1/CD35 have an enhanced immune response to T-dependent antigens but fail to correct the effect of premature CR2 expression. Immunobiology 217: 147-157. PMID: 21783272
213. Elvington, A., Atkinson, C., Kulik, L., Zhu, H., Yu, J., Kindy, M.S., **Holers, V.M.**, and Tomlinson, S. 2012. Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J. Immunol. 188:1460-1468. PMCID: PMC3262954
214. Keith, R.C., Powers, J.L., Redente, E.F., Sergew, A., Martin, R.J., Gizinski, A., **Holers, V.M.**, Sakaguchi, S., and Riches, D.W. 2012. A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice. Exper. Lung Res. 38:55-66. PMID: 22185348
215. Li, K., Gor, J., **Holers, V.M.**, Storek, M.J., and Perkins, S.J. 2012. Solution structure of TT30, a novel complement therapeutic agent, provides insight into its joint binding to complement C3b and C3d. J. Mol. Biol. 418:248-263. PMID: 22387467

216. Weckbach, S., Neher, M., Losacco, J.T., Bolden, A.L., Kulik, L., Flierl, M.A., Bell, S.E., **Holers, V.M.**, and Stahel, P.F. 2012. Challenging the role of adaptive immunity in neurotrauma: Rag1(-/-) mice lacking mature B and T cells do not show neuroprotection after closed head injury. *J. Neurotrauma* 29: 1233-1242. PMCID: PMC3325549
217. Lynch, A.M., Eckel, R.H., Murphy, J.R., Gibbs, R.S., West, N.A., Giclas, P.C., Salmon, J.E., and **Holers, V.M.** 2012. Prepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia. *Am. J. Obstet. Gynecol.* 206: 428.e1-8. PMID: 22542119
218. Liubchenko, G.A., Appleberry, H.C., **Holers, V.M.**, Banda, N.K., Willis, V.C., and Lyubchenko, T. 2012. Potentially autoreactive naturally occurring transitional T3 B lymphocytes exhibit a unique signaling profile. *J. Autoimmun.* 38:293-303. PMCID: PMC3358596
219. Thurman, J.M., Tchepeleva, S.N., Haas, M., Panzer, S., Boackle, S.A., Glogowska, M.J., Quigg, R.J., and **Holers, V.M.** 2012. Complement alternative pathway activation in the autologous phase of nephrotoxic serum nephritis. *Am J. Physiol. – Renal Physiol.* 302:F1529-1536. PMCID: PMC3378099
220. Risitano, A.M., Notaro, R., Pascariello, C., Sica M. del Vecchio, L., Horvath, C.J., Fridkis-Hareli, M., Selleri, C., Lindorfer, M.A., Taylor, R.P., Luzzatto, L, and **Holers, V.M.** 2012. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment deposition. *Blood* 119:6307-6316. PMID: 22577173
221. Asokan, R., Banda, N.K., Szakonyi, G., Chen, X.S., and **Holers, V.M.** 2012. Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). *Mol. Immunol.* 53:99-110. PMCID: PMC3439536
222. Mikuls, T.R., Thiele, G.M., Deane, K.D., Payne, J.B., O'Dell, J.R., Yu, F., Salyes, H., Weisman, M.H., Gregersen, P.K., Buckner, J.H., Keating, R.M., Derber, L.A., Robinson, W.H., **Holers, V.M.**, and Norris, J.M. 2012. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. *Arth. Rheum.* 64:3522-3530. PMCID: PMC3467347
223. Hughes-Austin, J.M., Deane, K.D., Derber, L.A., Kolfenbach, J.R., Zerbe, G.O., Sokolove, J., Lahey, L.J., Weisman, M.H., Buckner, J.H., Mikuls, T.R., O'Dell, J.R., Keating, R.M., Gregersen, P.K., Robinson, W.H., **Holers, V.M.**, and Norris J.M. 2012. Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA). 72:901-907. PMCID: PMC3726193.
224. Liubchenko, G.A., Appleberry, H.C., Striebich, C.C., Franklin, K.E., Derber, L.A., **Holers, V.M.**, and Lyubchenko, T. 2013. Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes. 40:111-121. PMCID: PMC3546227
225. Hu, X., **Holers, V. M.**, Thurman, J.M., Schoeb, T.R., Ramos, T.N., and Barnum, S.R. 2013. Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE. *Mol. Immunol.* 54:302-308. PMCID: PMC3602149
226. Cordova, K.N., Willis, V.C., Haskins, K., and **Holers, V.M.** 2013. A citrullinated fibrinogen-specific T cell line enhances autoimmune arthritis in a mouse model of rheumatoid arthritis. *J. Immunol.* 190:1457-1465. PMCID: PMC4108985
227. Strassheim, D., Renner, B., Panzer, S., Fuquay, R., Kulik, L. Ljubanovic, D., **Holers, V.M.**, and Thurman, J.M. 2013. IgM contributes to glomerular injury in FSGS. *J. Am. Soc. Neph.* 24: 393-406. PMCID: PMC3582199
228. Banda, N.K., Mehta, G., Ferreira, V.P., Cortes, C., Pickering, M.C, Pangburn, M.K., Arend, W.P, and **Holers, V.M.** 2013. Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis. *J. Immunol.* 190: 3560-3569. PMCID: PMC3607402
229. Thurman, J.M., Kulik, L, Orth, H., Wong, M., Renner, B., Sargsan, S.A., Mitchell, L.M., Hourcade, D.E., Hannan, J.P., Kovacs, J.M., Coughlin, B., Woodell, A.S., Pickering, M.C. Rohrer, B., and **Holers, V.M.**

2013. Detection of complement activation using monoclonal antibodies against C3d. J. Clin. Invest. 123: 2218-2230. PMCID: PMC 3635726
230. Joseph, K., Kulik, L., Coughlin, B., Kunchithapautham, K., Bandyopadhyay, M., Thiel, S., Thielens, N.M., **Holers, V.M.**, and Rohrer, B. 2013. Oxidative stress sensitizes retinal pigmented epithelial (RPE) cells to complement-mediated injury in a natural antibody-, lectin pathway-, and phospholipid epitope-dependent manner. J. Biol. Chem. 288: 12753-12765. PMCID: PMC3642321
231. Hughes-Austin, J.M., Deane, K.D., Derber, L.A., Kolfenbach, J.R., Zerbe, G.O., Sokolove, J., Lahey, L.J., Weisman, M.H., Buckner, J.H., Mikuls, T.R., O'Dell, J.R., Keating, R.M., Gregersen, P.K., Robinson, W.H., **Holers, V.M.**, and Norris, J.M. 2013. Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis. Ann. Rheum. Dis. 72: 901-907. PMCID: PMC3726193
232. Keith, R.C., Sokolove, J., Edelman, B.L., Lahey, L., Redente, E.F., **Holers, V.M.**, Sakaguchi, S., Robinson, W.H., and Riches, D.W. 2013. Testosterone is protective in the sexually dimorphic development of arthritis and lung disease in SKG mice. Arth. Rheum. 65:1487-1493. PMCID: PMC3672393
233. Arend, W.P., Mehta, G., Antonioli, A.H., Takahashi, M., Takahashi, K., Stahl, G.L., **Holers, V.M.**, and Banda, N.K. 2013. Role of adipocytes and fibroblasts in activation of the alternative pathway of complement in inflammatory arthritis in mice. J. Immunol. 10:6423-6433. PMCID: PMC3679294
234. Young, K.A., Deane, K.D., Derber, L.A., Hughes-Austin, J.M., Wagner, C.A., Sokolove, J., Weisman, M.H., Buckner, J.H., Mikuls, T.R., O'Dell, J.R., Keating, R.M., Gregersen, P.K., Robinson, W.H., **Holers, V.M.**, and Norris, J.M. 2013. Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis. Arth. Rheum. 65: 1995-2004. PMCID: PMC3729718
235. Demoruelle, M.K., Parish, M.C., Derber, L.A., Kolfenbach, J.R., Hughes-Austin, J.M., Weisman, M.H., Gilliland, W., Edison, J.D., Buckner, J.H., Mikuls, T.R., O'Dell, J.R., Keating, R.M., Gregersen, P.K., **Holers, V.M.**, and Deane, K.D. 2013. Performance of anti-cyclic citrullinated peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease. Arth. Rheum. 65: 2243-2252. PMCID: PMC3776020
236. Gan, R.W., Deane, K.D., Zerbe, G.O., Demoruelle, M.K., Weisman, M.H., Buckner, J.H., Gregersen, P.K., Mikuls, T.R., O'Dell, J.R., Keating, R.M., **Holers, V.M.**, and Norris, J.M. 2013. Relationship between air pollution and positivity of RA-related autoantibodies in individuals without established RA: a report on SERA. Ann. Rheum. Dis. 72:2002-2005. PMCID: PMC3828364
237. Walitt, B., Mackey, R., Kuller, L., Deane, K.D., Robinson, W., **Holers, V.M.**, Chang, W.-F., and Moreland, L. 2013. Predictive value of autoantibody testing for validating self-reported diagnoses of rheumatoid arthritis in the Women's Health Initiative. Am. J. Epidemiol. 177:877-893 PMCID: PMC4023293
238. Willis, V.C, Demoruelle, M.K., Derber, L.A., Chartier-Logan, C.J., Parish, M.C., Pedraza, I.F., Weisman, M.H., Norris, J.M., **Holers, V.M.**, and Deane, K.D. 2013. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arth. Rheum. 65:2545-2554. PMCID: PMC4066465
239. Wu, T.C., Yang, S., Haven, S., **Holers, V.M.**, Lundberg, A.S., Wu, H., and Cataland, S.R. 2013. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 11:1925-1927. PMID:23927533
240. Kuller, L.H., Mackey, R.H., Walitt, B.T., Deane, K.D., **Holers, V.M.**, Robinson, W.H., Sokolove, J., Chang, Y., and Moreland, L.W. 2013. Rheumatoid arthritis in the Women's Health Initiative: methods and baseline evaluation. Am. J. Epidemiol. 179:917-926. PMCID: PMC3969537

241. Kuller, L.H., Mackey, R.H., Walitt, B.T., Deane, K.D., **Holers, V.M.**, Robinson, W.H., Sokolove, J., Chang, Y., Liu, S., Parks, C.G., Wright, N.C., and Moreland, L.W. 2014. Determinants of mortality among postmenopausal women in the Women's Health Initiative who report rheumatoid arthritis. Arth. Rheum. 66:498-507. PMCID: PMC5638120
242. Banda, N.K., Mehta, G., Kjaer, T.R., Takahashi, M., Schaack, J., Morrison, T.E., Thiel, S., Arend, W.P., and **Holers, V.M.** 2014. Essential role for the lectin pathway in collagen antibody-induced arthritis revealed through use of adenovirus programming complement inhibitor MAP44 expression. J. Immunol. 193:2455-2468. PMCID: PMC4134985
243. Cataland, S.R., **Holers, V.M.**, Geyer, S., Yang, S., and Wu, H.M. 2014. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 123:3733-3738. PMID: 24695849
244. Young, K.A., Terrell, D.R., Guthridge, J.M., Kamen, D.L., Gilkeson, G.S., Karp, D.R., Ishimori, M.L., Weisman, M.H., **Holers, V.M.**, Harley, J.B., Norris, J.M., and James, J.A. 2014. Smoking is not associated with autoantibody production in systemic lupus erythematosus patients, unaffected first-degree relatives, nor healthy controls. Lupus 23:360-369, 2014 PMCID: PMC3954895
245. Neher, M.D., Rich, M.C, Keene, C.N., Weckbach, S., Bolden, A.L., Losacco, J.T., Patane, J., Flierl, M.A., Kulik, L., **Holers, V.M.**, and Stahel, P.F. Deficiency of complement receptors CR2/CR1 in *Cr2*^{-/-} mice reduces the extent of secondary brain damage after closed head injury. J. Neuroinflammation 11:95, 2014. PMCID: PMC4050415
246. Yui, J., **Holers, V.M.**, Yang, S., Wu, H.M., and Cataland, S.R. 2014. Clinical utility of complement biomarkers in the diagnosis and treatment of acute thrombotic microangiopathies. Brit. J. of Haematology 167:697-698. PMID: 25040791
247. Atkinson, C., Qiao, F., Yang, X., Zhu, P., Reaves, N., Kulik, L., Goddard, M., **Holers, V.M.**, and Tomlinson, S. 2015. Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation 131:1171-1180. PMCID: PMC4382916
248. Mehta, G., Scheinman, R.I., **Holers, V.M.**, and Banda, N.K. 2015. A new approach for the treatment of arthritis in mice with a novel conjugate of an anti-C5aR1 antibody and C5 small interfering RNA. J. Immunol. 194:5446-5554. PMCID: PMC4433857
249. Kulik, L., Hewitt, F.B., Willis, V.C., Rodriguez, R., Tomlinson, S., and **Holers, V.M.** 2015. A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease. Mol. Immunol. 63:479-488. PMCID: PMC4303539
250. Mackey, R.H., Kuller, L.H., Deane, K.D., Walitt, B.T., Chang, Y.F., **Holers, V.M.**, Robinson, W.H., Tracy, R.P., Hlatky, M.A., Eaton, C.B., Liu, S., Freiberg, M.S., Talabi, M.B., Schelbert, E.B., and Moreland, L.W. 2015. Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the Women's Health Initiative. Arth. Rheum. 67:2311-2322. PMCID: PMC4551571
251. Liang, M.H., Couto, M.C., Duarte, C.C., Gall, V., White, P., Naides, S., Schumacher, H.R. Jr., Hwang, A.S., **Holers, V.M.**, Deane, K.D., Gupta, S., Ho, I.C., Finckh, A., Kopec, J., Choi, C.B., Sayre, E.C. 2015. An internet-based technique for the identification of persons with symptoms of inflammatory polyarthritis of less than 12 weeks. Clin. Rheum. 34:465-470. PMID: 25339123
252. Gan, R.W., Trouw, L.A., Shi, J., Toes, R.E., Huizinga, T.W., Demoruelle, M.K., Kolfenbach, J.R., Zerbe, G.O., Deane, K., Edison, J.D., Gilliland, W.R., Norris, J.M., and **Holers, V.M.** 2015. Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. J. Rheum. 42:572-579. PMCID: PMC4383711
253. Cruickshank, M.N., Dods, J., Taylor, R.L., Karimi, M., Fenwick, E.J., Quail, E.A., Rea, A.J., **Holers, V.M.**, Abraham, L.J., and Ulgiati, D. 2015. Analysis of tandem E-box motifs within human Complement

receptor 2 (CR2/CD21) promoter reveals cell specific roles for RP58, E2A, USF and localized chromatin accessibility. Intl. J. Biochem. Cell Biol. 64:107-119. PMID: 25817480

254. Panzer, S.E., Laskowski, J., Renner, B., Kulik, L., Ljubanovic, D., Huber, K.M., Zhong, W., Pickering, M.C., **Holers, V. M.**, and Thurman, J.M. 2015. IgM exacerbates glomerular disease progression in complement-induced glomerulopathy. Kidney Intl. 88):528-537. PMCID: PMC4556608
255. Inturi, S., Wang, G., Chen, F., Banda, N.K., Holers, **V.M.**, Wu, L., Moghimi, S.M., and Simberg, D. 2015. Modulatory role of surface coating of superparamagnetic iron oxide nanoworms in complement opsonization and leukocyte uptake. Acs Nano. 9:10758-10768. PMCID:PMC5224875
256. Renner, B., Tong, H.H., Laskowski, J., Jonscher, K., Goetz, L., Woolaver, R., Hannan J., Li, Y.X., Hourcade, D., Pickering, M.C., **Holers, V.M.**, and Thurman, J.M. 2016. Annexin A2 enhances complement activation by inhibiting factor H. J. Immunol. 196:1355-1365. PMCID: PMC4724541
257. Gan, R.W., Young, K.A., Zerbe, G.O., Demoruelle, M.K., Weisman, M.H., Buckner, J.H., Gregersen, P.K., Mikuls, T.R., O'Dell, J.R., Keating, R.M., Clare-Salzler, M.J., Deane, K.D., **Holers, V.M.**, and Norris, J.M. 2016. Lower omega-3 fatty acids are associated with the presence of anti-cyclic citrullinated peptide autoantibodies in a population at risk for future rheumatoid arthritis: a nested case-control study. Rheumatology 55:367-376. PMCID: PMC5009416
258. Lynch, A.M., Wagner, B.D., Deterding, R.R., Giclas, P.C., Gibbs, R.S., Janoff, E.N., **Holers, V.M.**, and Santoro, N.F.. 2016. The relationship of circulating proteins in early pregnancy with preterm birth. Am. J. Obstet. Gynecol. 2016 Apr;214(4):517.e1-8. PMCID: PMC5145264
259. Rich, M.C., Keene, C.N., Neher, M.D., Johnson, K., Yu, Z.X., Ganivet, A., **Holers, V.M.**, and Stahel, P.F. 2016. Site-targeted complement inhibition by a complement receptor 2-conjugated inhibitor (mTT30) ameliorates post-injury neuropathology in mouse brains. Neurosci. Lett. 617: 188-194. PMID: 26892188
260. Lynch, A.M., Wagner, B.D., Giclas, P.C., West, N.A., Gibbs, R.S., and **Holers, V.M.** 2016. The relationship of longitudinal levels of complement Bb during pregnancy and preeclampsia. Am. J. Reproduc. Immunol. 75:104-111. PMCID: PMC5145263
261. Laskowski, J., Renner, B., Le Quintrec, M., Panzer, S., Hannan, J.P., Ljubanovic, D., Ruseva, M.M., Borza, D.B., Antonioli, A.H., Pickering, M.C., **Holers, V.M.**, and Thurman, J.M. 2016. Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. Kidney Int. 90:109-122. PMCID: PMC4912413
262. Kinslow, J.D., Blum, L.K., Deane, K.D., Demoruelle, M.K., Okamoto, Y., Parish, M., Kongpachith, S., Lahey, L.J., Norris, J.M., Robinson, W.H., and **Holers, V.M.** 2016. IgA Plasmablasts are elevated in subjects at risk for future rheumatoid arthritis. Arth. Rheum. PMCID: PMC5042824
263. Wang, G., Chen, F., Banda, N.K., **Holers, V.M.**, Wu, L., Moghimi, S.M., and Simberg, D.. 2016. Activation of human complement system by dextran-coated iron oxide nanoparticles is not affected by dextran/Fe ratio, hydroxyl modifications, and crosslinking. Front. Immunol. 7:418. PMCID: PMC5056169
264. Chang, H.-H., Liu, G.-Y., Dwivedi, N., Sun, B., Okamoto, Y., Kinslow, J.D., Deane, K.D., Demoruelle, M.K., Norris, J.M., Thompson, P.R., Sparks, J.A., Rao, D.A, Karlson, E.W., Hung, H.-C., **Holers, V.M.**, and Ho, I.-C. 2016. A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22. JCI Insight 1(17):e90045. PMCID: PMC5070957
265. Hannan, J.P., Laskowski, J., Thurman, J.M., Hageman, G.S., and **Holers, V.M.** 2016. Mapping the complement factor H-related protein 1 (CFHR1):C3b/C3d interactions. PLoS One. 11(11):e0166200. PMCID: PMC5096715
266. Banda, N.K., Acharya, S., Scheinman, R.I., Mehta, G., Coulombe, M., Takahashi, M., Sekine, H., Thiel, S., Fujita, T., and **Holers, V.M.** 2016. Mannan-binding lectin-associated serine protease 1/3 cleavage of pro-factor D into factor D in vivo and attenuation of collagen antibody-induced arthritis through their

- targeted inhibition by RNA interference-mediated gene silencing. *J. Immunol.* 197:3680-3694. PMCID: PMC5113144
267. Willis, V.C., Banda, N.K., Cordova, K.N., Chandra, P.E., Robinson, W.H., Cooper, D.C., Lugo, D., Mehta, G., Taylor, S., Tak, P.P., Prinjha, R.K., Lewis, H.D., and **Holers V.M.** 2017. Protein arginine deiminase 4 inhibition is sufficient for the amelioration of collagen-induced arthritis. *Clin. Exp. Immunol.* 188:263-274. PMCID: PMC5383440
 268. Gan R.W., Demoruelle, M.K., Deane, K.D., Weisman, M.H., Buckner, J.H., Gregersen, P.K., Mikuls, T.R., O'Dell, J.R., Keating, R.M., Fingerlin, T.E., Zerbe, G.O., Clare-Salzler, M.J., **Holers, V.M.**, and Norris, J.M. 2017. Omega-3 fatty acids are associated with a lower prevalence of autoantibodies in shared epitope-positive subjects at risk for rheumatoid arthritis. *Ann. Rheum. Dis.* 76:147-152. PMCID: PMC5371398
 269. Demoruelle, M.K., Harrall, K.K., Ho, L., Purmalek, M.M., Seto, N.L., Rothfuss, H.M., Weisman, M.H., Solomon, J.J., Fischer, A., Okamoto, Y., Kelmenson, L.B., Parish, M.C., Feser, M., Fleischer, C., Anderson, C., Mahler, M., Norris, J.M., Kaplan, M.J., Cherrington, B.D., **Holers, V.M.**, and Deane, K.D. 2017. Anti-citrullinated protein antibodies are associated with neutrophil extracellular traps in the sputum in relatives of rheumatoid arthritis patients. *Arth. Rheum.* 69:1165-1175. PMCID: PMC5449213
 270. Birru Talabi, M., Mackey, R.H., Kuller, L.H., Dorman, J.S., Deane, K.D., Robinson, W.H., Walitt, B.T., Chang, Y., **Holers, V.M.**, Liu, S., and Moreland, L.W. 2017. Human leukocyte antigen shared epitope and inflammation, cardiovascular disease, cancer, and mortality among postmenopausal women in the Women's Health Initiative rheumatoid arthritis study. *Am. J. Epidemiol.* 186:245-254. PMCID: PMC5860272
 271. Banda, N.K., Acharya, S., Scheinman, R.I., Mehta, G., Takahashi, M., Endo, Y., Zhou, W., Farrar, C.A., Sacks, S.H., Fujita, T., Sekine, H., and **Holers, V.M.** 2017. Deconstructing the lectin pathway in the pathogenesis of experimental inflammatory arthritis: Essential role of the lectin ficolin B and mannose-binding protein-associated serine protease 2. *J. Immunol.* 199:1835-1845. PMCID: PMC5568486
 272. Narang, A., Qiao, F., Atkinson, C., Zhu, H., Yang, X., Kulik, L., **Holers, V.M.**, and Tomlinson, S. 2017. Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury drive secondary injury by activating complement. *J. Neuroinflamm.* doi:10.1186/s12974-017-0894-6. PMCID: PMC5477255
 273. Wang, G., Griffin, J.I., Inturi, S., Brenneman, B., Banda, N.K., **Holers, V.M.**, Moghimi, S.M., and Simberg, D. 2017. D. In vitro and in vivo differences in murine third complement component (C3) opsonization and macrophage/leukocyte responses to antibody-functionalized iron oxide nanoworms. *Front. Immunol.* doi: 10.3389/fimmu.2017.00151. PMCID: PMC5309246
 274. Chen, F., Wang, G., Griffin, J.I., Brenneman, B., Banda, N.K., **Holers, V.M.**, Backos, D.S., Wu, L., Moghimi, S.M., and Simberg, D.. 2017. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. *Nat. Nanotechnol.* 12:387-393. PMCID: PMC5617637
 275. Gan, R.W., Bemis, E.A., Demoruelle, M.K., Striebich, C.C., Brake, S., Feser, M.L., Moss, L., Clare-Salzler, M., **Holers, V.M.**, Deane, K.D., and Norris, J.M. 2017. The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anti-citrullinated protein antibody positive population. *Rheumatology* 56:2229-2236. PMCID: PMC5850337
 276. Hughes-Austin, J.M., Gan, R.W., Deane, K.D., Weisman, M.H., Demoruelle, M.K., Sokolove, J., Robinson, W.H., **Holers, V.M.**, Norris, J.M., and Ix, J.H. 2017. Association of antibodies to citrullinated protein antigens with blood pressure in first-degree relatives of rheumatoid arthritis patients: The studies of the etiology of rheumatoid arthritis. *Am. J. Neph.* 46:481-487. PMCID: PMC5788181
 277. Antonioli, A.H., White, J., Crawford, F., Renner, B., Marchbank, K.J., Hannan, J.P., Thurman, J.M., Marrack, P., and **Holers, V.M.** 2018. Modulation of the alternative pathway of complement by murine factor H-related proteins. *J. Immunol.* 200:316-326. PMCID: PMC5736413

278. He, Y.G., Pappworth, I.Y., Rossbach, A., Paulin, J., Mavimba, T., Hayes, C., Kulik, L., **Holers, V.M.**, Knight, A.M., and Marchbank, K.J. 2018. A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice. Immunobiology 223:125-134. PMCID: PMC5849677
279. Mihai, S., Hirose, M., Wang, Y., Thurman, J.M., **Holers, V.M.**, Morgan, B.P., Kohl, J., Zillikens, D., Ludwig, R.J., and Nimmerjahn, F. 2018. Specific inhibition of complement activation significantly ameliorates autoimmune blistering disease in mice. Front. Immunol. 9:535. PMCID: PMC5865061
280. Demoruelle, M.K., Bowers, E., Lahey, L.J., Sokolove, J., Purmalek, M., Seto, N.L., Weisman, M.H., Norris, J.M., Kaplan, M.J., **Holers, V.M.**, Robinson, W.H., and Deane, K.D. 2018. Antibody responses to citrullinated and noncitrullinated antigens in the sputum of subjects with rheumatoid arthritis and subjects at risk for development of rheumatoid arthritis. Arth. Rheum. 70:516-527. PMCID: PMC5876113
281. Goetz, L., Laskowski, J., Renner, B., Pickering, M.C., Kulik, L., Klawitter, J., Stites, E., Christians, U., van der Vlag, J., Ravichandran, K., **Holers, V.M.**, and Thurman, J.M. 2018. Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM. Eur. J. Immunol. 48:791-802. PMCID: PMC5992014
282. Okamoto, T., Mathai, S.K., Hennessy, C.E., Hancock, L.A., Walts, A.D., Stefanski, A.L., Brown, K.K., Lynch, D.A., Cosgrove, G.P., Groshong, S.D., Cool, C.D., Schwarz, M.I., Banda, N.K., Thurman, J.M., Yang, I.V., **Holers, V.M.**, and Schwartz, D.A. 2018. The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis. Am. J. Physiol. - Lung Cell. & Mol. Physiol. 315:L1-L10. PMCID: PMC6087895
283. Hughes-Austin, J.M., Deane, K.D., Giles, J.T., Derber, L.A., Zerbe, G.O., Dabelea, D.M., Sokolove, J., Robinson, W.H., **Holers, V.M.**, and Norris, J.M. 2018. Plasma adiponectin levels are associated with circulating inflammatory cytokines in autoantibody positive first-degree relatives of rheumatoid arthritis patients. PLoS ONE 13(6):e0199578. PMCID: PMC6016921
284. Donlin, L.T., Rao, D.A., Wei, K., Slowikowski, K., McGeachy, M.J., Turner, J.D., Meednu, N., Mizoguchi, F., Gutierrez-Arcelus, M., Lieb, D.J., Keegan, J., Muskat, K., Hillman, J., Roza, C., Ricker, E., Eisenhaure, T.M., Li, S., Browne, E.P., Chicoine, A., Sutherby, D., Noma, A., Accelerating Medicines Partnership RA/SLE Network, Nusbaum, C., Kelly, S., Pernis, A.B., Ivashkiv, L.B., Goodman, S.M., Robinson, W.H., Utz, P.J., Lederer, J.A., Gravallese, E.M., Boyce, B.F., Hacohen, N., Pitzalis, C., Gregersen, P.K., Firestein, G.S., Raychaudhuri, S., Moreland, L.W., **Holers, V.M.**, Bykerk, V.P., Filer, A., Boyle, D.L., Brenner, M.B., and Anolik, J.H. 2018. Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissue. Arth. Res. Ther. 20:139. PMCID: PMC6042350
285. Verheul, M.K., Bohringer, S., van Delft, M.A.M., Jones, J.D., Rigby, W.F.C., Gan, R.W., **Holers, V.M.**, Edison, J.D., Deane, K.D., Janssen, K.M.J., Westra, J., Brink, M., Rantapaa-Dahlqvist, S., Huizinga, T.W.J., van der Helm-van Mil, A.H.M., van der Woude, D., Toes, R.E.M., and Trouw, L.A. 2018. Triple positivity for three autoantibodies, ACPA, RF and anti-CarP antibodies is highly specific for rheumatoid arthritis: implications for very early identification of individuals at risk to develop rheumatoid arthritis. Arth. Rheum. 70:1721-1731. PMID: 29781231
286. Banda, N.K., Desai, D., Scheinman, R.I., Pihl, R., Sekine, H., Fujita, T., Sharma, V., Hansen, A.G., Garred, P., Thiel, S., Borodovsky, A., and **Holers, V.M.** 2018. Targeting of liver mannan-binding lectin-associated serine protease-3 with RNA interference ameliorates disease in a mouse model of rheumatoid arthritis. ImmunoHorizons 2:274-295. PMCID: PMC6220895
287. Lingampalli, N., Sokolove, J., Lahey, L.J., Edison, J.D., Gilliland, W.R., **Holers, V.M.**, Deane, K.D., and Robinson, W.H. 2018. Combination of anti-citrullinated protein antibodies and rheumatoid factor is associated with increased systemic inflammatory mediators and more rapid progression from preclinical to clinical rheumatoid arthritis. Clinical Immunology 195:119-126. PMID: 29842946
288. Jalal, D., Renner, B., Laskowski, J., Stites, E., Cooper, J., Valente, K., You, Z., Perrenoud, L., Le Quintrec, M., Muhamed, I., Christians, U., Klawitter, J., Lindorfer, M.A., Taylor, R.P., **Holers, V.M.**, and

- Thurman, J.M. 2018. Endothelial microparticles and systemic complement activation in patients with chronic kidney disease. J. Am. Heart Assoc. 7(14): e007818. PMCID: PMC6064828
289. Okamoto, T., Mathai, S.K., Hennessy, C.E., Hancock, L.A., Walts, A.D., Stefanski, A.L., Brown, K.K., Lynch, D.A., Cosgrove, G.P., Groshong, S.D., Cool, C.D., Schwarz, M.I., Banda, N.K., Thurman, J.M., Yang, I.V., **Holers, V.M.**, and Schwartz, D.A. 2018. The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis. American J Physiol - Lung Cell & Molec Physiol. 315:L1-L10. PMCID: PMC6087895
 290. Bemis, E.A., Norris, J.M., Seifert, J., Frazer-Abel, A., Okamoto, Y., Feser, M.L., Demoruelle, M.K., Deane, K.D., Banda, N.K., and **Holers, V.M.** 2019. Complement and its environmental determinants in the progression of human rheumatoid arthritis. Mol. Immunol. 112:256-265. PMID: 31207549
 291. Hernandez, G., Mills, T.S., Rabe, J.L., Chavez, J.S., Kuldane, S., Kirkpatrick, G., Noetzli, L., Jubair, W.K., Zanche, M., Meyers, J.R., Stevens, B.M., Fleenor, C.J., Adane, B., Dinarello, C.A., Ashton, J., Jordan, C.T., Di Paola, J., Hagman, J.R., **Holers, V.M.**, Kuhn, K.A., and Pietras, E.M. 2019. Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. Haematologica 105:585-597. PMCID: PMC7049366
 292. Berens, H.M., Polinski, K.J., Mikuls, T.R., Khatler, S., August, J., Visser, A., Mahler, M., Weisman, M., O'Dell, J.R., Keating, R.M., Buckner, J.H., Gregersen, P.K., Norris, J.M., **Holers, V.M.**, Deane, K.D., and Demoruelle, M.K. 2019. J. Rheum. 46: 1556-1559. PMCID: PMC6800826
 293. Zhang, F., Wei, K., Slowikowski, K., Fonseka, C.Y., Rao, D.A., Kelly, S., Goodman, S.M., Tabechian, D., Hughes, L.B., Salomon-Escoto, K., Watts, G.F.M., Jonsson, A.H., Rangel-Moreno, J., Meednu, N., Rozo, C., Apruzzese, W., Eisenhaure, T., Lieb, D.J., Boyle, D.L., Mandelin, A.M., Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium, Boyce, B.F., DiCarlo, E., Gravallese, E.M., Gregersen, P.K., Moreland, L., Firestein, G.S., Hachohen, N., Nusbaum, C., Lederer, J.A., Perlman, H., Pitzalis, C., Filer, A., **Holers, V.M.**, Bykerk, V.P., Donlin, L.T., Anolik, J., Brenner, M.B., and Raychaudhuri, S. 2019. Nature Immunol. 20:928-942. PMCID: PMC6602051
 294. Gifford, G., Vu, V.P., Banda, N.K., **Holers, V.M.**, Wang, G., Groman, E.V., Backos, D., Scheinman, R., Moghimi, S.M., and Simberg, D. 2019. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. J. Control. Release. 302:181-189. PMCID: PMC6684249
 295. James, J.A., Chen, H., Young, K.A., Bemis, E.A., Seifert, J., Bourn, R.L., Deane, K.D., Demoruelle, M.K., Feser, M., O'Dell, J.R., Weisman, M.H., Keating, R.M., Gaffney, P.M., Kelly, J.A., Langefeld, C.D., Harley, J.B., Robinson, W., Hafler, D.A., O'Connor, K.C., Buckner, J., Guthridge, J.M., Norris, J.M., and **Holers, V.M.** 2019. Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients. EBioMedicine. 42:76-85. PMCID: PMC6491794
 296. Stathopoulos, P., Chastre, A., Waters, P., Irani, S., Fichtner, M.L., Benotti, E.S., Guthridge, J.M., Seifert, J., Nowak, R.J., Buckner, J.H., **Holers, V.M.**, James, J.A., Hafler, D.A., and O'Connor, K.C. 2019. Autoantibodies against neurologic antigens in nonneurologic autoimmunity. J. Immunol. 202:2210-2219. PMCID: PMC6452031
 297. Kulik, L., Laskowski, J., Renner, B., Woolaver, R., Zhang, L., Lyubchenko, T., You, Z., Thurman, J.M., and **Holers, V.M.** 2019. Targeting the immune complex-bound complement C3d ligand as a novel therapy for lupus. J. Immunol. 203:3136-3137. PMCID: PMC6900485
 298. Mastellos, D.C., Blom, A.M., Connolly, E.S., Daha, M.R., Geisbrecht, B.V., Ghebrehiwet, B., Gros, P., Hajishengallis, G., **Holers, V.M.**, Huber-Lang, M., Kinoshita, T., Mollnes, T.E., Montgomery, R.A., Morgan, B.P., Nilsson, B., Pio, R., Ricklin, D., Risitano, A.M., Taylor, R.P., Mantovani, A., Ioannidis, J.P.A., and Lambris, J.D. 2019. 'Stealth' corporate innovation: an emerging threat for therapeutic drug development. Nat. Immunol. 20:1409-1413. PMCID: PMC7368001

299. Frid, M.G., McKeon, B.A., Thurman, J.M., Maron, B.A., Li, M., Zhang, H., Kumar, S., Sullivan, T., Laskowsky, J., Fini, M.A., Hu, S., Tudor, R.M., Gandjeva, A., Wilkins, M.R., Rhodes, C.J., Ghataorhe, P., Leopold, J.A., Wang, R.S., **Holers, V.M.**, and Stenmark, K.R. 2020. Immunoglobulin-driven complement activation regulates pro-inflammatory remodeling in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 201:224-239. PMCID: PMC6961755301.
300. Polinski, K.J., Bemis, E.A., Feser, M., Seifert, J., Demoruelle, M.K., Striebich, C.C., Brake, S., O'Dell, J.R., Mikuls, T.R., Weisman, M.H., Gregersen, P.K., Keating, R.M., Buckner, J., Nicassio, P., **Holers, V.M.**, Deane, K.D., and Norris, J.M. 2020. Perceived stress and inflammatory arthritis: a prospective investigation in the Studies of the Etiologies of Rheumatoid Arthritis (SERA) cohort. Arth. Care Res. 72:1766-1771. PMCID: PMC7145743
301. Lynch, A.M., Mandava, N., Patnaik, J.L., Frazer-Abel, A.A., Wagner, B.D., Palestine, A.G., Mathias, M.T., Siringo, F.S., Cathcart, J.N., and **Holers, V.M.** 2020. Systemic activation of the complement system in patients with advanced age-related macular degeneration. Eur. J. Ophthalmol. 30:1061-1068. PMID: 31203676
302. Kelmenson, L.B., Wagner, B.D., McNair, B.K., Frazer-Abel, A., Demoruelle, M.K., Bergstedt, D.T., Feser, M.L., Moss, L.K., Parish, M.C., Mewshaw, E.A., Mikuls, T.R., Edison, J.D., **Holers, V.M.**, and Deane, K.D. 2020. Timing of elevations of autoantibody isotypes in rheumatoid arthritis prior to disease diagnosis. Arth. Rheum. 72:251-261. PMCID: PMC6994340
303. James, J.A., Guthridge, J.M., Chen, H., Lu, R., Bourn, R.L., Bean, K., Munroe, M.E., Smith, M., Chakravarty, E., Baer, A.N., Noaiseh, G., Parke, A., Boyle, K., Keyes-Elstein, L., Coca, A., Utset, T., Genovese, M.C., Pascual, V., Utz, P.J., **Holers, V.M.**, Deane, K.D., Sivils, K.L., Aberle, T., Wallace, D.J., McNamara, J., Franchimont, N., and St. Clair, E.W. 2020. Unique Sjögren's syndrome patient subsets defined by molecular features. Rheumatology 51:860-868. PMCID: PMC7188221
304. Mandava, N., Tirado-Gonzalez, V., Geiger, M.D., Patnaik, J.L., Frazer-Abel, A., Lynch, A.M. Mandava, N., Palestine, A.G., **Holers, V.M.**, Wagner, J.D., Sanchez-Santos, I., Meizner, D., Quiroz-Mercado, H., and Smith, J.M. 2020. Complement activation in the vitreous of patients with proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 61:39. PMCID: PMC7520707
305. Lynch, A.M., Palestine, A.G., Wagner, B.D., Patnaik, J.L., Frazer-Abel, A., Mathia, M.T., Siringo, F.S., **Holers, V.M.**, and Mandava, N. 2020. Complement factors and reticular pseudodrusen in intermediate age-related macular degeneration staged by multimodal imaging. BMJ. Open Ophthalmol. Jan 14;5(1):e000361. PMCID: PMC7254108
306. Ayyappan P., Harms, R.Z., Seifert, J.A., Bemis, E.A., Feser, M.L., Deane, K.D., Demoruelle, M.K., Mikuls, T.R., **Holers, V.M.**, and Sarvetnick, N.E. 2020. Heightened levels of antimicrobial response factors in patients with rheumatoid arthritis. Front. Immunol. 11:427. PMCID: PMC7100537
307. **Holers, V.M.**, Borodovsky, A., Scheinman, R.I., Ho, N., Ramirez, J.R., Dobo, J., Gal, P., Lindenberger, J., Hansen, A.G., Desai, E., Pihl, R., Thiel, S., and Banda, N.K. 2020. Key components of the complement lectin pathway are not only required for the development of inflammatory arthritis but also regulate the transcription of factor D. Front. Immunol. 11:201. PMCID: PMC7046807
308. Song, Y.J., Choi, I.A., Meylan, F., Demoruelle, M.K., Farley, T., Richard, A.C., Hawley, E., Botson, J., Hong, Y.J., Lee, E.Y., Mian, S.R., Hamilton, B.C., Thiele, G.M., Mikuls, T.R., Gara, N., Ward, C.D., Lamberth, S., Deane, K.D., Heller, T., Ward, M.M., Lee, D.M., Migone, T.S., Stohl, W., O'Dell, J.R., Norris, J.M., **Holers, V.M.**, Gregersen, P., Song, Y.W., and Siegel, R.M. 2020. Circulating TNF-like protein 1A (TLA1A) is elevated in rheumatoid arthritis and depends on TNF. Arth. Res. Ther. 22:106. PMCID: PMC7204024
309. Hernandez, G., Mills, T.S., Rabe, J.L., Chavez, J.S., Kuldane, S., Kirkpatrick, G., Noetzli, L., Jubair, W.K., Zanche, M., Myers, J. R., Stevens, B.M., Fleenor, C.J., Adane, B., Dinarello, C.A., Ashton, J., Jordan, C.T., Di Paola, J., Hagman, J.R., **Holers, V.M.**, Kuhn, K.A., and Pietras, E.M. 2020. Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. Haematologica 105:585-597. PMCID: PMC7049366

310. Banda, N.K., Tomlinson, S., Scheinman, R.I., Ho, N., Ramirez, J.R., Mehta, G., Wang, G., Vu, V.P., Simberg, D., Kulik, L., and **Holers, V.M.** 2020. C2 IgM natural antibody enhances inflammation and its use in the recombinant single chain antibody-fused complement inhibitor C2-rry to target therapeutics to joints attenuates arthritis in mice. Front. Immunol. 11:575154. PMCID: PMC7596757
311. Bemis, E.A., Demoruelle, M.K., Seifert, J.A., Polinski, K.J., Weisman, M.H., Buckner, J.H., Gregersen, P.K., Mikuls, T.R., O'Dell, J.R., Keating, R.M., Deane, K.D., **Holers, V.M.**, and Norris, J.M. 2021. Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting. Ann. Rheum. Dis. 80:154-161 PMCID: PMC7855648
312. Juge, P.-A., Lee, J.S., Lau, J., Kawano-Dourado, L. ... **Holers, V.M.**, ...and Dieude, P. 2021. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur. Respir. J. Feb 11;57(2):2000337. PMCID: PMC8212188
313. Takahashi, KI, Banda, N.K., **Holers, V.M.**, and Van Cott, E.M. 2021. Complement component factor B has thrombin-like activity. Biochem. Biophys. Res. Comm. 552:17-22. PMCID: PMC8035301
314. Demoruelle, M.K., Wang, H., Davis, R.L., Visser, A., Hoang, J., Norris, J.M., **Holers, V.M.**, Deane, K.D., and Darrah, E. 2021. Anti-peptidyl deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis. Arth. Res. Ther. 23(1):163. PMCID: PMC8182933
315. Li, C., Patel, K., Tu, Z., Yang, X., Kulik, L., Alawieh, A., Allen, P., Cheng, Q., Wallace, C., Kilkenny, J., Kwon, J., Gibney, B., Cantu, E., Sharma, A., Pipkin, M., Machuca, T., Emtiazjoo, A., Goddard, M., **Holers, V.M.**, Nadig, S., Christie, J., Tomlinson, S., and Atkinson, C. 2021. A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am. J. Transplant. 21:2067-2078. PMCID: PMC8246004
316. Polinski, K.J., Armstrong, M., Manke, J., Seifert, J., Crume, T., Yang, F., Clare-Salzler, M., **Holers, V.M.**, Reisdorph, N., and Norris, J.M. 2021. Collection and storage of human plasma for measurement of oxylipins. Metabolites 11(3):137. PMCID: PMC7996814
317. Polinski, K.J., Bemis, E.A., Yang, F., Crume, T., Demoruelle, M.K., Feser, M., Seifert, J., O'Dell, J.R., Mikuls, T.R., Weisman, M.H., Gregersen, P.K., Keating, R.M., Buckner, J., Reisdorph, N., Deane, K.D., Clare-Salzler, M., **Holers, V.M.**, and Norris, J.M. 2021. Association of lipid mediators with development of future incident inflammatory arthritis in an anti-citrullinated protein antibody-positive population. Arth. Rheum. 73:955-962. PMCID: PMC8169523
318. Mangalea, M.R., Paez-Espino, D., Kieft, K., Chatterjee, A., Chriswell, M.E., Seifert, J.A., Feser, M.L., Demoruelle, M.K., Sakatos, A., Anantharaman, K., Deane, K.D., Kuhn, K.A., **Holers, V.M.**, and Duerkop, B.A. 2021. Individuals at-risk for rheumatoid arthritis harbor differential intestinal bacteriophages communities with distinct metabolic potential. Cell Host Microbe 29:726-739.e5. PMCID: PMC8186507
319. Okamoto, Y., Ghosh, T., Okamoto, T., Schuyler, R.P., Seifert, J., Charry, L.L., Visser, A., Feser, M., Fleischer, C., Pedrick, C., August, J., Moss, L., Bemis, E.A., Norris, J.M., Kuhn, K.A., Demoruelle, M.K., Deane, K.D., Ghosh, D., **Holers, V.M.***, and Hsieh, E.W.Y.* 2021. Subjects at-risk for future development of rheumatoid arthritis demonstrate a PAD4- and TLR-dependent enhanced histone H3 citrullination and proinflammatory cytokine production in CD14^{hi} monocytes. J. Autoimmunity. 117:102581. *co-senior authors PMCID: PMC7855988
320. Wagner, B.D., Patnaik, J.L., Palestine, A.G., Frazer-Abel, A.A., Baldermann, R., **Holers, V.M.**, Mathias, M.T., Mandava, N., and Lynch, A.M. 2021. Association of systemic inflammatory factors with progression to advanced age-related macular degeneration. Ophthalm. Epidemiol. 1-10, Apr 08. PMCID: PMC8497647
321. Bettner, L.F., Peterson, R.A., Bergstedt, D.T., Kelmenson, L.B., Demoruelle, M.K., Mikuls, T.R., Edison, J.D., Parish, M.C., Feser, M.L., Frazer-Abel, A.A., Moss, L.K., Mahler, M., **Holers, V.M.**, and Deane,

- K.D. 2021. Combinations of anti-cyclic citrullinated protein antibody, rheumatoid factor, and serum calprotectin positivity are associated with the diagnosis of rheumatoid arthritis within 3 years. ACR Open Rheum. doi: 10.1002/acr2.11309. PMCID: PMC8516104
322. Hughes-Austin, J.M., Ix, J.H., Ward, S.R., Weisman, M.H., O'Dell, J.R., Mikuls, T.R., Buckner, J.H., Gregersen, P.K., Keating, R.M., Demoruelle, M.K., Deane, K.D., **Holers, V.M.**, and Norris, J.M. 2021. Evaluating associations of joint swelling, joint stiffness and joint pain with physical activity in first-degree relatives of patients with rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA), a prospective cohort study. BMJ Open 11(9):e050883. PMCID: PMC8442039
 323. Trachtman, H., Laskowski, J., Lee, C., Renner, B., Feemster, A., Parikh, S., Panzer, S.E., Zhong, W., Cravedi, P., Cantarelli, C., Kulik, L., You, Z., Satchell, S., Rovin, B., Liu, F., Kalled, S.L., **Holers, V.M.**, Jalal, D., and Thurman, J.M. 2021. Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. Am. Journal of Physiology - Renal Physiology 321:F505-F516. PMCID: PMC8560405
 324. Mankia, K., Siddle, H.J., Kerschbaumer, A., Alpizar Rodriguez, D., Catrina, A.I., Canete, J.D., Cope, A.P., Daen, C.I., Deane, K.D., El Gabalawy, H., Finckh, A., **Holers, V.M.**, Koloumas, M., Ometto, F., Raza, K., Zabalán, C., van der Helm-van Mil, A., van Schaardenburg, D., Aletaha, D., and Emery, P. 2021. EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. Ann. Rheum. Dis. 80:1286-1298. PMCID: PMC8458095
 325. Wahid, A.A., Dunphy, R.W., Macpherson, A., Gibson, B.G., Kulik, L., Whale, K., Back, C., Hallam, T.M., Alkhawaja, B., Martin, R.L., Meschede, I., Laabei, M., Lawson, A.D.G., **Holers, V.M.**, Watts, A.G., Crennell, S.J., Harris, C.L., Marchbank, K.J., and van den Elsen, J.M.H. Insights into the structure-function relationships of dimeric C3d fragments. 2021. Front. Immunol. 12:714055. PMCID: PMC8381054
 326. **Holers, V.M.**, La Rosa, F.G., and Banda, N.K. 2021. A potential new mouse model of axial spondyloarthritis involving the complement system. Immune Netw. 2021 Dec 15;21(6):e45. doi: 10.4110/in.2021.21.e45. PMCID: PMC8733187
 327. Li, C., Patel, K., Tu, Z., Yang, X., Kulik, L., Alawieh, A., Allen, P., Cheng, Q., Wallace, C., Kilkenny, J., Kwon, J., Gibney, B., Cantu, E., Sharma, A., Pipkin, M., Machuca, T., Emtiazjoo, A., Goddard, M., **Holers, V.M.**, Nadig, S., Christie, J., Tomlinson, S., and Atkinson, C. 2021. A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am J Transplant. 21:2067-2078. PMCID: PMC8246004
 328. Fechtner, S., Berens, H., Bemis, E., Johnson, R.L., Guthridge, C.J., Carlson, N.E., Demoruelle, M.K., Harley, J.B., Edison, J.D., Norris, J.A., Robinson, W.H., Deane, K.D., James, J.A., and **Holers, V.M.** 2022. Antibody responses to Epstein-Barr virus in the preclinical period of rheumatoid arthritis suggest the presence of increased viral reactivation cycles. Arth. Rheum. 74:597-603. PMCID: PMC8957485
 329. Okamoto, Y., Devoe, S., Seto, N., Minarchick, V., Wilson, T., Rothfuss, H.M., Mohning, M.P., Arbet, J., Kroehl, M., Visser, A., August, J., Thomas, S.M., Charry, L.L., Fleischer, C., Feser, M.L., Frazer-Abel, A.A., Norris, J.M., Cherrington, B.D., Janssen, W.J., Kaplan, M.J., Deane, K.D., **Holers, V.M.**, and Demoruelle, M.K. 2022. Association of sputum neutrophil extracellular trap subsets with IgA anti-citrullinated protein antibodies in subjects at risk for rheumatoid arthritis. Arth. Rheum. 74:38-48. PMCID: PMC8712364
 330. Schriek, P., Ching, A.C., Moily, N.S., Moffat, J., Beattie, L., Steiner, T.M., Hosking, L.M., Thurman, J.M., **Holers, V.M.**, Ishido, S., Lahoud, M.H., Caminschi, I., Heath, W.R., Mintern, J.D., and Villadangos, J.A. 2022. Marginal zone B cells acquire dendritic cell functions by trogocytosis. Science 375(6581):eabf7470. doi: 10.1126/science.abf7470. PMID: 35143312
 331. Wong, C.J., Wang, L., **Holers, V.M.**, Frazer-Abel, A., van der Maarel, S.M., Tawil, R., Statland, J.M., and Tapscott, S.J. 2022. Elevated plasma complement components in facioscapulohumeral dystrophy. Hum. Mol. Genet. 31:1821-1829. PMCID: PMC 9169453

332. Sasaki, T., Bracero, S., Keegan, J., Chen, L., Cao, Y., Stevens, E., Qu, Y., Wang, G., Nguyen, J., Sparks, J.A., **Holers, V.M.**, Alves, S.E., Lederer, J.A., Costenbader, K.H., and Rao, D.A. 2022. Longitudinal immune cell profiling in early systemic lupus erythematosus. Arth. Rheum. 74:1808-1821. PMID: PMC10238884
333. Wagner, B.D., Patnaik, J.L., Palestine, A.G., Frazer-Abel, A.A., Baldermann, R., **Holers, V.M.**, Mathias, M.T., Mandava, N., and Lynch, A.M. 2022. Association of systemic inflammatory factors with progression to advanced age-related macular degeneration. Ophthalm. Epidemiol. 29:139-148. PMID: PMC8497647
334. Smith, J.M., Mandava, N., Tirado-Gonzalez, V., Garcia-Santisteban, R., Geiger, M.D., Patnaik, J.L., Frazer-Abel, A., Lynch, A.M., Mandava, N., **Holers, V.M.**, Wagner, B.D., Sanchez-Santos, I., Meizner, D., Quiroz-Mercado, H., and Palestine, A.G. 2022. Correlation of complement activation in aqueous and vitreous in patients with proliferative diabetic retinopathy. Transl. Vis. Sci. Technol. doi: 10.1167/tvst.11.4.13. PMID: PMC9034714
335. Marin, A.I., Poppelaars, F., Wagner, B.D., Palestine, A.G., Patnaik, J.L., **Holers, V.M.**, Frazer-Abel, A.A., Mathias, M.T., Manoharan, N., Fonteh, C.N., Mandava, N., Lynch, A.M., and University of Colorado Retina Research Group. 2022. Sex and age-related differences in complement factors among patients with intermediate age-related macular degeneration. Transl. Vis. Sci. Technol. doi: 10.1167/tvst.11.5.22. PMID: PMC9145081
336. Fahnoe, K.C., Liu, F., Morgan, J.G., Ryan, S.T., Storek, M., Stark, E.G., Taylor, F.R., **Holers, V.M.**, Thurman, J.M., Wawersik, S., Kalled, S.L., and Violette SM. 2022. Development and optimization of bifunctional fusion proteins to locally modulate complement activation in diseased tissue. Front Immunol. doi: 10.3389/fimmu.2022.869725. PMID: PMC9244803
337. Bergstedt, D.T., Tarter, W.J., Peterson, R.A., Feser, M.L., Parish, M.C., Striebich, C.C., Demoruelle, M.K., Moss, L., Bemis, E.A., Norris, J.M., **Holers, V.M.**, Edison, J.D., Thiele, G.M., Mikuls, T.R., and Deane KD. 2022. Antibodies to citrullinated protein antigens, rheumatoid factor isotypes and the shared epitope and the near-term development of clinically-apparent rheumatoid arthritis. Front Immunol. doi: 10.3389/fimmu.2022.916277. PMID: PMC9265214
338. Banda, N.K., Deane, K.D., Bemis, E.A., Strickland, C., Seifert, J., Jordan, K., Goldman, K., Morgan, B.P., Moreland, L.W., Lewis, M.J., Pitzalis, C., and **Holers V.M.** 2022. Analysis of complement gene expression, clinical associations, and biodistribution of complement proteins in the synovium of early rheumatoid arthritis patients reveals unique pathophysiologic features. J. Immunol. 208:2482-2496. PMID: PMC9133225
339. Vanderlinden, L.A., Bemis, E.A., Seifert, J., Guthridge, J.M., Young, K.A., Demoruelle, M.K., Feser, M., DeJager, W., Macwana, S., Mikuls, T.R., O'Dell, J.R., Weisman, M.H., Buckner, J., Keating, R.M., Gaffney, P.M., Kelly, J.A., Langefeld, C.D., Deane, K.D., James, J.A., **Holers, V.M.**, and Norris, J.M. 2022. Relationship between a vitamin D genetic risk score and autoantibodies among first-degree relatives of probands with rheumatoid arthritis and systemic lupus erythematosus. Front. Immunol. doi: 10.3389/fimmu.2022.881332. PMID: PMC9205604
340. Tsaltzkan, V., Nguyen, K., Eaglin, C., **Holers, V.M.**, Deane, K.D., and Firestein, G.S. 2022. Comparison of web-based advertising and a social media platform as recruitment tools for underserved and hard-to-reach populations in rheumatology clinical research. ACR Open Rheumatol. 4:623-630. PMID: PMC9274346
341. Chriswell, M.E., Lefferts, A.R., Clay, R.R., Hsu, A.R., Seifert, J., Feser, M.L., Rims, C., Bloom, M.S., Bemis, E.A., Li, S., Maerz, M.D., Frank, D.N., Demoruelle, M.K., Deane, K.D., James, E.A., Buckner, J.H., Robinson, W.H., **Holers, V.M.**, and Kuhn, K.A. 2022. Clonal IgA and IgG autoantibodies from individuals at risk for rheumatoid arthritis identify an arthritogenic strain of *Subdoligranulum*. Science Translational Medicine. doi: 10.1126/scitranslmed.abn5166. Epub 2022 Oct 26 PMID: PMC9804515
342. Renner, B., Laskowski, J., Poppelaars, F., Ferreira, V.P., Blaine, J., Antonioli, A.H., Hannan, J.P., Kovacs, J.M., van Kooten, C., You, Z., Pickering, M.C., **Holers, V.M.**, and Thurman, J.M. 2022. Factor

H related proteins modulate complement activation on kidney cells. Kidney Intl. 102:1331-1344. PMID: PMC9691546

343. Seifert, J.A., Bemis, E.A., Ramsden, K., Lowell, C., Polinski, K., Fleischer, C., Demoruelle, M.K., Buckner, J., Gregersen, P.K., Keating, R.M., Mikuls, T.R., O'Dell, J.R., Weisman, M.H., Deane, K.D., Norris, J.M., Steere, A.C., and **Holers, V.M.** 2023. Association of antibodies to *Prevotella copri* in anti-CCP-positive individuals at-risk for developing rheumatoid arthritis and in those with early or established rheumatoid arthritis. Arth. Rheum. 75:507-516. PMID: PMC10065886
344. **Holers, V.M.**, Frank, R.M., Clauw, A., Seifert, J., Zuscik, M., Asokan, S., Striebich, C., Clay, M.R., Moreland, L.W., and Banda, N.K. 2023. Potential causal role of synovial complement system activation in the development of post-traumatic osteoarthritis after anterior cruciate ligament injury or meniscus tear. Front. Immunol. 2023 doi: 10.3389/fimmu.2023.1146563. PMID: PMC10189880
345. Renner, B., Poppelaars, F., Laskowski, J., Serkova, N.J., Kulik, L., **Holers, V.M.**, and Thurman, J.M. 2023. Noninvasive detection of iC3b/C3d deposits in the kidney using a novel bioluminescent imaging probe. J. Am. Soc. Nephrol. 34:1151-1154. PMID: PMC10356150
346. Brewer, R.C., Lanz, T.V., Hale, C.R., Sepich-Poore, G.D., Martino, C., Swafford, A.D., Carroll, T.S., Kongpachith, S., Blum, L.K., Elliott, S.E., Blachere, N.E., Parveen, S., Fak, J., Yao, V., Troyanskaya, O., Frank, M.O., Bloom, M.S., Jahanbani, S., Gomez, A.M., Iyer, R., Ramadoss, N.S., Sharpe, O., Chandrasekaran, S., Kelmenson, L.B., Wang, Q., Wong, H., Torres, H.L., Wiesen, M., Graves, D.T., Deane, K.D., **Holers, V.M.**, Knight, R., Darnell, R.B., Robinson, W.H., and Orange, D.E. 2023. Oral mucosal breaks trigger anti-citrullinated bacterial and human protein antibody responses in rheumatoid arthritis. Sci. Transl. Med. doi: 10.1126/scitranslmed.abq8476. Epub 2023 Feb 22. PMID: PMC10496947
347. Moon, J.S., Younis, S., Ramadoss, N.S., Iyer, R., Sheth, K., Sharpe, O., Rao, N.L., Becart, S., Carman, J.A., James, E.A., Buckner, J.H., Deane, K.D., **Holers, V.M.**, Goodman, S.M., Donlin, L.T., Davis, M.M., and Robinson, W.H. 2023. Cytotoxic CD8 T cells target citrullinated antigens in rheumatoid arthritis. Nat. Commun. doi:10.1038/s41467-022-35264-8. PMID: PMC9852471
348. Sarkar, S., Elliott, E.C., Henry, H.R., Ludovico, I.D., Melchior, J.T., Frazer-Abel, A., Webb-Robertson, B.J., Davidson, W.S., **Holers, V.M.**, Rewers, M.J., Metz, T.O., and Nakayasu, E.S. 2023. Systematic review of type 1 diabetes biomarkers reveals regulation in circulating proteins related to complement, lipid metabolism, and immune response. Update in: Clin. Proteomics. 20:38. PMID: PMC9980237
349. Dunlap, G., Wagner, A., Meednu, N., Zhang, F., Jonsson, A.H., Wei, K., Sakaue, S., Nathan, A.; Accelerating Medicines Partnership Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Network; Bykerk, V.P., Donlin, L.T., Goodman, S.M., Firestein, G.S., Boyle, D.L., **Holers, V.M.**, Moreland, L.W., Tabechian, D., Pitzalis, C., Filer, A., Raychaudhuri, S., Brenner, M.B., McDavid, A., Rao, D.A., and Anolik, J.H. 2024. Clonal associations of lymphocyte subsets and functional states revealed by single cell antigen receptor profiling of T and B cells in rheumatoid arthritis synovium. Nat. Commun. doi: 10.1101/2023.03.18.533282. PMID: PMC10055242
350. Webb-Robertson, B.M., Nakayasu, E.S., Dong, F., Waugh, K.C., Flores, J., Bramer, L.M., Schepmoes, A., Gao, Y., Fillmore, T., Onengut-Gumuscu, S., Frazer-Abel, A., Rich, S.S., **Holers, V.M.**, Metz, T.O., and Rewers, M.J. 2024. Decrease in multiple complement protein levels is associated with the development of islet autoimmunity and type 1 diabetes. iScience 27:108769. PMID: PMC10370226
351. Onengut-Gumuscu, S., Webb-Robertson, B.M., Sarkar, S., Manichaikul, A., Hu, X., Frazer-Abel, A., **Holers, V.M.**, Rewers, M.J., and Rich, S.S. 2023. Genetic variants in the complement system and their potential link in the aetiology of type 1 diabetes. Diabetes Metab. Res. Rev. Aug 30:e3716. doi: 10.1002/dmrr.3716. PMID:37649398
352. Whelan, R., Feemster, A., Laskowski, J., Renner, B., Kulik, L., Poppelaars, F., Lee, C., **Holers, V.M.**, and Thurman, J.M. 2023. Female but not male mice deficient in soluble IgM Are susceptible to chemically induced glomerular injury. J. Immunol. 211:1240-1248. PMID:PMC10592129

353. Fechtner, S., Allen, B.E., Chriswell, M.E., Jubair, W.K., Robertson, C.E., Kofonow, J.N., Frank, D.N., **Holers, V.M.**, and Kuhn, K.A. 2023. 3,3-dimethyl-1-butanol and its metabolite 3,3-dimethylbutyrate ameliorate collagen-induced arthritis independent of choline trimethylamine lyase activity. *Inflammation*. 2024 Aug 17. doi: 10.1007/s10753-024-02126-y . PMCID: PMC10503834
354. Weisenfeld, D., Zhang, F., Donlin, L., Jonsson, A.H., Apruzzese, W., Campbell, D.; Accelerating Medicines Partnership Program: RA/SLE Network; Rao, D.A., Wei, K., **Holers, V.M.**, Gravallesse, E., Moreland, L., Goodman, S., Brenner, M., Raychaudhuri, S., Filer, A., Anolik, J., Bykerk, V., and Liao, K.P. 2024. Associations between rheumatoid arthritis clinical factors with synovial cell types and states. *Arth. Rheum.* 76:356-362. PMCID: PMC10922423
355. Li, Y., Jacques, S., Gaikwad, H., Wang, G., Banda, N.K., **Holers, V.M.**, Scheinman, R.I., Tomlinson, S., Moghimi, S.M., and Simberg, D. 2023. Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins. *Nat. Nanotechnol.* doi:10.1038/s41565-023-01514-z. PMCID: PMC11034866
356. Mueller, A.A., Sasaki, T., Keegan, J.W., Nguyen, J.P., Griffith, A., Horisberger, A.M., Licata, T., Fieg, E., Cao, Y., Elahee, M., Marks, K.E., Simmons, D.P., Briere, L.C., Cobban, L.A., Pallais, J.C., High, F.A., Walker, M.A., Linnoila, J.J., Sparks, J.A., **Holers, V.M.**, Costenbader, K.H., Sweetser, D.A., Krier, J.B., Loscalzo, J., Lederer, J.A., and Rao, D.A. 2023. High-dimensional immunophenotyping reveals immune cell aberrations in patients with undiagnosed inflammatory and autoimmune diseases. *J. Clin. Invest.* doi:10.1172/JCI169619. PMCID: PMC10721141
357. Zhang, F., Jonsson, A.H., Nathan, A., Millard, N., Curtis, M., Xiao, Q., Gutierrez-Arcelus, M., Apruzzese, W., Watts, G.F.M., Weisenfeld, D., Nayar, S., Rangel-Moreno, J., Meednu, N., Marks, K.E., Mantel, I., Kang, J.B., Rumker, L., Mears, J., Slowikowski, K., Weinand, K., Orange, D.E., Geraldino-Pardilla, L., Deane, K.D., Tabechian, D., Ceponis, A., Firestein, G.S., Maybury, M., Sahbudin, I., Ben-Artzi, A., Mandelin, A.M., Nerviani, A., Lewis, M.J., Rivellesse, F., Pitzalis, C., Hughes, L.B., Horowitz, D., DiCarlo, E., Gravallesse, E.M., Boyce, B.F.; Accelerating Medicines Partnership: RA/SLE Network; Moreland, L.W., Goodman, S.M., Perlman, H., **Holers, V.M.**, Liao, K.P., Filer, A., Bykerk, V.P., Wei, K., Rao, D.A., Donlin, L.T., Anolik, J.H., Brenner, M.B., and Raychaudhuri, S. 2023. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. *Nature*. 623:616-624. PMCID: PMC10651487
358. James, E.A.*, **Holers, V.M.***, Iyer, R., Prideaux, E.B., Rao, N.L., Rims, C., Muir, V.S., Posso, S.E., Bloom, M.S., Zia, A., Elliott, S.E., Adamska, J.Z., Ai, R., Brewer, R.C., Seifert, J.A., Moss, L., Barzideh, S., Demoruelle, M.K., Striebich, C.C., Okamoto, Y., Sainbayar, E., Crook, A.A., Peterson, R.A., Vanderlinden, L.A., Wang, W., Boyle, D.L., Robinson, W.H., Buckner, J.H., Firestein, G.S., and Deane, K.D. 2023. Multifaceted immune dysregulation characterizes individuals at-risk for rheumatoid arthritis. *Nat. Commun.* doi:10.1038/s41467-023-43091-8. *Co-first author. PMCID: PMC10665556
359. **Holers V.M.**, Frank, R.M., Zuscik, M., Keeter, C., Scheinman, R.I., Striebich, C., Simberg, D., Clay, M.R., Moreland, L.W., and Banda, N.K. 2024. Decay-accelerating factor differentially associates with complement-mediated damage in synovium after meniscus tear as compared to anterior cruciate ligament injury. *Immune Netw.* 29;24(2):e17. PMCID: PMC11076301
360. Kang, J.B., Shen, A.Z., Gurajala, S., Nathan, A., Rumker, L., Aguiar, V.R.C., Valencia, C., Lagattuta, K.A., Zhang, F., Jonsson, A.H., Yazar, S., Alquicira-Hernandez, J., Khalili, H., Ananthakrishnan, A.N., Jagadeesh, K., Dey, K.; **Accelerating Medicines Partnership in RA/SLE Network**; Daly, M.J., Xavier, R.J., Donlin, L.T., Anolik, J.H., Powell, J.E., Rao, D.A., Brenner, M.B., Gutierrez-Arcelus, M., Luo, Y., Sakaue, S., and Raychaudhuri, S.. 2023. Mapping the dynamic genetic regulatory architecture of HLA genes at single-cell resolution. *Nat. Genet.* 55:2255-2268. PMCID: PMC10787945
361. Izmirly, P.M., Kim, M.Y., Carlucci, P.M., Preisinger, K., Cohen, B.Z., Deonaraine, K., Zaminski, D., Dall'Era, M., Kalunian, K., Fava, A., Belmont, H.M., Wu, M., Putterman, C., Anolik, J., Barnas, J.L., Diamond, B., Davidson, A., Wofsy, D., Kamen, D., James, J.A., Guthridge, J.M., Apruzzese, W., Rao, D.A., Weisman, M.H.; **Accelerating Medicines Partnership in RA/SLE Network**, Petri, M., Buyon, J., and Furie, R. 2024. Longitudinal patterns and predictors of response to standard-of-care therapy in

lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network. *Arth. Res. Ther.* doi: 10.1186/s13075-024-03275-z. PMCID: PMC10877793

362. Liu, F., Ryan, S.T., Fahnoe, K.C., Morgan, J.G., Cheung, A.E., Storek, M.J., Best, A., Chen, H.A., Locatelli, M., Xu, S., Schmidt, E., Schmidt-Jiménez, L.F., Bieber, K., Henderson, J.M., Lian, C.G., Verschoor, A., Ludwig, R.J., Benigni, A., Remuzzi, G., Salant, D.J., Kalled, S.L., Thurman, J.M., **Holers, V.M.**, Violette, S.M., and Wawersik, S. 2024. C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement. 2024. *Mol. Ther.* doi: 10.1016/j.ymthe.2024.02.001. PMCID: PMC11163200
363. Takada, H., Demoruelle, M.K., Deane, K.D., Nakamura, S., Katsumata, Y., Ikari, K., Buckner, J.H., Robinson, W.H., Seifert, J.A., Feser, M.L., Moss, L., Norris, J.M., Harigai, M., Hsieh, E.W.Y., **Holers, V.M.**, and Okamoto, Y. 2024. Expansion of HLA-DR positive peripheral helper T and naive B cells in anticitrullinated protein antibody-positive individuals at risk for rheumatoid arthritis. *Arth. Rheum.* 76:1023-1035. PMCID: PMC11213678
364. Bai, Z., Bartelo, N., Aslam, M., Murphy, E.A., Hale, C.R., Blachere, N.E., Parveen, S., Spolaore, E., DiCarlo, E., Gravallesse, E.M., Smith, M.H. **Accelerating Medicines Partnership in RA/SLE Network**, Frank, M.O., Jiang, C.S., Zhang, H., Pyrgaki, C., Lewis, M.J., Sikandar, S., Pitzalis, C., Lesnak, J.B., Mazhar, K., Price, T.J., Malfait, A.M., Miller, R.E., Zhang, F., Goodman, S., Darnell, R.B., Wang, F., and Orange, D.E. 2024. Synovial fibroblast gene expression is associated with sensory nerve growth and pain in rheumatoid arthritis. *Sci. Transl. Med.* doi: 10.1126/scitranslmed.adk3506. PMCID: PMC11931728
365. **Holers, V.M.**, Frank, R.M., Zuscik, M., Keeter, C., Scheinman, R.I., Striebich, C., Simberg, D., Clay, M.R., Moreland, L.W., and Banda, N.K. 2024. Decay-accelerating factor differentially associates with complement-mediated damage in synovium after meniscus tear as compared to anterior cruciate ligament injury. *Immune Netw.* doi: 10.4110/in.2024.24.e17. PMCID: PMC11076301
366. Weinand, K., Sakaue, S., Nathan, A., Jonsson, A.H., Zhang, F., Watts, G.F.M., Al Suqri, M., Zhu, Z., **Accelerating Medicines Partnership in RA/SLE Network**, Rao, D.A., Anolik, J.H., Brenner, M.B., Donlin, L.T., Wei, K., and Raychaudhuri, S. 2024. The chromatin landscape of pathogenic transcriptional cell states in rheumatoid arthritis. *Nat Commun.* 15:4650. PMCID: PMC10104143
367. Goff, S.H., Bergstedt, D.T., Feser, M.L., Moss, L., Mikuls, T.R., Edison, J.D., **Holers, V.M.**, Martinez-Prat, L., Aure, M.A.R., Mahler, M., and Deane, K.D. 2024. Multi-autoantibody testing identifies expansion of reactivity to targeted antigens before a diagnosis of rheumatoid arthritis. *ACR Open Rheumatol.* 2024 doi: 10.1002/acr2.11704. PMCID: PMC11506557
368. Law, C., Wacleche, V.S., Cao, Y., Pillai, A., Sowerby, J., Hancock, B., Horisberger, A., Bracero, S., Skidanova, V., Li, Z., Adejorin, I., Dillon, E., Benque, I.J., Nunez, D.P., Simmons, D.P., Keegan, J., Chen, L., Baker, T., Brohawn, P.Z., Al-Mossawi, H., Hao, L.Y., Jones, B., Rao, N., Qu, Y., Alves, S.E. **Accelerating Medicines Partnership in RA/SLE Network**, Jonsson, A.H., Shaw, K.S., Vleugels, R.A., Massarotti, E., Costenbader, K.H., Brenner, M.B., Lederer, J.A., Hultquist, J.F., Choi, J., and Rao, D.A.. 2024. Interferon subverts an AHR-JUN axis to promote CXCL13 T cells in lupus. *Nature* 631:857-866. PMCID: PMC11628166
369. Bell, R.D., Brendel, M., Konnaris, M.A., Xiang, J., Otero, M., Fontana, M.A., Bai, Z. **Accelerating Medicines Partnership in RA/SLE Network**, Krenitsky, D.M., Meednu, N., Rangel-Moreno, J., Scheel-Toellner, D., Carr, H., Nayar, S., McMurray, J., DiCarlo, E., Anolik, J.H., Donlin, L.T., Orange, D.E., Kenney, H.M., Schwarz, E.M., Filer, A., Ivashkiv, L.B., and Wang, F. 2024. Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue. *Nat. Commun.* doi: 10.1038/s41467-024-51012-6. PMCID: PMC11362542
370. Petrow, E., Feng, C., Frazer-Abel, A., Marangoni, R.G., Lutz, K., Nichols, W.C., **Holers, V.M.**, Ritchlin, C., White, R.J. 3rd, and Korman, B.D. 2024. Utility of factor D and other alternative complement factors as biomarkers in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). *Semin Arth. Rheum.* doi: 10.1016/j.semarthrit.2024.152554. PMCID: PMC11606736

371. Faust, H.J., Cheng, T.Y., Korsunsky, I., Watts, G.F.M., Gal-Oz, S.T., Trim, W.V., Kongthong, S., Jonsson, A.H., Simmons, D.P., Zhang, F., Padera, R., Chubinskaya, S., **Accelerating Medicines Partnership in RA/SLE Network**, Wei, K., Raychaudhuri, S., Lynch, L., Moody, D.B., and Brenner, M.B. 2024. Adipocyte associated glucocorticoid signaling regulates normal fibroblast function which is lost in inflammatory arthritis. Nat. Commun. doi: 10.1038/s41467-024-52586-x. PMCID: PMC11564742
372. Carlucci, P.M., Preisinger, K., Deonaraine, K.K., Zaminski, D., Dall'Era, M., Gold, H.T., Kalunian, K., Fava, A., Belmont, H.M., Wu, M., Putterman, C., Anolik, J., Barnas, J.L., Furie, R., Diamond, B., Davidson, A., Wofsy, D., Kamen, D., James, J.A., Guthridge, J.M., Apruzzese, W., Rao, D., Weisman, M.H., Izmirly, P.M., Buyon, J., Petri, M., and **Accelerating Medicines Partnership in RA/SLE Network**. 2025. Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network. Rheumatol. 64:1193-1200. PMCID: PMC11879353
373. Inamo, J., Keegan, J., Griffith, A., Ghosh, T., Horisberger, A., Howard, K., Pulford, J.F., Murzin, E., Hancock, B., Dominguez, S.T., Gurra, M.G., Gurajala, S., Jonsson, A.H., Seifert, J.A., Feser, M.L., Norris, J.M., Cao, Y., Apruzzese, W., Bridges, S.L., Bykerk, V.P., Goodman, S., Donlin, L.T., Firestein, G.S., Bathon, J.M., Hughes, L.B., Filer, A., Pitzalis, C., Anolik, J.H., Moreland, L., Hachohen, N., Guthridge, J.M., James, J.A., Cuda, C.M., Perlman, H., Brenner, M.B., Raychaudhuri, S., Sparks, J.A.; Accelerating Medicines Partnership RA/SLE Network, **Holers, V.M.***, Deane, K.D.*, Lederer, J.*, Rao, D.A.*, and Zhang, F.* 2025. Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis. J. Clin. Invest. 17;135(6):e185217. doi: 10.1172/JCI185217. *Co-senior author.PMCID: PMC11910230
374. Zaim, R.S., Savage, A.K., Gillespie, M.A., Castillo, J.D., Bennett, C., Torgerson, T.R., Becker, L.A., Mahler, M., Moss, L., Feser, M.L., Edison, J.D., Mikuls, T.R., **Holers, V.M.**, Li, X.J., and Deane, K.D. 2025. Serum proteomic signatures before the diagnosis of rheumatoid arthritis: evolving biologic pathways and specific periods of disease development. Arth. Rheum. Apr 6. doi: 10.1002/art.43175. PMID: 40189919
375. Lynch, A.M., Grove, N.C., Wagner, B.D., Palestine, A.G., **Holers, V.M.**, Frazer-Abel, A.A., Gnanaraj, R., Lisker-Cervantes, A., Patnaik, J.L., de Carlo Forest, T.E., Auer, E.A., McReynolds, A.J., Mathias, M.T., Manoharan, N., Rodriguez De Cordoba, S., and Mandava, N. 2025. Dynamic risk of systemic complement activation with time to progression to advanced age-related macular degeneration. JAMA Ophthalmol. Jun 12:e251608. doi: 10.1001/jamaophthalmol.2025.1608. PMCID: PMC12163720
376. Banda, N.K., Moreland, L.W., Deane, K.D., Simberg, D., Scheinman, R.I., Frank, R.M., Seifert, J.A.; Accelerating Medicines Partnership (AMP) RA/SLE Network, Lau, R., Pitzalis, C., Lewis, M.J., and **Holers, V.M.** 2025. Analysis of human factor H-related gene and protein expressed in rheumatoid arthritis synovium identifies a novel mechanism promoting dysregulated complement pathway activation. Sci. Rep. Jun 4;15(1):19633. doi: 10.1038/s41598-025-03589-1. PMCID: PMC12137822

BOOK CHAPTERS, EDITORIALS AND REVIEWS:

1. **Holers, V. M.**, Cole, J. L., Lublin, D. M., Seya, T., and Atkinson, J. P. 1985. Human C3b- and C4b-regulatory proteins: A new multi-gene family. Immunol. Today 6:188-192.
2. Dykman, T. R., **Holers, V. M.**, and Atkinson, J. P. 1985. Function and structure of the C3b/C4b complement receptor, CR1 in Microbiology Loretta Leive (ed). ASM Publ. p.19-22.
3. Atkinson, J. P., Kaine, J. L., **Holers, V. M.**, and Chan, A. C. 1986. Complement and the Rheumatic Diseases in An Introduction to the Complement System (Ed. Ross, G.D.) Academic Press. New York. p.197-211.
4. **Holers, V. M.** 1988. Complement receptors in The Year in Immunology (Ed. Crusse, J.M., and Lewis, R.E.) S. Karger, Basel. p.231-240.
5. Hourcade, D., **Holers, V. M.**, and Atkinson, J. P. 1989. The regulators of complement activation (RCA) gene cluster in Adv. in Immunol. F.J. Dixon (ed) 45:381-416.

6. **Holers, V. M.**, and Brown, E. J. 1992. Integrins in inflammation and the immune response in Scope Immunology Monograph. B. Schwartz, (ed) p.98-110.
7. Krych, M., Atkinson, J. P., and **Holers, V. M.** 1992. Complement receptors in Curr. Opin. Immunol., Current Biology Ltd, London 4:8-13.
8. **Holers, V. M.**, Kinoshita, T., and Molina, H. 1992. Evolution of mouse and human complement C3 binding proteins: divergence of form but conservation of function. Immunol. Today 13:231-236.
9. Moulds, J., Krych, M., **Holers, V. M.**, Liszewski, K., and Atkinson, J.P. 1992. Genetics of the complement system and rheumatic diseases in Rheumatic Disease Clinics of North America. B. Dudlick, (ed) 18:893-914.
10. **Holers, V. M.** 1995. Complement in Principles and Practices of Clinical Immunology. Rich, R. (ed), Mosby, St. Louis, MO. p.363-391.
11. **Holers, V. M.** 1997. Complement Receptors in Manual of Clinical Laboratory Immunology. (Ed. Rose, N. R., de Macario, E. C., Folds, J. D., Lane, H. C., and Nakamura, R. M.), ASM Press. p.192-202.
12. **Holers, V. M.** 1997. Complement Deficiencies and SLE in Rheumatology, Second Edition. (Ed. Klippel, J. H. and Dieppe, P. A.), Mosby-Wolfe, London, UK. p.8.6-8.8.
13. **Holers, V. M.** 1997. The Complement System in Rheumatology, Second Edition. (Ed. Klippel, J. H. and Dieppe, P. A.), Mosby-Wolfe, London, UK. p.4.1-4.8.
14. Smyth, C.J., and **Holers, V. M.** 1998 (editors) Gout, Hyperuricemia and Other Crystal-Associated Arthropathies. Marcel Dekker, New York, NY.
15. **Holers, V. M.** 1998. Complement Receptor Type 2 (CR2/CD21) as a Central Link between Innate and Acquired Immunity. In Clinical Immunology Newsletter 18: 7-10.
16. Guthridge, J. G., and **Holers, V. M.** 1999. Complement Receptor Type 2 in The Complement Factsbook (Ed. Morley, B. and Walport, M. L.), Academic Press, London, UK.
17. **Holers, V. M.** 1999. Complement in Principles of Molecular Rheumatology (Ed. Tsokos, G.), Humana Press, Totowa, NJ. p.145-160.
18. **Holers, V.M.** 1999. Complement deficiency states, disease susceptibility and infection risk in Systemic Lupus Erythematosus. Arth. Rheum. 42:2023-2025.
19. Lambris, J. D., and **Holers, V.M.** 2000 (editors) Therapeutic Interventions in the Complement System. Humana Press, Inc., Totowa, NJ.
20. **Holers, V.M.** 2000. Complement as a regulatory and effector pathway in Therapeutic Interventions in the Complement System (Ed. Lambris, J. D., and Holers, V.M.). Humana Press, Inc., Totowa, NJ. p.1-32.
21. **Holers, V. M.** 2000. Phenotypes of complement knockouts. Immunopharmacology. 49:125-131.
22. **Holers, V. M.**, 2001. Complement in Clinical Immunology (Ed. R. Rich), Mosby, Philadelphia, PA. p.21.1-21.18.
23. **Holers, V. M.**, 2001. Complement deficiencies in Clinical Immunology (Ed. R. Rich), Mosby, Philadelphia, PA. p.36.1-36.10.
24. Nichols, T., Karp, D. R., **Holers, V. M.**, 2001. Gamma-glutamyl transpeptidase (CD224). Prot. Rev. Web 3:7-11.
25. **Holers, V. M.**, 2002. Immunogenetics of rheumatic diseases in Rheumatology Secrets (Ed. S. West), Hanley and Belfus, Inc., Philadelphia, PA. p.28-38.
26. **Holers, V. M.**, 2002. Tolerance and autoimmunity in Rheumatology Secrets (Ed. S. West), Hanley and Belfus, Inc., Philadelphia, PA. p.38-44.

27. Karp, D. R., and **Holers, V. M.**, 2003. Complement in health and disease in Cecil Textbook of Medicine (Ed. L. Goldman and D. Ausiello), W. B. Saunders, Inc., Orlando, FL. p. 233-240.
28. Hannan, J., Young, K., Szakonyi, G., Overduin, M. J., Perkins, S. J., and **Holers, V. M.** 2002. Structure-function of complement receptor (CR) 2 and CR2-C3d complexes. Biochem. Soc. Trans. 30:983-989.
29. Perkins, S. J., Gilbert, H. E., Aslam, M., Hannan, J., **Holers, V. M.**, and Goodship, T. H. J. 2002. Solution structures of complement components by X-ray and neutron scattering and analytical ultracentrifugation. Biochem. Soc. Trans. 30:996-1006.
30. Boackle, S. A., and **Holers, V. M.**, 2002. Role of complement in the development of autoimmunity in Current Directions in Autoimmunity (Ed., D. Nemazee and A. N. Theofilopoulos), Karger, Basel, Switzerland. p. 154-168.
31. Salmon, J. E., Girardi, G., and **Holers, V. M.**, 2002. Complement activation as a mediator of antiphospholipid antibody-induced pregnancy loss and thrombosis. Ann. Rheum. Dis. 61 (supplement II): II46-II50.
32. **Holers, V. M.**, 2003. Complement receptors in Biological Therapy in Rheumatology (Ed. J. S. Smolen and P. E. Lipsky), Martin Dunitz, Inc., London, UK. p.167-180.
33. **Holers, V. M.**, 2003. Short Analytic Review: The complement system as a therapeutic target in autoimmunity. Clin. Imm. 107:140-151.
34. Majka, D. S., and **Holers, V. M.** 2003. Can we accurately predict the development of rheumatoid arthritis in the preclinical phase? Arth. Rheum. 48:2701-2705.
35. Boackle, S. A., and **Holers, V. M.**, 2004. Complement receptor 2 and autoimmunity in Current Directions in Autoimmunity (Ed., G. Tsokos), Karger, Basel, Switzerland. p. 33-48.
36. **Holers, V.M.**, and Thurman, J.S. 2004. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Molec. Immunol. 41:147-152.
37. Hannan, J. P., Szakonyi, G., Asokan, R., Chen, X., and **Holers, V. M.** 2004. Complement receptor CR2/CD21 and CR2-C3d complexes in Structural Biology of the Complement System (Ed. J. D. Lambris), Marcell Dekker, Inc., New York, NY. p. 143-160.
38. **Holers, V.M.** 2004. Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus. J. Clin. Invest. 114:616-619.
39. Carroll, M.C., and **Holers, V. M.**, 2005. Innate Autoimmunity in Advances in Immunology 86:137-157.
40. **Holers, V. M.** 2005. Complement receptors and the shaping of the natural antibody repertoire. Springer Semin. Immunopath. 26:405-423.
41. Thurman, J.M., and **Holers, V. M.** 2006. The central role of the alternative complement pathway in human disease. J. Immunol. 176:1305-1310.
42. Thurman, J.M., and **Holers, V. M.** 2006. Complement deficient mice as model systems for kidney diseases in Complement and Kidney Disease (Ed., P. Zipfel), Birkhauser-Verlag, Basel, Switzerland. p. 49-63.
43. **Holers, V. M.** 2006. Viewpoint: Are anti-cyclic citrullinated peptide antibodies pathogenic in rheumatoid arthritis? Nature Clin. Prac. Rheum. 2:400-401.
44. Majka, D.S., and **Holers, V. M.** 2006. Cigarette smoking and the risk of systemic lupus erythematosus and rheumatoid arthritis. Ann. Rheum. Dis. 65L561-563.
45. Karp, D. R., and **Holers, V. M.**, 2007. Complement in health and disease in Cecil Textbook of Medicine (Ed. L. Goldman and D. Ausiello), W. B. Saunders, Inc., Orlando, FL. p. 47:282-288.

46. **Holers, V.M.**, and Kulik, L. 2007. Complement receptor 2, natural antibodies and innate immunity: inter-relationships in B cell selection and activation. Mol. Immunol. 44:64-72.
47. **Holers, V. M.** 2007. Antibodies to citrullinated proteins: pathogenic and diagnostic significance. Curr. Rheum. Reports. 9:396-400.
48. **Holers, V. M.** 2008. Tolerance and autoimmunity in Rheumatology Secrets (Ed. S. West), Hanley and Belfus, Inc., Philadelphia, PA.
49. **Holers, V.M.** 2008. Systemic lupus erythematosus: the complement system. in Rheumatology 4th Edition (Ed, M.C. Hochberg, A.J. Silman, J.S. Smolen, M.H. Weisman and M.E. Weinblatt), Mosby, Inc. St. Louis, MO. p. 1243-1252.
50. **Holers, V.M.**, and Salmon, J.E. 2008. Complement and pregnancy loss in Contemporary Targeted Therapies in Rheumatology (Ed, J.S. Smolen and P.E. Lipsky), Informa Healthcare, Abington, UK.
51. **Holers, V. M.** 2008. The spectrum of complement alternative pathway mediated diseases. Immunol. Rev. 223:300-316. PMID: 18613844
52. **Holers, V. M.** 2009. Complement in Rheumatoid Arthritis. in Rheumatoid Arthritis (Ed, M.C. Hochberg, A.J. Silman, J.S. Smolen, M.H. Weisman and M.E. Weinblatt), Mosby, Inc. St. Louis, MO.
53. Karp, D. R., and **Holers, V. M.**, 2009. Complement in health and disease in Cecil Textbook of Medicine, W. B. Saunders, Inc., Orlando, FL.
54. Deane, K.D., **Norris, J.M.**, and **Holers, V.M.** 2010. Pre-clinical rheumatoid arthritis: identification, evaluation and future directions for investigation. Rheum. Dis. Clin. NA 13:236-241. PMCID: PMC2879710
55. **Holers, V.M.** 2010. Systemic lupus erythematosus: the complement system. in Rheumatology 5th Edition (Ed, M.C. Hochberg, A.J. Silman, J.S. Smolen, M.H. Weisman and M.E. Weinblatt), Mosby, Inc. St. Louis, MO.
56. Rohrer, B., Long, Q., Coughlin, B., Renner, B., Huang, Y., Kunchithapautham, K., Ferreira, V., Pangburn, M., Gilkeson, G., Thurman, J., Tomlinson, S., and **Holers, V.M.** 2010. A targeted inhibitor of the complement alternative pathway in models of age-related macular degeneration. in Inflammation and retinal disease: complement biology and pathology. Adv. Exp. Med. Biol. 703: 137-149. PMID: 20711712
57. Edelhauser, H.F., Rowe-Rendleman, C.L., Robinson, M.R., Dawson, D.G., Chader, G.J., Grossniklaus, H.E., Rittenhouse, K.D., Wilson, C.G., Weber, D.A., Kuppermann, B.D., Csaky, K.G., Olsen, T.W., Kompella, U.B., **Holers, V.M.**, Hageman, G.S., Gilger, B.C., Campochiaro, P.A., Whitcup, S.M., and Wong, W.T. 2010. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Inv. Ophthalmol. Vis. Sci. 51:5403-5420. PMCID: PMC3061492
58. Karp, D. R., and **Holers, V. M.** 2011. Complement in health and disease in Cecil Textbook of Medicine, W. B. Saunders, Inc., Orlando, FL.
59. **Holers, V.M.**, Rohrer, B., and Tomlinson, S. 2013. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv. Exp. Med. Biol. 734:137-154. PMID: 22990700
60. **Holers, V.M.**, and Deane, K.D. 2013. Preclinical features of rheumatoid arthritis in Rheumatology 6th Edition (Ed, M.C. Hochberg, A.J. Silman, J.S. Smolen, M.H. Weisman and M.E. Weinblatt), Elsevier, Philadelphia, PA.
61. **Holers, V.M.** 2013. Human C3 glomerulopathy provides unique insights into complement factor H related protein function. J. Clin. Invest. 123:2357-2360. PMCID: PMC3668810
62. Whitcup, S.M., Sodhi, A., Atkinson, J.P., **Holers, V.M.**, Sinha, D., Rohrer, B., and Dick, A.D. 2013. The role of the immune response in age-related macular degeneration. Intl. J. Inflamm. 2013:348092 PMCID: PMC3676958

63. **Holers, V.M.** 2013. Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis. Curr. Opin. Immunol. 25:728-735. PMCID: PMC3895448
64. Pickering, M.C., D'Agati, V.D., Nester, C.M., Smith, R.J., Haas, M., Appel, G.B., Alpers, C.E., Bajema, I.M., Bedrosian, C., Braun, M., Doyle, M., Fakhouri, F., Fervenza, F.C., Fogo, A.B., Fremeaux-Bacchi, V., Gale, D.P., Goicoechea de Jorge, E., Griffin, G., Harris, C.L., **Holers, V.M.**, Johnson, S., Lavin, P.J., Medjeral-Thomas, N., Morgan, B.P., Nast, C.C., Noel, L.H., Peters, D.K., Rodriguez de Cordoba, S., Servais, A., Sethi, S., Song, W.C., Tamburini, P., Thurman, J.M., Zavros, M., and Cook, H.T. 2013. C3 Glomerulopathy: consensus report. Kidney Intl. 84:1079-1089. PMCID: PMC3842953
65. **Holers, V.M.** 2014. Complement and its receptors: new insights into human disease. Ann. Rev. Immunol. 32:433-459. PMID: 24499275
66. Demoruelle, M.K., Deane, K.D., and **Holers, V.M.** 2014. When and where does inflammation begin in rheumatoid arthritis? Curr. Opin. Rheum. 26:64-71. PMCID: PMC4033623
67. **Holers, V.M.** and Deane, K.D. 2014. Preclinical features of rheumatoid arthritis. in Rheumatology 6th Edition (Ed, M.C. Hochberg, A.J. Silman, J.S. Smolen, M.H. Weisman and M.E. Weinblatt), Mosby, Inc. St. Louis, MO.
68. **Holers, V.M.** 2014. Insights from populations at risk for the future development of classified rheumatoid arthritis. Rheum. Dis. Clin. NA 40:605-620, PMCID: PMC4250577
69. Raza, K., Klareskog, L., and **Holers, V.M.** 2016. Predicting and preventing the development of rheumatoid arthritis. Rheumatology 55:367-376. PMID: 26224307
70. **Holers V.M.**, Tomlinson, S., Kulik, L., Atkinson, C., Rohrer, B., Banda, N., and Thurman, J.M.. 2016. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin. Immunol. 28:260-267. PMCID: PMC4987277
71. **Holers, V.M.** 2016. Targeting mechanisms at sites of complement activation for imaging and therapy. Immunobiology 221:726-732. PMCID: PMC4627863
72. Thurman, J.M., Frazer-Abel, A., and **Holers, V.M.** 2017. The evolving landscape for complement therapeutics in rheumatic and autoimmune diseases. Arth. Rheum. 69:2102-2113. PMCID: PMC5659941
73. Deane, K.D., Striebich, C.C., and **Holers, V.M.** 2017. Editorial: Prevention of rheumatoid arthritis: Now is the time, but how to proceed? Arth. Rheum. 69:873-877. PMCID: PMC5406258
74. Deane, K.D., Demoruelle, M.K., Kelmenson, L.B., Kuhn, K.A., Norris, J.M. and **Holers, V.M.** 2017. Genetic and environmental risk factors for rheumatoid arthritis. Best Practice & Research in Clinical Rheumatology 31:3-18, 2017. PMCID: PMC5726551
75. **Holers, V.M.**, and Banda, N.K. 2018. Complement in the initiation and evolution of rheumatoid arthritis. Front. Immunol. 9:1057. PMCID: PMC5985368
76. Tenner, A.J., Atkinson, J.P., and **Holers, V.M.** 2018. Preface to the special issue for the 27th International Complement Workshop. Mol. Immunol. 102:1-2. PMID: 30060927
77. **Holers, V.M.**, Demoruelle, M.K., Kuhn, K.A., Buckner, J.H., Robinson, W.H., Okamoto, Y., Norris, J.M., and Deane, K.D. 2018. Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction. Nature Reviews Rheumatology 14:542-557. PMCID: PMC6704378
78. Deane, K.D., and **Holers, V.M.** 2019. The natural history of rheumatoid arthritis. Clin. Therap. May 14. PMID: 31196652
79. Raza, K., **Holers, V.M.**, and Gerlag, D. 2019. Nomenclature for the phases of the development of rheumatoid arthritis. Clin. Therap. May 03. PMID: 31196657
80. **Holers, V.M.** and Trouw, L. 2019; Complement system. Kelly & Firestein's Textbook of Rheumatology, 11th Edition. Elsevier, Philadelphia, PA.

81. Slight-Webb, S., Bourn, R.L., **Holers, V.M.**, and James, J.A. 2019. Shared and unique immune alterations in pre-clinical autoimmunity. Curr. Opin. Immunol. 61:60-68. PMCID: PMC6901719
82. Huizinga, T.W., **Holers, V.M.**, Anolik, J., Brenner, M.B., Buckley, C.D., Bykerk, V., Connolly, S.E., Deane, K.D., Guo, J., Hodge, M., Hoffmann, S., Nestle, F., Pitzalis, C. Raychaudhuri, S., Yamamoto, K., Li, Z., Klareskog, L. 2020. Disruptive innovation in rheumatology: new networks of global public-private partnerships are needed to take advantage of scientific progress. Ann. Rheum. Dis. 79:553-555. PMID: 32139419
83. Deane, K.D., and **Holers, V.M.** 2021. Rheumatoid arthritis: Pathogenesis, prediction and prevention – an emerging paradigm shift. Arth. Rheum. 73: 181-193. PMCID: PMC7772259
84. **Holers, V.M.** 2021. Challenges and opportunities: Using omics to generate testable insights into pathogenic mechanisms in preclinical seropositive rheumatoid arthritis. Arth. Rheum. 73:1-4. PMID: 32776474
85. Nigrovic, P.A., Colbert, R.A., **Holers, V.M.**, Ozen, S., Ruperto, N., Thompson, S.D., Wedderburn, L.R., Yeung, R.S.M., and Martini, A. 2021. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nature Reviews Rheumatology 17:257-269. PMID: 33731872
86. **Holers, V.M.**, Kuhn, K.A., Demoruelle, M.K., Norris, J.M., Firestein, G.S., James, E.A., Robinson, W.H., Buckner, J.H., and Deane, K.D. 2022. Mechanism-driven strategies for prevention of rheumatoid arthritis. Rheumatol. Autoimmun. 2: 109-119. PMCID: PMC9610829
87. Olsen, N.J., Okuda, D.T., **Holers, V.M.**, and Karp, D.R. 2022. Editorial: Understanding the concept of pre-clinical autoimmunity. Front. Immunol. doi: 10.3389/fimmu.2022.983310. PMCID: PMC9355672
88. West, S.G., and **Holers, V.M.** 2022. Clinical academic rheumatology: Still getting more than you pay for. Arth. Care Res. 74:1039-1040. PMID: 36194068
89. **Holers, V.M.** 2023. Contributions of animal models to mechanistic understandings of antibody-dependent disease and roles of the amplification loop. Immunol. Rev. 313:181-193. PMID: 36111456
90. Kemper, C., Ferreira, V.P., Paz, J.T., **Holers, V.M.**, Lionakis, M.S., and Alexander, J.J. 2023. Complement: The Road Less Traveled. J. Immunol. 210:119-125. PMCID: PMC10038130
91. **Holers, V. M.** 2023. Complement therapeutics are coming of age in rheumatology. Nat. Rev. Rheumatol. 19:470-485. PMID: 37337038.
92. **Holers, V. M.** 2023. Are there causal mucosal drivers in the preclinical development of rheumatoid arthritis? Semin. Art. Rheum. doi: 10.1016/j.semarthrit.2023.152324. PMID: 38030540
93. **Holers, V.M.** and Trouw, L. 2024; Complement system. Kelly & Firestein's Textbook of Rheumatology, 12th Edition. Elsevier, Philadelphia, PA
94. **Holers, V.M.**, Demoruelle, K.M., Buckner, J.H., James, E.A., Firestein, G.S., Robinson, W.H., Steere, A.C., Zhang, F., Norris, J.M., Kuhn, K.A., and Deane, K.D. 2024. Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis. Nature Reviews Rheumatology 20:601-613. PMID: 39251771
95. Deane, K.D., **Holers, V.M.**, Emery, P., Mankia, K., El-Gabalawy, H., Sparks, J.A., Costenbader, K.H., Schett, G., van der Helm-van Mil, A., van Schaardenburg, D., Thomas, R., and Cope, A.P. 2024. Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease. Ann. Rheum. Dis. doi: 10.1136/ard-2023-224211. PMID: 39242182
96. **Holers, V.M.** Rheumatoid arthritis prevention: We need to identify new targets for "NextGen" therapeutic trials. Semin. Arth. Rheum. 2024. Feb;70S:152577. doi: 10.1016/j.semarthrit.2024.152577. PMID: 39551676 Liu, F., Wawersik, S., Tomlinson, S., Thurman, J.M., and
97. **Holers, V.M.** 2025. Tissue-targeted regulators of complement for amelioration of human disease: rationale and novel therapeutic strategies. J. Immunol. 2025 Apr 21:vkaf053. doi: 10.1093/jimmun/vkaf053. PMID: 40258303

98. **Holers V.M.** 2025. Systemic lupus erythematosus as the paradigm for understanding the complex immune relationships and therapeutic opportunities for targeting complement in autoimmune diseases. Immunobiology 2025 May;230(3):152915. doi: 10.1016/j.imbio.2025. PMID: 40409177
99. Shelef, M.A., and **Holers V.M.** 2025. Ever-expanding connections between peptidylarginine deiminase 4 and rheumatoid arthritis. Arth. Rheum. 2025 Apr 4. doi: 10.1002/art.43170. PMID: 40181788
100. Poppelaars, F., **Holers, V.M.**, and Thurman, J.M. 2025. Friend or foe: assessing the value of animal models for facilitating clinical breakthroughs in complement research. J. Clin. Invest. 2025 Jun 16;135(12):e188347. doi: 10.1172/JCI188347. PMID: 40519165

OTHER MEDIA:

1. **Holers, V.M.** and Frazer-Abel, A. (2019, April 30). The complement system - an introduction for undergraduates [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 3, 2019, from <https://hstalks.com/bs/3930/>.

INVITED LECTURES (1993-Present):

1. Washington University School of Medicine; St. Louis, MO; January 11, 1993; Immunology Seminar "Of mice and men: complement and the immune response"
2. Monsanto Corporate Research; St. Louis, MO; January 12, 1993; Immunology Seminar Series "Models of complement in the immune response"
3. Glaxo Institute for Molecular Biology; Geneva, Switzerland; April 1, 1993; Special Seminar Speaker "Complement receptor 2 in the immune response"
4. Ohio State University; Columbus, OH; April 5, 1994; Immunology Seminar "Regulation of B lymphocyte fate by CD21, a receptor for C3, CD23 and the Epstein-Barr virus"
5. University of Texas Southwestern Medical Center; Dallas, TX; September 30, 1994; Special Seminar Speaker "Roles of complement receptor 2 in B lymphocyte development and differentiation"
6. NYU Medical Center; New York, NY; December 15, 1994; Immunology Club Seminar Series "Complement receptors and regulatory proteins: evolutionary and immunologic lessons from mouse models"
7. Experimental Biology/AAI Meeting; Atlanta, GA; April 12, 1995; Mini-Symposium Speaker "Complement receptors"
8. IBC USA Conference: Controlling the Complement System; Boston, MA; May 9, 1995; Special Lecture "Characterization of mouse homologues of human complement receptors and regulatory proteins: analysis in the mouse MRL/lpr model of SLE"
9. University of Pennsylvania School of Medicine; Philadelphia, PA; March 28, 1996; Complement Seminar "Complement receptors and the cellular immune response"
10. Case Western Reserve University School of Medicine; Cleveland, OH; April 30, 1996; Immunology Seminar Series "Complement and the cellular immune response"
11. Department of Microbiology, UCHSC; October 11, 1996; Microbiology Seminar Series "Complement inhibitors: therapy for inflammatory and autoimmune disease?"
12. American Society of Nephrology National Meeting; New Orleans, LA; November 3, 1996; Clinical Science Symposium "Complement regulators and receptors in experimental and human SLE"
13. Webb-Waring Lung Institute; Denver, CO; January 7, 1997; Seminar Series "An association between complement receptors and glutathione regulation?"
14. Department of Pathology; Harvard Medical School, Boston, MA; March 5, 1997; Pathology Seminar Series "Complement, inflammation and autoimmunity"

15. Division of Rheumatology; Northwestern University Medical School; Chicago, IL; March 11, 1997; MAMDC Seminar Series "CD21, autoimmunity and the cellular immune response"
16. University of Virginia School of Medicine; Charlottesville, VA; March 12, 1998; Beirne Carter Center Immunology Series "Complement as a regulator of multiple phases of the immune response"
17. University of Cologne; Cologne, Germany; September 16, 1998; Department of Genetics Symposium "CD21, Immunity and Autoimmunity"
18. British Society for Immunology Meeting; Harrogate, UK; December 2, 1998; Invited Symposium Speaker "Manipulating complement regulatory protein levels in vivo demonstrates the importance of the complement system in murine models"
19. University of Alabama Birmingham; Birmingham, AL; January 12, 1999; Microbiology Seminar Series "Complement and the immune response: regulatory and effector roles"
20. University of Colorado Health Sciences Center; Denver, CO; March 17, 1999; Medical Grand Rounds "Complement inhibitors as new therapeutics for rheumatic diseases"
21. University of Washington School of Medicine; Seattle, WA; April 6, 1999; Special Seminar "Complement and the immune response: regulatory and effector roles"
22. University of Iowa School of Medicine; Iowa City, IA; May 5, 1999; Kroc Lecturer – Immunology Seminar "Complement and the immune response: regulatory and effector roles"
23. Henry Kunkel Society Meeting, International Conference on Autoantibodies and Autoimmunity; Oslo, Norway; June 27, 1999; Invited Speaker "Complement inhibitors as therapeutics for inflammatory and autoimmune diseases"
24. University of Nebraska School of Medicine; Omaha, NE; October 1, 1999; Medical Grand Rounds "Complement inhibitors as new therapeutics for autoimmune diseases"
25. Wake Forest University, Bowman Gray School of Medicine; Winston Salem, NC; October 14, 1999; Microbiology/Immunology Seminar "Manipulation of complement activities as a therapeutic strategy"
26. American College of Rheumatology Basic Research Conference; Boston, MA; November 13, 1999; Invited Symposium Speaker "The complex roles of complement proteins: protection from as well as effector mechanisms in humoral autoimmunity"
27. Hospital for Special Surgery, Weill Medical College of Cornell University; New York, NY; December 13, 1999; Immunology Lecture Series "Complement and the immune response: regulatory and effector roles"
28. Hopital Cochin; Paris, France; March 18, 2000; Immunology Series "Complement: regulatory and effector roles"
29. University of Wales College of Medicine; Cardiff, Wales; June 9, 2000; Immunology Series "Complement and the immune response: regulatory and effector roles"
30. National Institutes of Health; Bethesda, MD; September 4, 2001; NIH Conference: Role of Innate Immunity in the Etiopathology of Autoimmunity "Complement receptors in the regulation of self-reactive B cells"
31. Oklahoma Medical Research Foundation; Oklahoma City, OK; September 9, 2001; First International Lupus Genetics Conference "Complement Receptor 2: Role of genetic and acquired deficiencies in SLE"
32. American College of Rheumatology Annual Meeting; San Francisco, CA; November 13, 2001; Invited Symposium Speaker "Autoimmunity and the complement conundrum"
33. University of Pennsylvania School of Medicine; Philadelphia, PA; January 22, 2002; Immunology Colloquium "Complement, immunity and autoimmunity"

34. University of Pennsylvania School of Medicine; Philadelphia, PA; January 22, 2002; Medicine Grand Rounds "Therapeutic opportunities by targeting the complement system"
35. University of Alabama Birmingham; Birmingham, AL; March 5, 2002; Microbiology Seminar Series "Complement, immunity and autoimmunity"
36. University of Virginia School of Medicine; Charlottesville, VA; March 18, 2002; Beirne Carter Center Immunology Series "Complement, immunity and autoimmunity"
37. FASEB Summer Research Conference – Tucson, AZ; August 4, 2002; Invited Symposium Speaker "Impact of structure-function analyses on the understanding of complement receptor 2 roles in normal immune responses and autoimmunity"
38. National Institutes of Health; Bethesda, MD; September 12, 2002; International Workshop on Autoantibodies as Predictors of Autoimmune Diseases "Pre-clinical autoimmunity in rheumatoid arthritis"
39. Center for Blood Research; Boston, MA; March 25, 2003; Research Seminar "CR2/CD21: A model for understanding interactions of innate and acquired immune systems"
40. Massachusetts Institute of Technology; Cambridge, MA; March 25, 2003; B Cell Bash "Premature introduction of complement receptor signals alters B cell development and immune responses: mechanisms and implications"
41. National Institutes of Health; Bethesda, MD; March 31, 2003; Biomarkers for the Assessment of Systemic Lupus Erythematosus Meeting "Complement"
42. Medical University of South Carolina; Charleston, SC; April 9, 2003; Pfizer Visiting Professor/Medical Grand Rounds "Complement as a therapeutic target for human disease"
43. AAI Annual Meeting; Denver, CO; May 7, 2003; Major Symposium Speaker "Complement and the immune response: from shaping the repertoire to mediating effector functions"
44. Second Workshop on Complement Associated Diseases, Animal Models and Therapeutics; Mykocos, Greece; June 4, 2003; Invited Symposium Speaker "Diminished responses to antigenic challenge in mice that prematurely express Complement Receptor 2 (CR2/CD21) during B cell development"
45. Transplantation Society Basic Sciences Symposium; Keystone, CO; September 16, 2003; Plenary Session Speaker "Complement and the regulation of immunity"
46. University of Nebraska School of Medicine; Omaha, NE; October 10, 2003; Medical Grand Rounds "Evolution of autoimmunity in rheumatoid arthritis: insights into etiology?"
47. American College of Rheumatology Basic Research Conference; Orlando, FL; October 24, 2003; Invited Speaker "Complement in rheumatoid arthritis"
48. American Society of Nephrology Advances in Research Conference; Orlando, FL; November 13, 2003; Invited Symposium Speaker "Therapeutic approaches to the complement system"
49. Northwestern University School of Medicine; Chicago, IL; December 16, 2003; Microbiology-Immunology Seminar Series "CR2/CD21: A model for understanding the interactions between innate and acquired immunity"
50. Washington University School of Medicine; St. Louis, MO; January 12, 2004; Immunology Research Seminar "Innate recognition of self: mechanisms and consequences"
51. Washington University School of Medicine; St. Louis, MO; January 14, 2004; Rheumatology Translational Research Seminar "Evolution of autoimmunity in rheumatoid arthritis: insights into pathogenesis?"
52. Cedars Sinai Medical Center; Los Angeles, CA; August 24, 2004; Division of Rheumatology Grand Rounds "Evolution of autoimmunity in rheumatoid arthritis: insights into pathogenesis?"

53. International Congress of the Transplantation Society; Vienna, Austria; September 7, 2004; State-of-the-Art Symposium "Innate immunity and transplant rejection"
54. Hospital Charite – Benjamin Franklin; Berlin, Germany; September 10, 2004; Department of Trauma Surgery Grand Rounds "Role of alternative complement pathway in tissue injury"
55. Global Arthritis Research Network; Montreal, Canada; September 22, 2004; Symposium Speaker "Innate immunity and rheumatic disease"
56. Hospital for Special Surgery; New York, NY; December 15, 2004; Rheumatology Grand Rounds "Evolution of autoimmunity in rheumatoid arthritis: insights into pathogenesis – and prevention?"
57. NIDDK Glomerular Disease Workshop; Bethesda, MD; January 24, 2005; Invited Symposium Speaker "Complement, therapeutics and glomerular disease"
58. Duke University Medical Center; Durham, NC; February 1, 2005; Rheumatology Grand Rounds "Evolution of autoimmunity in rheumatoid arthritis: insights into pathogenesis – and prevention?"
59. Duke University Medical Center; Durham, NC; February 1, 2005; Immunology Seminar "CR2/CD21, immunity and autoimmunity"
60. University of Texas Southwestern Medical Center; Dallas, TX; March 9, 2005; Excellence in Immunology Lecture "Autoimmune and pathogenic mechanisms in inflammatory arthritis"
61. University of Texas Southwestern Medical Center; Dallas, TX; March 10, 2005; Rheumatology Grand Rounds "Evolution of autoimmunity in rheumatoid arthritis: insights into pathogenesis – and prevention?"
62. University of Colorado Health Sciences Center; Denver, CO; April 22, 2005; Research Symposium on the Health of Women and Girls "Progress in prevention strategies for autoimmune diseases"
63. FASEB Summer Research Conference – Immunoreceptors; Tucson, AZ; July 24, 2005; Invited Speaker "Complement Receptor 2: Novel ligands and new perspectives on structure-function relationships "
64. AMLI Annual Meeting; Denver, CO; August 23, 2005; Plenary Session Speaker "Unexpected role of the alternative pathway in disease"
65. Global Arthritis Research Network Symposium; Vienna, Austria; September 15, 2005; Invited Speaker "Antibodies to citrullinated proteins enhance tissue injury in inflammatory arthritis"
66. Johns Hopkins University School of Medicine; Baltimore, MD; December 14, 2005; Molecular Pathology Seminar Series "Unexpected role of the alternative complement pathway in tissue injury"
67. University of California San Diego; San Diego, CA; February 28, 2006; Symposium on Inflammation and Autoimmunity "Pathogenesis of early rheumatoid arthritis"
68. EULAR: Annual European Congress of Rheumatology; Amsterdam, Netherlands; June 21, 2006; Invited Speaker "Pathogenesis of autoantibodies"
69. FOCIS: Federation of Clinical Immunology Societies Meeting; San Francisco, CA; June 2, 2006; Symposium on Autoantigens "Evolution and pathogenesis of autoantibodies to citrullinated antigens in rheumatoid arthritis"
70. American College of Rheumatology Annual Meeting; Washington, DC; November 10, 2006; ACR Basic Research Conference "Alternative pathway mediating rheumatic diseases: scientific rationale and evidence for causality?"
71. American College of Rheumatology Annual Meeting; Washington, DC; November 11, 2006; ACR Frontiers in Translational Research "Identifying individuals at risk for developing rheumatoid arthritis in the asymptomatic stage: is it possible?"

72. Brigham and Women's Hospital; Boston, MA; February 6, 2007; Rheumatology Grand Rounds "Evolution and mechanisms of pathogenic autoimmunity in rheumatoid arthritis"
73. FOCIS: Federation of Clinical Immunology Societies Meeting; San Diego, CA; June 9, 2007; Symposium, Immune Responses to Modified Self Antigens "Citruination: Target of pathogenic autoimmunity in rheumatoid arthritis"
74. University of Toronto; Toronto, Canada; June 26, 2007; Ogryzlo Day Keynote Presentation "Evolution and mechanisms of pathogenic autoimmunity in rheumatoid arthritis"
75. Emory University School of Medicine; February 12, 2008; Medicine Grand Rounds "The emergence of complement targeted therapies"
76. Emory University School of Medicine; February 13, 2008; Pfizer Visiting Professor Rheumatology Grand Rounds Lecture "Evolution and mechanisms of pathogenic autoimmunity in rheumatoid arthritis"
77. ARVO Annual Meeting, April 27, 2008; Invited Special Interest Group Symposium Speaker "New concepts regarding the role of the alternative pathway of complement in disease pathogenesis"
78. Feinstein Institute for Medical Research; May 28, 2008; Rheumatology Grand Rounds Conference "Evolution and mechanisms of pathogenic autoimmunity in rheumatoid arthritis"
79. University of Geneva; October 3, 2008; Department of Immunology Seminar "Evolution and mechanisms of pathogenic autoimmunity in rheumatoid arthritis"
80. National Jewish Health; November 21, 2008; Kauvar Conference on Excellence in Research Keynote Speaker "Natural history of rheumatoid arthritis: methods to study early disease pathogenesis"
81. Imperial College London, Hammersmith Hospital; February 12, 2009; Frontiers in Rheumatology: Eric Bywaters Lecture "Evolution of autoimmunity in rheumatoid arthritis: insights into pathogenesis and the potential for prevention"
82. Imperial College London, Hammersmith Hospital; February 13, 2009; Immunology Seminar "Importance and mechanisms of alternative complement pathway mediated injury in immune complex disease"
83. University of Nebraska School of Medicine; April 24, 2009; Medicine Grand Rounds "Rheumatoid arthritis pathogenesis and implications for disease management: today and tomorrow"
84. Cincinnati Children's Hospital; May 6, 2009; Combined Research Conference "Evolution of autoimmunity in rheumatoid arthritis: insights into pathogenesis and the potential for prevention"
85. University of Texas Southwestern School of Medicine; August 21, 2009; Medicine Grand Rounds, Kroc Lectureship "Rheumatoid arthritis pathogenesis and implications for disease management: today and tomorrow"
86. University of Colorado Denver; September 30, 2009; Structural Biology Research Seminar "Complement receptor type 2 (CR2/CD21): approaches to understanding immune-related structure-function relationships in their biologic context"
87. Hospital for Special Surgery; November 12, 2009; Alumni Association Meeting: Christian Lecture "Rheumatoid arthritis pathogenesis and implications for disease management today and tomorrow"
88. Hospital for Special Surgery; November 13, 2009; Alumni Association Meeting: Freyberg Lecture "Complement in the pathogenesis of inflammatory arthritis: new concepts and emerging therapeutic approaches"
89. University of California San Francisco; April 27, 2010; Rheumatology Seminar Series "Rheumatoid arthritis: early phase natural history studies provide insights into pathogenesis and reveal opportunities for primary prevention"
90. University of Toledo; October 16, 2010; 2010 Workshop on Infection and Immunity "The properdin system and the Ohio connection: evolution of a new human therapeutic paradigm"

91. American College of Rheumatology Annual Meeting; November 9, 2010; Basic Science Symposium Invited Speaker “Experimental arthritis and anti-CCP”
92. American Society of Nephrology; November 18, 2010; Renal Week Invited Speaker “Complement dysfunction in pre-eclampsia and related diseases of pregnancy”
93. Mario Negri Institute for Pharmacological Research; May 7, 2011 2nd International Conference on Membranous Nephropathy “Site-directed complement inhibitors”
94. University of Leiden; August 24, 2011; European Meeting on Complement in Human Disease “Complement therapeutics in human disease: Opportunities and challenges into the 21st century”
95. Estes Park, CO; September 15, 2011; 12th Annual Colorado Immunology Conference “Antibodies to citrullinated protein antigens (ACPA) and peptidyl arginine deiminases in the pathogenesis of rheumatoid arthritis: perpetrators or innocent bystanders”
96. University of Colorado School of Medicine; November 2, 2011; Medical Grand Rounds “Complement therapeutics 2011: PNH, aHUS, AMD and beyond”
97. Barbara Davis Center for Childhood Diabetes; December 13, 2011; DERC Research in Progress Seminar “Bridging the gap between academic science and pharmaceutical development to improve the complement therapeutics pipeline”
98. University of California San Diego; January 10, 2012; Rheumatology, Allergy and Immunology Seminar Series “Rheumatoid arthritis: early stage natural history studies provide insights into pathogenesis and new potential opportunities for prevention”
99. University of California San Diego; January 11, 2012; Department of Medicine Grand Rounds Nathan J. Zvaifler Rheumatology Lectureship: “Complement therapeutics come of age in hemolytic, thrombotic microangiopathic, and potentially ophthalmologic and autoimmune diseases”
100. Santa Fe, NM; January 22, 2012; Keystone Symposium on Rheumatoid Arthritis: Molecular and Clinical Insights “When does RA begin: inflammatory and autoimmune signatures precede clinical onset”
101. Department of Rheumatology, NYU Hospital for Joint Diseases; February 9, 2012; Rheumatology Basic Science Seminar “Complement in the pathogenesis of inflammatory arthritis: new concepts and emerging therapeutic approaches”
102. Department of Rheumatology, NYU Hospital for Joint Diseases; February 9, 2012; Rheumatology Grand Rounds “Insights from natural history studies into the early pathogenesis and strategies for prevention of rheumatoid arthritis”
103. Rheumatism Society of the District of Columbia; March 21, 2012; Invited Speaker “Rheumatoid arthritis: early stage natural history studies provide insights into pathogenesis and new potential opportunities for prevention”
104. Aplastic Anemia and MDS International Foundation; March 23, 2012; Bone Marrow Failure Symposium Invited Lecture “Complement: taming the double-edged sword for therapeutic benefit”
105. Division of Rheumatology, University of Massachusetts Medical School; April 12, 2012; Leaders in Rheumatology Speaker Series “Rheumatoid arthritis: early stage natural history studies provide new insights into pathogenesis and potential opportunities for prevention”
106. Division of Rheumatology, University of Massachusetts Medical School; April 13, 2012; Rheumatology Research Seminar “Complement in the pathogenesis of human disease and inflammatory arthritis: new concepts and emerging therapeutic approaches”
107. Feinstein Institute for Medical Research; April 25, 2012; Rheumatology Research Conference “Rheumatoid arthritis: early stage natural history studies provide new insights into pathogenesis and potential opportunities for prevention”

108. University of Colorado Denver; May 3, 2012; Department of Medicine Innovations Conference
“Bridging the gap between academic science and drug development - to improve the complement therapeutics pipeline”
109. XV International Symposium on Retinal Degeneration; July 16, 2012; Bad Gogging, Germany; Plenary Lecture “Context-specific roles for complement in innate and adaptive immune responses”
110. 1st C3 Glomerulopathy Meeting; August 19, 2012; Hinxton, UK; Invited Speaker “Targeted C3 inhibitors”
111. Lupus 2012 – New Targets, New Approaches; September 29, 2012; Whistler, Canada; Invited Speaker “Evaluating the B cell C3d:CR2 innate-adaptive immune interaction as a therapeutic target in lupus”
112. American College of Rheumatology Annual Scientific Meeting; November 11, 2012; Washington, DC; Basic Science Symposium Invited Speaker “Question: is rheumatoid arthritis a preventable disease”
113. 3rd International Pre-RA/RA-Risk Workshop January 28, 2013; Stockholm, Sweden; Invited Speaker “Insights into the earliest phases of RA obtained from studies of high risk individuals identified through family and community health fair screening”
114. 3rd International Pre-RA/RA-Risk Workshop; January 29, 2013; Stockholm, Sweden; Invited Speaker “Update on events in the lungs before onset of RA: The Denver experience”
115. Karolinska Institute Min-Symposium; January 29, 2013; Stockholm, Sweden; Invited Speaker “The earliest phases of RA; family studies using experiences from pre-diabetes studies”
116. Johns Hopkins University; March 1, 2013; Baltimore, MD; Rheumatology Rounds Presentation “Initiation and early evolution of rheumatoid arthritis: insights from mechanism-focused natural history studies”
117. Ohio State University; March 21, 2013; Columbus, Ohio; Medicine Grand Rounds “Complement therapies come of age: genetic drivers and pathophysiologic outcomes”
118. New York University; April 25, 2013; New York, NY; Immunology Club Seminar Speaker “Citruinated protein autoreactivity in the pathogenesis of rheumatoid arthritis”
119. American College of Rheumatology Annual Scientific Meeting; October 25, 2013; San Diego, CA; Preclinical Rheumatic Disease Research Conference Speaker “Why is the study of preclinical phases of rheumatic disease important?”
120. American College of Rheumatology Annual Scientific Meeting; October 30, 2013; San Diego, CA; Basic Science State of the Art Lecture “Emerging and unexpected regulatory roles for complement in the rheumatic diseases”
121. British Society for Immunology Congress; December 3, 2013; Liverpool, England; Invited Speaker “Complement in the pathogenesis of inflammatory arthritis”
122. University of Birmingham; December 4, 2013; Birmingham, England; Division of Rheumatology Seminar “Natural history of rheumatoid arthritis: lessons and insights from studies of at-risk individuals”
123. Cardiff University Institute of Infection and Immunity; December 6, 2013; Cardiff, Wales; Complement Mini-Symposium “The CR2:C3d interface: utilization for therapeutic and diagnostic considerations”
124. University of California Irvine; February 27, 2014; Irvine, CA; Institute for Immunology Seminar “Complement therapeutics come of age: current status and evolving approaches to targeted therapy”
125. University of Alabama Birmingham; March 19, 2014; Birmingham AL; Department of Medicine Grand Rounds: Cochrane Lectureship “Rheumatoid arthritis; Preclinical natural history studies provide key insights into disease initiation, pathogenesis and prevention”

126. University of Alabama Birmingham; March 20, 2014; Birmingham AL; Rheumatology Grand Rounds "Natural history of rheumatoid arthritis: What we learn from studies of at-risk individuals"
127. University of Alabama Birmingham; March 20, 2014; Birmingham AL; Program in Immunology Seminar "Complement in the pathogenesis of inflammatory arthritis: How animal models inform the new era of human therapeutics"
128. University of Colorado; April 10, 2014; Denver, CO; Research and Innovation Conference "Studies of the etiology of rheumatoid arthritis: a multi-disciplinary approach"
129. New York University; April 16, 2014; New York, NY; Rheumatology Grand Rounds "Natural history of rheumatoid arthritis: What we learn from studies of at-risk individuals"
130. University of Pittsburgh; May 22, 2014; Pittsburgh, PA; Department of Medicine Research Day Plenary Speaker "Early natural history studies provide novel insights into pathogenesis and opportunities for prevention of rheumatoid arthritis"
131. University of Pittsburgh; May 23, 2014; Pittsburgh, PA; Rheumatology Grand Rounds "Natural history of rheumatoid arthritis: Lessons and insights from studies of at-risk individuals"
132. University of Pittsburgh; May 23, 2014; Pittsburgh, PA; Department of Medicine Grand Rounds "Complement therapeutics (finally) come of age: current uses and emerging opportunities"
133. University of Colorado Denver; June 2, 2014; Denver, CO; Technology Transfer Office Awards Luncheon Featured Speaker "Living in the 'tidal pool': bridging the gap between academic science and pharmaceutical development"
134. Oregon Health & Science University; January 7, 2015; Portland, OR; Rheumatology Grand Rounds "Natural history of rheumatoid arthritis: Mechanic insights from studies of at-risk individuals"
135. University of Colorado Denver; January 28, 2015; Denver, CO; Department of Medicine Grand Rounds "Moving the bar from treatment to prevention of autoimmune disease: the case for rheumatoid arthritis"
136. NIAMS Intramural Research Program; February 6, 2015; Bethesda, MD; Rheumatology Grand Rounds "Natural history of rheumatoid arthritis: mechanistic insights from studies of at-risk individuals"
137. Royal Society Hooke Committee Complement Meeting; February 23, 2015; Chicheley, UK; Complement: Drive of Inflammation and Therapeutic Target in Diverse Diseases Speaker "Targeting sites of complement activation for imaging and therapy"
138. University of Chicago; March 17, 2015; Chicago, IL; Rheumatology Grand Rounds "Natural history of rheumatoid arthritis: Mechanic insights from studies of at-risk individuals"
139. University of Colorado Denver; April 30, 2015; Denver, CO; Structural Biology and Biochemistry Symposium "Living in the 'Tidal Pool': Bridging the gap between academic science and pharmaceutical development"
140. PEGS: The Essential Protein Engineering Summit; May 5, 2015; Boston, MA; Biologics for Autoimmune Disease Session "The complement system as a target for biologics against autoimmune diseases"
141. University of Colorado Denver; May 7, 2015; Denver, CO; Department of Medicine Faculty Research and Innovation Conference "Targeting mechanisms of local complement activation for diagnostic and therapeutic applications"
142. FOCIS Meeting; June 25, 2015; San Diego, CA; Best of Rheumatology Session "Characterizing the molecular origins of human rheumatoid arthritis"
143. Aegean 8th International Conference on Complement Therapeutics; September 3, 2015; Chania, Greece; Invited Speaker "Pathogenic natural antibodies: common neoepitopes found across multiple disease models and use as targeting modules for novel complement inhibitors"

144. American College of Rheumatology Basic Research Conference; November 6, 2015; San Francisco, CA: Invited Speaker “The intersection of genes and environment in the initiation and early development of rheumatoid arthritis”
145. Rheumatology Research Foundation Memorial Lectureship; November 10, 2015; San Francisco, CA; “Rheumatoid arthritis: mechanisms and predictors of pre-clinical RA”
146. American College of Rheumatology Annual Scientific Meeting; November 10, 2015; Rheumatology Research Foundation Disease Targeted Research Special Session “Pathogenic humoral autoimmunity in the transition to clinically apparent arthritis”
147. Uppsala University; November 20, 2015; Uppsala, Sweden; Research Seminar “Targeting the complement C3d:CR2 interface for therapeutic and diagnostic purposes”
148. University of Leeds; February 24, 2016; Leeds, England; Yorkshire Regional Rheumatology Seminar “Pre-RA: The evolution of autoimmunity in rheumatoid arthritis”
149. European Workshop on Rheumatology Research; February 26, 2016; York, England; Invited Speaker “Insights into the initiation and preclinical pathogenesis of rheumatoid arthritis from studies of at-risk populations”
150. Northwestern University; March 17, 2016; Chicago, IL; Rheumatology Grand Rounds “Insights into the initiation and preclinical pathogenesis of rheumatoid arthritis from studies of at-risk populations”
151. University of Washington; March 25, 2016; Seattle, WA; Lane Lectureship/Rheumatology Seminar “The mucosal hypothesis and the molecular origins of rheumatoid arthritis”
152. Ohio State University; April 26, 2016; Columbus, OH; Everett D. Reese Immunology and Rheumatology Seminar “Insights from studies of at-risk populations into the initiation and preclinical pathogenesis of rheumatoid arthritis”
153. Harvard Medical School; April 28, 2016; Boston, MA; Medical Grand Rounds Bauer Lectureship “Insights into the initiation and preclinical pathogenesis of rheumatoid arthritis from studies of at-risk populations”
154. Aegean 9th International Conference on Complement Therapeutics; June 29, 2016; Rhodes, Greece; Invited Speaker “Amelioration of disease in the MRL/*lpr* model of lupus by treatment with an anti-C3d monoclonal antibody that blocks C3d:CR2 ligand:receptor interactions”
155. Colorado Immunology Conference; September 1, 2016; Steamboat Springs, CO; Invited Speaker “Rheumatoid arthritis and the mucosal origins hypothesis”
156. 8th International Forum on Rheumatoid Arthritis; October 22, 2016; Tokyo, Japan; Invited Speaker “Studies of at-risk populations provide insights into the origins, pathogenesis and prevention of rheumatoid arthritis”
157. NYU Langone Seminar in Advanced Rheumatology; March 16, 2017; New York, NY; Invited Speaker “Treating early and pre-clinical rheumatoid arthritis”
158. Cleveland Clinic Biologic Therapies Summit VII; April 6, 2017; Cleveland, OH; Invited Speaker “Pre-rheumatoid arthritis: Can we define it and prevent its progression?”
159. New York Academy of Science “Complement Pathways in Disease”; April 25, 2017; New York, NY; Invited Speaker “Harnessing innate immune recognition of injured tissues for therapeutic and diagnostic purposes”
160. University of Arizona SCARI Lectureship; May 19, 2017; Tucson, AZ; Invited Professorship “Studies of at-risk populations provide insights into the origins, pathogenesis and prevention of rheumatoid arthritis”

161. Brigham and Women's Hospital-Harvard Medical School Rheumatology Grand Rounds; May 23, 2017; Boston, MA; "Studies of at-risk populations provide insights into the origins and pathogenesis of pre-clinical rheumatoid arthritis"
162. 10th International Conference on Complement Therapeutics; June 27, 2017; Crete, Greece; Invited Speaker "Interconnections and key roles of alternative and lectin pathway components in the pathogenesis of experimental rheumatoid arthritis"
163. Karolinska Institute Research Seminar Series; September 6, 2017; Stockholm, Sweden; Invited Speaker "Studies of at-risk populations provide insights into the mucosal origins and causal pathogenesis of pre-clinical rheumatoid arthritis"
164. Vanderbilt University Division of Rheumatology Seminar Series; January 25, 2018; Nashville, TN; Invited Speaker "Rheumatoid Arthritis and the Mucosal Origins Hypothesis"
165. Vanderbilt University Department of Medicine Grand Rounds Riven Lectureship; January 25, 2018; Nashville, TN; Invited Professorship "Pathogenesis and Prevention of Rheumatoid Arthritis"
166. University of Colorado School of Medicine; January 31, 2018; Aurora, CO; Human Immunology and Immunotherapeutics Initiative Translational Immunology Case Study Seminar Series; Invited Speaker "Molecular Drivers of 'Asymptomatic Autoimmunity'; Evolution of the Rheumatoid Arthritis Molecular Origins Hypothesis"
167. Cleveland Clinic Medicine Grand Rounds; March 8, 2018; Cleveland, OH; Invited Professor "New Ideas in the Pathogenesis and Prevention of Rheumatoid Arthritis"
168. Frontiers of Rheumatology: 36th Carl M. Pearson Memorial Symposium; April 13, 2018; Marina del Rey, CA; Invited Speaker "Pathogenesis and Prevention of Rheumatoid Arthritis"
169. Cincinnati Children's Hospital P30 Seminar Series; June 6, 2018; Cincinnati, OH; Invited Speaker "Rheumatoid Arthritis and the Mucosal Origins Hypothesis"
170. JDRF Revisiting Autoimmunity: Common Mechanisms Meeting "Innate-Adaptive Interface - Have We Ignored Innate Immunity?" Session; June 19, 2018; San Francisco, CA; Invited Speaker "Insights from the Development of the Rheumatoid Arthritis Mucosal Origins Hypothesis"
171. FOCIS Meeting Session "New Mechanisms for Old Players: Complement"; June 23, 2018; San Francisco, CA; Invited Speaker "Complement: Taming the Hydra for Therapeutic Benefit"
172. University of Lübeck International Research Training Group "Inflammation in Allergy and Infection" Distinguished Lecture Series; July 5, 2018; Lübeck, Germany; Visiting Professor "Studies of At-Risk Populations Provide Insights into the Pre-Clinical Pathogenesis and Prevention of Rheumatoid Arthritis"
173. University of Colorado SPARK Program; August 22, 2018; Invited Speaker "Living in the 'Tidal Pool': Faculty Considerations in Bridging the Gaps Between Academic Roles and Pharmaceutical Development"
174. 10th International Forum on Rheumatoid Arthritis: September 14, 2018; Beijing, China; Publication Workshop Invited Speaker "Using Informative Murine Models to Address Human Clinical Research Questions: An Evolving Paradigm"
175. 10th International Forum on Rheumatoid Arthritis: September 15, 2018; Beijing, China; Invited Speaker "Rheumatoid Arthritis and the Mucosal Origins Hypothesis: Does Protection Turn to Destruction?"
176. Precision Medicine in Autoimmunity Conference: October 12, 2018; Denver, CO; Invited Speaker "Natural History Studies of Rheumatic/Autoimmune Diseases in Biomarker Discovery: A Rich Source of Potential Mechanistic and Predictive Information"

177. Symposium Honoring John Atkinson at Washington University School of Medicine; November 12, 2018; St. Louis, MO; Invited Speaker "Multiple Roles of Complement in the Initiation and Evolution of Rheumatoid Arthritis"
178. Barbara Davis Center for Childhood Diabetes Grand Rounds; January 8, 2019; Aurora, CO; Invited Speaker "Rheumatoid Arthritis and the Mucosal Origins Hypothesis: Insights into Pathogenesis and Prevention"
179. Cleveland Clinic Lerner Research Institute Department of Inflammation and Immunity Seminar; January 22, 2019; Cleveland, OH; Invited Speaker "Multiple Pathogenic Roles of Complement in the Evolution of Rheumatoid Arthritis"
180. Israel Institute for Advanced Studies Conference on Complement Regulation and Human Disease; February 12, 2019; Edmond J. Safra Campus, Givat Ram, Jerusalem, Israel; Invited Speaker "Complement in the Evolution of Rheumatoid Arthritis: A Dual Edge Sword"
181. University of Colorado Division of Renal Medicine and Hypertension Research Seminar; March 4, 2019; Aurora, CO; Invited Speaker "Explorations of the Roles of Complement in the Development of Lupus Nephritis Through a Molecular Dissection of the C3d:CR2 Ligand:Receptor Interaction"
182. RheumNow Live; March 22, 2019; Ft. Worth, TX; Invited Speaker "Insights into Preclinical Rheumatoid Arthritis"
183. General Assembly and Scientific Meeting of the Japan College of Rheumatology Presidential Symposium; April 15, 2019; Kyoto, Japan; Plenary Speaker "Rheumatoid Arthritis and the Mucosal Origins Hypothesis: Implications for Pathogenesis and Prevention"
184. ACR 2019 Biologic Classification of Disease Consensus Conference; May 10, 2019; Atlanta GA; Invited Speaker "Classification of Rheumatoid Arthritis Preclinical Disease"
185. European Congress of Rheumatology (EULAR) 2019; June 14, 2019; Madrid, Spain; Invited Symposium Speaker "Is Complement a Critical Ingredient in the Development of Rheumatoid Arthritis?"
186. 11th International Forum on Rheumatoid Arthritis; September 25-27, 2019; Washington, DC; Co-Organizer and Invited Speaker "Identification of Novel Targets in Rheumatoid Arthritis?"
187. American College of Rheumatology Annual Scientific Meeting; November 10, 2019; Atlanta, GA; Invited Symposium Speaker "Emerging Complement-Based Therapeutics"
188. American College of Rheumatology Annual Scientific Meeting; November 13, 2019; Atlanta, GA; Invited Symposium Speaker "Complement-Mediated Regulation of Rheumatoid Arthritis"
189. John P. Atkinson Endowed Lectureship; January 16, 2020; St. Louis, MO; Inaugural Speaker "Complement in Human Disease: Current and Emerging Therapeutic Opportunities"
190. American College of Rheumatology Winter Symposium; January 30, 2020; Snowmass, CO; Invited Speaker "Emerging Insights into the Molecular Origins, Preclinical Evolution and Prevention of Rheumatoid Arthritis"
191. American College of Rheumatology Winter Symposium; January 31, 2020; Snowmass, CO; Invited Speaker "Complement Therapeutics: New Strategies, Indications and Clinical Impact"
192. University of North Carolina Thurston Arthritis Research Center Visiting Professor; February 14, 2020; Invited Lecture "Emerging Insights into the Molecular Origins, Preclinical Evolution and Prevention of Rheumatoid Arthritis"
193. 13th Annual Perspectives in Rheumatic Disease; September 12, 2020; Virtual Conference; Invited Speaker "Predicting and Preventing Rheumatoid Arthritis: Is the Future Close?"
194. 12th International Forum on Rheumatoid Arthritis; September 18, 2020; Virtual Conference; Invited Speaker "Identification of Novel Therapeutic Targets in Preclinical Rheumatoid Arthritis"

195. American College of Rheumatology Annual Scientific Meeting; November 8, 2020; Virtual Conference; Invited Symposium Speaker “Transitioning from “RA Drugs” Today to Mechanism-Based Interventions Tomorrow”
196. University of Colorado Department of Medicine Research and Innovation Conference; December 10, 2020; Aurora, CO; Invited Seminar Speaker “Transitioning from “RA Drugs” Today to Mechanism-Based Interventions Tomorrow in Preclinical Rheumatoid Arthritis: A Team Science Approach”
197. GSK Research Seminar; December 11, 2020; Virtual Seminar; Invited Speaker “Complement Regulation of Rheumatoid Arthritis: From Preclinical Initiation to Clinical Disease Transitions”
198. University of Colorado Division of Rheumatology Research Seminar; December 15, 2020; Aurora, CO; Invited Speaker “Role of Complement in the Asymptomatic Preclinical Evolution of Autoimmunity and Subsequent Development of Clinically Apparent Joint Disease in Rheumatoid Arthritis”
199. University of Texas Austin Dell Medical School Internal Medicine Virtual Grand Rounds; January 13, 2021; Austin, TX; Invited Speaker “Complement Therapeutics: New Strategies, Indications, and Clinical Impact”
200. Asia Pacific League of Associations for Rheumatology (APLAR) Hybrid Congress 2021; August 28, 2021; Kyoto, Japan; Invited Plenary Speaker “Insights into Pathogenesis and Prevention from Studies of Systemic and Local Immune Dysregulation in Preclinical Rheumatoid Arthritis”
201. 13th International Conference on Complement Therapeutics; September 11, 2021; Ioannina, Greece; Invited Speaker “Biomarker Studies in Asymptomatic Preclinical Rheumatoid Arthritis Subjects and in Early Rheumatoid Arthritis Suggest Multiple Independent Pathogenic Roles for Complement Activation”
202. 13th International Forum on Rheumatoid Arthritis Virtual Conference; September 18, 2021; Invited Speaker “Causal Insights into Rheumatoid Arthritis from Studies of Innate and Adaptive Immune Dysregulation in At-Risk Individuals”
203. Hanson Wade 5th Annual Complement-based Drug Development Summit; October 27, 2021; Invited Speaker “Next-Gen Complement Therapeutics: Opportunities for Indication Expansion and Tissue Targeted Immunomodulation”
204. Hospital for Special Surgery Research Meeting Contemporary Topics in Inflammatory Arthritis Keynote Speaker; May 6, 2022; New York, NY; “Rheumatoid Arthritis and the Mucosal Origins Hypothesis: Insights into Pathogenesis, Prediction and Prevention”
205. American Association of Immunologists (AAI); May 7, 2022; Portland, OR; Invited Speaker “Stage- and Context-Dependent Roles of Complement in Rheumatoid Arthritis”
206. Perspectives in Rheumatology Meeting; September 8, 2022; Las Vegas NV; Invited Lecture “Complement Biology for the Clinician: The New Relevance”
207. 14th International Forum on Rheumatoid Arthritis Virtual Conference; September 16, 2022; Invited Speaker “Rheumatoid Arthritis and the Case for Causal Endotypes in the Preclinical Period”
208. Lupus 21st Century Meeting; September 22, 2022; Tucson AZ; Invited Lecture “Complement Therapeutics: Current Status and Evolving Relevance to Lupus”
209. St. Louis Rheumatology Association; November 30, 2022; St. Louis MO; Invited Lecture “Complement Therapeutics for the Rheumatologist, and Beyond”
210. Washington University School of Medicine Division of Rheumatology; December 1, 2022; Krock Invited Grand Rounds Speaker “Rheumatoid Arthritis and the Case for Causal Mucosal Endotypes in the Preclinical Period”

211. NIEHS (National Institute of Environmental Health Sciences); December 13, 2022; Durham NC; Distinguished Lectureship “The Environmental Drivers of Preclinical Rheumatoid Arthritis”
212. NYU Seminar in Advanced Rheumatology; March 16, 2023; New York City, NY; Weissmann Lectureship Keynote “Rheumatoid Arthritis and the Case for Causal Mucosal Endotypes in the Preclinical Period”
213. Advances in Targeted Therapies Meeting; March 24, 2023; Nice, France; Invited Speaker “The Case for Causal Mucosal Drivers in Individuals At-Risk for Rheumatoid Arthritis”
214. 15th International Conference on Complement Therapeutics; May 30, 2023; Chania, Greece; Invited Speaker “RNA Profiling and Protein Expression Studies in the Synovium of Patients with Rheumatoid Arthritis and Post-Traumatic Knee Injury Identify Causal Pathogenic Mechanisms for Complement Activation in Both Diseases”
215. EULAR 2024 Risk Factors for RA Study Group; June 2, 2023; Milan, Italy; Invited Speaker “Are There Distinct Mucosal Endotypes that Initiate and Drive Pre-RA Evolution”
216. Gates Summer Internship Program; August, 2023; Denver, CO; Keynote Speaker “Living in the ‘Tidal Pool’ at the Intersection of Academy Discovery Research and Patient Impact”
217. Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Medicine and Rheumatology, Queen Mary University; August 30, 2023; London, UK; Invited Speaker “Preclinical Rheumatoid Arthritis: Biomarker, Omics and Mucosal Studies of At-Risk Individuals”
218. 15th International Forum on Rheumatoid Arthritis Virtual Conference; September 16, 2023; Invited Speaker “Reflections on the Evolving Therapeutic Landscape in Rheumatoid Arthritis Prevention”
219. Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases; February 9, 2024; Breckenridge, CO; Invited Speaker “Preclinical Pathogenesis and Prevention of Rheumatoid Arthritis”
220. University of Massachusetts Chan Medical School Department of Medicine Grand Rounds; March 28, 2024; Worcester, MA; Invited Speaker “Emerging Opportunities in Rheumatoid Arthritis: The Study of At-Risk Individuals Informs the Pathway to Prevention”
221. University of Massachusetts Chan Medical School Division of Rheumatology Grand Rounds; March 29, 2024; Worcester, MA; Invited Speaker “Complement Therapeutics for the Rheumatologist, and Beyond”
222. UCSD/UCLA/Cedars Sinai MARC Virtual Seminar Series; April 4, 2024; Invited Speaker “Complement Therapeutics for the Rheumatologist and Beyond – With a Focus on Lupus”
223. Rheumatoid Arthritis Research Summit; April 12, 2024; New York, NY; Invited Speaker “Preclinical Rheumatoid Arthritis and Prevention: It’s Time for “NextGen” Therapeutic Trials – But What Are the Right Targets?”
224. DOM REACH Program: Innovation and Entrepreneurship; May 21, 2024; Aurora, CO; Invited Speaker “The Long and Winding Road to Patient Impact”
225. Ninth Annual Colton Center Symposium: Advances in Autoimmunity; June 7, 2024; New York, NY; Keynote Speaker “The Search for Drivers and Therapeutic Targets in Pre-Rheumatoid Arthritis”
226. SPARK/REACH Educational Conference; June 26, 2024; Aurora, CO; Invited Speaker “Effective Management of Faculty and Trainee Conflict of Interest in Individual Commercialization Efforts: Overview, Case Studies and Discussion”
227. 26th Asia-Pacific League of Associations for Rheumatology Congress; August 23, 2024; Singapore; Invited Speaker “Basic Science Update for RA: Recent Insights into the Pathogenic Mechanisms in Disease Throughout Its Natural History”

- 228. CCTSI K12 Scholars Program; September 27, 2024; Aurora, CO; Invited Speaker “Information and Opportunities in Innovation, Intellectual Property Generation and Commercialization for the Early Career Academic”
- 229. 16th International Forum on Rheumatoid Arthritis; October 18, 2024; Bamberg, Germany; Invited Speaker “Lessons from Hydroxychloroquine in StopRA and Implications for Next Generation Prevention Strategies”
- 230. University of Iowa Idiopathic Pulmonary Fibrosis and Complement Conference; November 22, 2024; Iowa City, IA; Invited Speaker “Complement Therapeutics: Now and Into the Future”
- 231. Mayo College of Medicine and Science Frontiers in Immunity and Inflammation Virtual Seminar Series; December 9, 2024; Invited Speaker “Complement Therapeutics for the Rheumatologist and Beyond”
- 232. University of Colorado Department of Medicine Grand Rounds; March 26, 2025; Aurora, CO; Invited Speaker “Rheumatoid Arthritis: New Paradigms and Opportunities in Pathogenesis, Prediction and Prevention for the 21st Century Physician”
- 233. 17th International Conference on Complement Therapeutics; May 12, 2025; Sisi, Greece; Invited Speaker “Using Rheumatoid Arthritis (RA) Patient Synovial Biopsy Studies and Murine Models to Interrogate the Complex Roles of Complement and Factor H-Related (FHR) Proteins in Human Disease”